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Abstract 
 
          Apoptosis is an important process in normal mammary gland physiology and 
has been implicated in mammary gland involution. In breast cancer cells, apoptotic 
resistance is an acquired feature that can promote tumour growth and progression. In 
order to assess the importance of apoptosis in these processes, caspases were directly 
inhibited by conditional expression of baculovirus p35 protein, a pan-caspase 
inhibitor, in the mammary glands of mice (rtTA/p35 mouse model). Inhibition of 
caspases during the first phase of involution in rtTA/p35 mice increased the number 
of sloughed luminal bodies which stained negatively for cleaved caspase-3. However, 
the total number of sloughed luminal bodies between mice with and without p35 
expression was not changed. This suggests that caspase activation is not essential for 
the sloughing of mammary epithelial cells into lumen of alveoli and the initiation of 
involution may be a caspase-independent event. The importance of apoptotic 
resistance in breast cancer progression was also addressed by crossing rtTA/p35 mice 
with mice over-expressing the ErbB2 oncogene (Neu). Expression of p35 in 
established Neu mammary tumours did not affect the growth rates of tumours relative 
to un-induced controls. However, an increased number of mice with lung and liver 
metastases were observed when p35 was induced. This result substantiates the 
importance of apoptotic resistance in promoting metastasis and warrants the targeting 
of apoptosis regulators as an anti-metastatic therapy. 
          The NF-κB signalling pathway regulates a range of anti-apoptotic genes and 
can also induce the expression of a variety of metastatic promoting genes. 
Accordingly, the role and potential of the NF-κB p52 subunit as a therapeutic target 
was investigated. Firstly, this was addressed by silencing the Nfkb2 gene, which 
encodes p100/p52, in mammary cancer cell lines. Interestingly, assessment of these 
cells in in vitro assays measuring motility and tumour initiating potential revealed 
opposing effects in differing cell lines upon Nfkb2 knockdown. In N202.1A cells (ER
-
ve
/ErbB2
+ve
), therapeutically beneficial effects were seen whereas in the 4T1 cell line 
(ER
+ve
/ErbB2
-ve
), malignancy was exacerbated. One explanation for the differential 
effects observed is that the negative regulatory subunit p100 and the transcriptional 
subunit p52 alternately have dominant roles in the respective cell lines. Although 
these results demonstrate a role for p52 in regulating tumour initiating potential in 
particular cell lines, the contextual outcomes indicate that targeting p52 at the gene 
vii 
 
level may be detrimental in cases where the loss of p100 outweighs the loss of p52. 
This indicates that strategies aimed at disrupting p52 activity should circumvent the 
loss of p100. Therefore, we addressed the possibility of diminishing p52 
transcriptional activity via promotion of repressive transcriptional complexes. As the 
formation of repressive complexes is favoured by phosphorylation of Ser-222 in p52, 
we addressed the effects of over-expressing the S222D p52 mutant in 4T1 cells. In in 
vitro assays assessing proliferation, colony forming potential, tumour initiating 
potential and motility, we did not observe any differences upon expression of S222D 
p52. However, over-expression of S222A p52 did increase the motility of 4T1 cells 
and this demonstrates that the lack of Ser-222 phosphorylation (promoting 
transcriptionally active complexes) can contribute to the malignancy of breast cancer 
cells. 
          Due to the context dependent effects of Nfkb2 silencing, it was important to 
identify the particular subtypes of breast cancer which are dependent on p52 activity. 
We assessed a cohort of BRCA2
-/-
 p53
-/-
 tumours for nuclear p52 staining along with 
markers for respective breast cancer subtypes by immuno-histochemistry and found a 
positive correlation between p52 and p63. This suggests that aberrant p52 activity 
may be common in basal-like breast cancers which typically express p63 and could 
benefit most from p52 targeted therapies. In summary, our results indicate that 
targeting p52 in breast cancer cells can be therapeutically beneficial but only in 
particular subtypes of breast cancer and by certain therapeutic strategies.               
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1 Introduction 
In this thesis, our initial aim was to investigate and substantiate the importance 
of apoptotic resistance in the formation of breast cancer metastases. For that purpose, 
a triple transgenic mouse model (rtTA/p35/Neu) was utilized. With this model, 
inducible expression of baculovirus p35 protein allows the effects of caspase 
inhibition on mammary tumour growth and metastasis formation to be addressed. The 
baculovirus p35 protein is an anti-apoptotic protein which helps the propagation of the 
virus (Clem et al., 1991) and is capable of inhibiting cell death in a variety of 
organisms including C. elegans, Drosophila melanogaster and mammalian cells 
(Beidler et al., 1995, Hay et al., 1994, Sugimoto et al., 1994). Baculovirus p35 protein 
is  a pan-caspase inhibitor and prevents apoptosis through direct interaction with 
caspases. 
 Based on the findings of our initial aim and that of published data (Pinkas et 
al., 2004), apoptotic resistance promotes the formation of breast cancer metastases.  
Hence, the consequent aim of the thesis was to address whether targeting of anti-
apoptotic signals in breast cancer cells would retard the formation of metastases. As 
the NF-κB pathway has been shown to be able to induce pro-survival signals in 
mammary epithelial cells (MECs) (Clarkson et al., 2000b) and regulate the 
tumourigenicity of breast cancer cells (Liu et al., 2010, Pratt et al., 2009), the potential 
of targeting this pathway, in particular the NF-κB p52 subunit was addressed. The 
effects of diminishing the activity of NF-κB p52 on breast cancer cell lines were 
investigated by silencing the gene which encodes p52 and through over-expression of 
an inhibitory form of p52.  
Since breast cancer is a heterogenous disease, it was also important to identify 
the specific subtypes which would most likely benefit from manipulation of p52 
activity. This was addressed by correlating levels of p52 with markers of particular 
subtypes of breast cancer in immuno-histochemical sections.  
 
1.1 The mammary gland 
1.1.1 Embryonic and fetal development of the mammary gland 
Mammals have a distinct ability to produce and secrete milk to nourish their 
progeny.  Although the mammary gland is only required to fulfill that role after 
gestation, the first signs of mammary gland morphogenesis can be traced in 
embryonic development. The mammary gland originates from a layer of epidermis 
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that bulges and forms a line on both sides of the embryonic mid-ventral line. This 
lateral line is located between the fore and hind limbs and has been described as the 
‘milk line’ (Kon and Cowie, 1961). The ‘milk line’ consists of epidermal cells which 
are columnar and multilayered. Placode formation at specific points of the milk line 
ensues and these placodes form invaginations into the mesenchymal layer beneath. 
This would lead to the formation of mammary buds which progressively extend into 
the mammary fat pad. Within this environment, ductal branching is stimulated and 
this gives rise to a rudimentary mammary tree by the time of birth (Figure 1.1) (Hens 
and Wysolmerski, 2005).  
 
1.1.2 Postnatal mammary gland morphogenesis 
The period between birth and puberty is when the mammary gland undergoes 
isometric growth in proportion to overall development of the organism. It is only 
during puberty when rapid allometric growth occurs. During this phase, various 
hormones influence branching and growth of the ductal tree by inducing the formation 
of terminal end buds (TEBs) at the tips of ducts (Silberstein, 2001). The TEBs 
progressively penetrate to the edges of the mammary fat pad and at the same time, 
side-branches are formed giving rise to a mature ductal tree. Tertiary branching and 
formation of lobulo-alveolar structures then occur and is governed by cycling ovarian 
hormones (Hovey et al., 2002). Within each estrous cycle, a transient increase of 
alveoli illustrates the mammary gland’s preparation for pregnancy. These alveoli 
would develop into the milk secreting units but regress in the absence of pregnancy 
associated hormones. The extent of alveolar budding varies between species and 
strains, largely because of variation in estrous hormone levels and cycle lengths.   
During pregnancy, increased levels of prolactin and progesterone induce 
extensive proliferation of ductal and alveolar epithelial cells. This is followed by 
differentiation of alveolar epithelial cells into milk secreting cells (Oakes et al., 2008). 
Lactation commences after progesterone withdrawal and involves the secretion of 
milk and lipids into the alveoli. The process of mammary gland involution 
commences upon cessation of lactation and can be induced experimentally in mice by 
forced weaning. As the milk producing alveoli are no longer required after lactation, 
involution is responsible for the removal of these structures and returning the gland to 
a state that is similar to pre-pregnancy (Figure 1.1) without invoking excessive 
inflammation.   
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1.1.3 Role of apoptosis during postnatal mammary gland development 
Apoptosis is a form of programmed cell death characterised by morphological 
changes which include chromatin condensation, nuclear fragmentation, cell shrinkage 
and membrane blebbing. A cell that has undergone apoptosis will then be engulfed by 
phagocytes to avoid inflammatory responses in the surrounding tissue, an important 
feature of this neat form of cell death (Savill and Fadok, 2000).  Apoptosis is an 
essential process in multicellular organisms not only during development where 
excess cells are removed to form well defined tissue ‘sculptures’, but also for tissue 
homeostasis in a mature organism (Meier et al., 2000, Prindull, 1995). 
 
1.1.3.1 Extrinsic and intrinsic apoptotic pathways  
There are two major pathways of apoptosis in mammals, namely, the extrinsic 
pathway which can be triggered through death receptors and the intrinsic pathway 
which is mitochondrial dependent (figure 1.2). The extrinsic pathway involves 
stimulation of death receptors such as CD95, DR4 or TNF-α receptor by their 
respective ligands, which then induces receptor oligomerization and recruitment of 
adaptor proteins with death domains. Caspase-8, the initiator caspase of the extrinsic 
pathway associates with the activated receptor and adaptor proteins forming a death-
inducing signalling complex (DISC). This is followed by autoactivation of caspase-8 
which subsequently activates the effector caspases (caspase-3, -6 and -7) (Ashkenazi 
and Dixit, 1998). Alternatively, the intrinsic pathway is mediated by release of 
cytochrome c from the mitochondrion into the cytoplasm, which associates with 
apoptosis protease-activating factor 1 (Apaf-1) and caspase-9 to form the 
‘apoptosome’. Consequently, the apoptosome induces activation of caspase-9 in the 
intrinsic pathway and this leads to cleavage of effector caspases, the point where both 
pathways converge (Shi, 2002). Consequently, other nucleases (e.g. CAD) and 
proteases which are responsible for the terminal stages of apoptosis are activated by 
the caspase cascade. Over-activation of caspase-8 via death receptor signalling can 
also lead to truncation of bid and mitochondrial membrane permeation. This can result 
in crosstalk from death receptor signalling through to the intrinsic pathway in certain 
cell types (Miller, 1997). 
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1.1.3.2  The caspase cascade and regulators of apoptosis 
On the whole, a series of proteolytic cascades involving caspases are integral 
to the apoptotic process (Figure 1.2). Caspases are cysteine proteases which cleave 
their respective substrates at aspartate residues (Vaux and Strasser, 1996). For that 
reason, they are synthesized as zymogens and their activation is regulated by various 
apoptosis regulators because over-activation of caspases will lead to degenerative 
diseases whereas over-inhibition would promote tumorigenesis (Degterev et al., 
2003). It is the balance of pro-apoptotic and anti-apoptotic regulators in a cell which 
determines the sensitivity of cells to a particular death stimulus. At the death receptor 
level, pro-survival proteins such as cellular FLICE inhibitory protein (c-FLIP) 
antagonize the activation of caspase-8. Similarly, pro- and anti-apoptotic proteins of 
the B-cell lymphoma 2 (Bcl-2) family govern mitochondrial permeation. In addition, 
inhibitor of apoptosis proteins (IAPs) can inhibit the effector caspases and caspase-9 
through direct binding. 
 
1.1.3.3 Apoptosis during mammary ductal morphogenesis 
As described, the extensive ductal network of the mammary gland is only 
formed during puberty. This involves the invasion of TEBs into the mammary fat pad 
and is driven by proliferation in these structures. Another important aspect of ductal 
morphogenesis is the formation of intact and hollow lumen as the TEB structures 
progress towards the edges of the mammary fat pad. Apoptosis has an important role 
in lumen formation and can be detected in a proportion of body cells in the TEB 
(Figure 1.3a).  Inhibition of apoptosis by specific overexpression of Bcl-2 under the 
whey acidic protein (WAP) promoter reduces the percentage and disrupts the 
localization of apoptotic cells within TEBs. Moreover, convoluted layers of cells can 
be observed in these TEB structures implicating a role for apoptosis in maintaining 
the integrity of TEBs as they progress (Humphreys et al., 1996). More specifically, 
the pro-apoptotic factor, Bim has been shown to be important for luminal clearance by 
inducing anoikis and the lack of it results in a delay in clearance but this can be 
compensated by alternative cell death mechanisms (Mailleux et al., 2007). Similarly, 
insights from in vitro experiments utilising MCF-10A cells show that lumen 
formation in acini can be delayed but not prevented by inhibiting apoptosis (Debnath 
et al., 2002). These studies demonstrate a role for apoptosis in the formation of the 
ductal network and acinar structures of the mammary gland. 
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1.1.3.4 Apoptosis during mammary gland involution 
There are two phases of involution in mice, a first reversible phase that occurs 
within 0-2 days post weaning and a second phase which involves remodeling of the 
mammary gland by matrix metallo-proteinases (MMPs). In the first phase, alveolar 
cells that are undergoing programmed cell death are shed into the lumen, giving rise 
to luminal bodies that stain positive for activated caspase-3 (Watson, 2006).  In the 
second phase, substantial remodelling of the gland occurs. Matrix metalloproteases 
(MMPs) regulate the collapse of alveoli structures and induces tissue remodelling 
which is accompanied by apoptosis (Green and Streuli, 2004).
 
The loss of 
extracellular matrix support contributes to cell death by induction of anoikis in the 
second phase (Figure 1.3b).  
As weaning occurs, milk stasis in the secretory structures of the gland leads to 
production of leukemia inhibitory factor (LIF) and transforming growth factor (TGF) 
β3. Both these factors are activators of signal transducer and activator of transcription 
(STAT) 3, (Kritikou et al., 2003, Nguyen and Pollard, 2000, Schere-Levy et al., 2003) 
which plays an important role in the initiation of involution. This is in line with the  
gene expression profile of mammary glands during the initial phase of involution,  
where acute phase response genes which are known targets of STAT 3 and NF-kB are 
expressed (Clarkson et al., 2004, Stein et al., 2004). In fact, conditional deletion of 
STAT 3 in the mammary gland reduces cell death, extends the reversible first phase 
and delays the onset of the second phase of involution (Chapman et al., 1999). The 
role of STAT 3 in the second phase is sustained by oncostatin M receptor (OSMR), 
which transduces signals from a cytokine, oncostatin M, capable of potently activating 
STAT3 in the mammary gland. Deletion of OSMR led to a reduction in the expression 
of MMPs and consequently, a reduction in MMP-dependent apoptosis (Tiffen et al., 
2008). 
The large number of luminal bodies is then cleared in the initial phase by non-
professional macrophages. These are epithelial cells capable of efferocytosis to 
internalize milk globules and cellular debris. The phagocytic process is dependent on 
phosphatidyl-serine exposure on the outer leaflet of the membrane, a characteristic 
feature of apoptotic cells (Monks and Henson, 2009). It is only by day 4 post-weaning 
that professional macrophages can be detected in the mammary gland and contribute 
to the clearance of apoptotic bodies. The importance of the clearing process is 
highlighted by knockout of c-mer proto-oncogene tyrosine kinase (MerTK) or milk fat  
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globule-EGF factor 8 (MFG-E8), molecules shown to have a role in cell uptake by 
macrophages. The deletion of these molecules respectively led to delayed clearance of 
apoptotic bodies which may result in secondary necrosis and increased inflammation. 
As a result, increased matrix deposition and fibrosis were observed in knockout 
glands and this led to the inability for the gland to regrow in a subsequent pregnancy 
(Atabai et al., 2005, Hanayama and Nagata, 2005, Sandah et al., 2010). Taken 
together, this demonstrates the importance of apoptosis in mammary tissue 
homeostasis and indicates that aberrant regulation of apoptosis in the mammary gland 
would be pathological. 
 
1.1.4 Mammary gland architecture 
The basic structure of the mammary gland is similar to other epithelial gland 
structures. Numerous alveoli or acini, the milk producing units, are connected to a 
network of ducts which supply the nipple. It can be illustrated as a ‘mammary tree’ 
where the nipple is the root from where ducts branch outwards (Figures 1.4 a-c), 
forming secondary and tertiary branches with multiple acini. This epithelial ‘tree’ 
structure is bounded within stroma which comprise mainly of fibroblasts and 
adipocytes (Hovey et al., 2002).  
At the cellular level, mammary ducts and acini are structures made up of two 
layers of polarized epithelium (Figure 1.4d). These structures are hollow and the inner 
layer of cells are termed the luminal cells because their apical surface is in contact 
with the lumen. The outer layer of ductal cells are termed basal cells, whereas in acini 
they are termed myoepithelial cells (Howard and Gusterson, 2000). However, the 
basal and myoepithelial cells do not differ functionally and are located between the 
luminal cells and a layer of basement membrane consisting of laminin (Adams and 
Watt, 1993). 
 
1.1.5 Key differences between human and murine mammary glands 
Although the murine mammary gland has provided many insights into 
mammary gland morphogenesis, it does not represent all the features of the human 
breast. Some key differences are present even in embryonic development. While the 
sexual dimorphism of the mammary gland occurs in utero for mice, the mammary 
glands of men and women are indistinguishable until puberty. More evidently, mice 
have five pairs of mammary glands compared to a pair in humans. This is a result of 
Chapter I: An introduction to the mammary gland, breast cancer and NF-κB signaling 
 
 
  SK Yeo                                                                 - 11 -                                               Cardiff University 
the milk line segregating into multiple placodes before mammary bud formation in 
mice (Kon and Cowie, 1961).  
Rigorous assessment of mammary gland architecture will also reveal that the 
milk secreting units between the two species differ. Alveolar buds feature along 
primary ducts in mice, while in humans, acini are within terminal ductal lobular units  
 (TDLU) (Figures 1.4 a-c). TDLUs are encapsulated by intralobular stroma made up 
mostly of fibroblasts along with some adipocytes. An additional layer of interlobular 
stroma borders the intralobular stroma. The interlobular stroma is more densely 
packed and is discernable from intralobular stroma by the expression of cell surface 
dipeptidyl peptidase IV (DPP IV).   Contrastingly, the stroma of mice is populated 
mainly by adipocytes.  (Richert et al., 2000, Howard and Gusterson, 2000). 
 
1.2 Breast cancer 
 
1.2.1 Breast carcinogenesis  
Uncontrolled cell growth gives rise to tumours which could either be benign or 
malignant. Benign tumours remain encapsulated whereas malignant ones have the 
ability to invade and form metastases. Such malignancies are described as cancers but 
they include various forms, each with different characteristics depending on their 
origin. Cancers derived from connective tissue such as muscle are termed sarcomas 
while those of epithelial lineage are carcinomas (Pecorino, 2008, Alison, 2001). 
Accordingly, cancers of glandular epithelia are adenocarcinomas and these are the 
most prevalent cancers in the breast. Owing to the different glandular structures in the 
breast, adenocarcinomas of the breast can be further divided into ductal carcinomas 
and lobular carcinomas, with the former being the more common form. Despite the 
heterogeneity of cancers, there are unifying traits which are acquired by most cancer 
cells and these have been described as the ‘hallmarks of cancer’. Essentially, a cancer 
cell would attain the ability to circumvent apoptosis, acquire independent growth 
stimuli, resist growth inhibitory signals, have inexhaustible replicative potential, 
induce angiogenesis and metastasize in its progress towards malignancy  (Hanahan 
and Weinberg, 2000b). It is acknowledged that genetic and epigenetic aberrations in 
cancer cells lead to the accumulation of these hallmark features. 
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Figure 1.4: Basic architecture of (a) mouse mammary gland and (b) human breast.     
(c) Structure of the ductal secreting unit; alveolar bud in mouse and TDLU in 
humans. (d) Arrangement of epithelial cells within an acinus.   
 
Nipple 
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1.2.2 Breast cancer progression 
In breast cancer, the conventional view of disease progression can be 
described based on histology of breast lesions (Figure 1.5a). The initial signs of 
carcinogenesis manifest in the form of hyperplasia, then atypical hyperplasia or an 
increase in cell number with abnormal nuclear morphology. This would progress into 
carcinoma in situ where cell numbers have increased to an extent where the lumen of 
a duct or acini is hardly visible but the basement membrane is still intact. 
Consequently, lesions would culminate with invasive carcinoma where tumour cells 
are no longer bound by a basement membrane and invade into the surrounding tissue 
(Bonadonna et al., 2006, Bombonati and Sgroi, 2011).  
 
1.2.3 The metastatic cascade 
Following that, scores of tumour cells will partake in the metastasis cascade 
but only a small portion of these cells successfully colonize secondary sites such as 
the lung and brain. This is mainly because it is an elaborate process (Figure 1.5b) 
where adequate angiogenesis needs to take place first, to provide a route by which 
tumour cells can reach a distant organ. Basically, angiogenesis is the process where 
either blood or lymph vessel sprouting is induced. Vascular endothelial growth factor 
(VEGF) proteins play an important part in the angiogenic process where VEGFA and 
VEGFC induce hemangiogenesis and lympangiogenesis respectively. It is also 
noteworthy that angiogenesis, a hallmark of cancer cells, enables adequate supply of 
nutrients and oxygen needed for a tumour to maintain its rapid growth. However, the 
importance of lymphangiogenesis is not fully understood and could be a consequent 
effect of hemangiogenesis (Cao, 2005) . With networks of vasculature within close 
proximity, the migration of tumour cells towards blood or lymphatic vessels is 
stimulated by chemokine gradients and leads to intravasation, circulation and 
extravasation of cells out of the respective vessels. This is not a new concept and 
conforms to  Paget’s ‘seed and soil’ hypothesis that metastases arise from cancer cells 
or ‘seeds’ and would only grow in suitable microenvironments, i.e. the ‘soil’(Paget, 
1889).  True enough, breast cancer cells with the ability to metastasize to lung, liver, 
lymph node or bone marrow express the C-X-C motif receptor 4 (CXCR4) receptor 
and are attracted towards C-X-C motif ligand 12 (CXCL12), its ligand which is 
expressed in the tissues mentioned (Muller et al., 2001). At the secondary site, these 
cells would then require the ability to adapt and colonize the new micro-environment 
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(Geiger and Peeper, 2009). Furthermore, only a select number of micro-metastases are 
capable of developing macro-metastases.   
 
1.2.4 Evading apoptosis: A hallmark of cancer cells 
Since the initial conception that decreased apoptosis in cancer cells can 
contribute to aberrant tissue turnover in tumours (Kerr et al., 1972), it is now well 
accepted that the ability to evade apoptosis is a hallmark of cancer cells (Hanahan and 
Weinberg, 2000a). Evidence for a role of anti-apoptotic proteins in tumourigenesis 
was provided through expression of Bcl-2 in haematopoietic cells, where it can 
cooperate with c-Myc to promote neoplastic progression (Vaux et al., 1988). This led 
to the notion that apoptosis regulators which are pro-survival can be potential 
oncogenes.         
 
1.2.5 Apoptosis as a multistep barrier to metastasis 
 In the elaborate metastatic process, there are various stages where cancer cells 
are exposed to death inducing stimuli. One of the early steps where apoptosis limits 
the efficiency of cancer cells to metastasize is when cells detach from surrounding 
cells and/or the extra-cellular matrix (ECM). In normal mammary epithelial cells, this 
would induce anoikis or cell death due to loss of adhesion (Martin and Leder, 2001, 
Streuli and Gilmore, 1999). Furthermore, it has been shown that tumour cells die 
when they come into contact with endothelial cells of blood vessels during 
intravastion (Wyckoff et al., 2000). Tumour cells that manage to circulate in vessels 
are further subjected to mechanical stress due to shear forces and also surveillance by 
immune cells such as natural killer (NK) cells (Kim et al., 2000, Weiss et al., 1993). 
Upon reaching secondary sites, tumour cells will then need to adapt to a foreign 
microenvironment and only a small percentage will give rise to micro-metastases 
(Wong et al., 2001). All these factors suggest that metastasis is an inefficient process 
and the ability to suppress apoptosis would be necessary for the formation of 
metastasis. In fact, over-expression of anti-apoptotic Bcl-2 family proteins in 
tumourigenic mammary epithelial cells have been shown to increase the metastatic 
potential of these cells, highlighting apoptosis as a limiting factor towards metastases 
formation (Bufalo et al., 1997, Martin et al., 2004, Pinkas et al., 2004). However, 
there are limitations with these studies as they involve transplants of cell lines into 
immuno-compromised mice. This means that the early steps of metastasis where 
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anoikis takes place and immune surveillance could be neglected. Hence, the 
development of more adequate models could provide additional insights into the role 
of apoptosis as a safeguard from metastasis and ways of reactivating apoptotic 
pathways in cancer cells (Mehlen and Puisieux, 2006). 
 
1.2.6 Epithelial to mesenchymal transition (EMT) and the acquisition of 
malignant traits 
The process of epithelial to mesenchymal transition (EMT) is important 
throughout embryonic development for organogenesis (Baum et al., 2008). Similarly 
during postnatal mammary gland development, EMT has been implicated during 
ductal morphogenesis in the TEBs where a motile phenotype is necessary for cells to 
invade through the mammary fat pad (Kouros-Mehr and Werb, 2006). Mammary 
epithelial cells at ductal branch points and the leading edge of the mammary ductal 
tree also exhibit mesenchymal features during morphogenesis (Fata et al., 2004, 
Nelson et al., 2006). Since the mammary gland develops extensively only after birth, 
it is not surprising that EMT can be induced in mammary epithelial cells postnatally.  
Some of the key features of EMT include the loss of E-cadherin expression 
along with cell-cell adhesion proteins (Figure 1.6). In line with this, a cell undergoing 
EMT would express mesenchymal markers such as N-cadherin, fibronectin and 
vimentin. A morphological change from cuboidal epithelial cells with apical-basal 
polarity to a more motile appearance with leading and trailing edge asymmetry is 
evident in this process (Christiansen and Rajasekaran, 2006). A large range of stimuli 
such as hypoxia, cell-stroma interactions and activation of signalling pathways, 
namely transforming growth factor β (TGF- β), NF-ΚB, hepatocyte growth factor 
(HGF), Wnt, Notch and Sonic Hedgehog (SHH) are able to induce EMT. These 
diverse stimuli converge in the expression of a group of EMT-inducers which are 
capable of orchestrating the EMT process. The EMT-inducers are a group of 
transcription factors which include Twist, Snail, Slug, Zeb1, Zeb2 and FoxC2 (Polyak 
and Weinberg, 2009). 
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Epithelial  Mesenchymal 
Apical / basolateral polarity  Leading / trailing edge assymetry 
Cell adhesion & contact inhibition  Cell motility & invasiveness 
Adherens, tight and gap junctions  Focal adhesions & transient gap junctions 
E-cadherin & cytokeratins  N-cadherin, vimentin, SMA & MMPs 
MET 
ECM 
ECM 
EMT 
Figure 1.6: Features of epithelial to mesenchymal transition (EMT). 
Illustration of epithelial and mesenchymal cells and the processes EMT and MET 
that govern the switch between the different cell states. (Meshed lines represent 
extracellular matrix ECM, SMA denotes smooth muscle actin, MMP denotes 
matrix metallo-proteases ).Table listing the main characteristics of epithelial and 
mesenchymal cell states. Adapted from Christiansen & Rajasekaran 2006.  
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In the context of cancer cells, the EMT program is similar to that in embryonic 
development but its activation is due to aberrant stimuli. EMT has been associated 
with tumour progression and metastasis because it confers cancer cells with more 
motile and invasive phenotypes (Hugo et al., 2007, Yang and Weinberg, 2008). These 
would be important in the early stages of the metastatic cascade when cancer cells 
invade through the basement membrane into surrounding tissue and intravasate. 
Moreover, there is also evidence to indicate that trans-differentiation of breast cancer 
cells via EMT confers them with stem-cell like phenotypes (Mani et al., 2008, Morel 
et al., 2008). Apart from EMT, mesenchymal to epithelial transition (MET), the 
reverse process has also been shown to be important for the colonization of cancer 
cells at secondary sites (Dykxhoorn et al., 2009). This correlates with observations 
where metastases maintain an epithelial phenotype similar to its primary tumour. It 
would also suggest that the mesenchymal state is transient in cancer cells and its 
maintenance can be influenced by the tumour micro-environment (May et al., 2011).       
 
1.2.7 Clonal evolution of tumours and breast cancer stem cells   
It has been a longstanding observation that heterogeneity exists within breast 
tumours. An obvious illustration of this phenomenon is in oestrogen receptor (ER) 
positive breast cancers where the levels of ER expression between cells in a tumour 
can vary considerably (Aubele et al., 1999). Accordingly, there is also evidence to 
support the fact that cells within a tumour acquire varying levels of genetic alterations 
(Fujii et al., 1996, Glockner et al., 2002). In the model of clonal selection, where it is 
proposed that cancers originate from a single cell, such heterogeneity can arise due to 
the acquisition of genetic changes that confers cells with a survival advantage. As a 
tumour progresses, sequential selection of cancer cells with increasing genetic 
alterations can give rise to progressively malignant clones (Nowell, 1976). 
Consequently, a tumour would comprise of cells with diverse genetic alterations and 
corresponding tumorigenic properties.   
Alternatively, the heterogeneity of tumour cells could also arise due to 
hierarchical differences between cancer cell populations. The ‘cancer stem cell’ 
(CaSC) concept states that cells within a tumour are not equal in their proliferative 
potential. Within this hierarchy, it is the CaSCs that fuel the growth of a tumour and 
have the ability to self-renew whereas the bulk of differentiated or post-mitotic cells 
lack tumour initiating potential. Hence, CaSCs have also been implicated in the 
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seeding and progression of metastases. Importantly, both clonal evolution and CaSC 
models need not be mutually exclusive and could coherently depict the progression of 
tumours. The existence of CaSCs were first shown in hematopoietic malignancies 
(Furth and Kahn, 1937, Lapidot et al., 1994) and more recently, the presence of 
CaSCs in breast tumours represented the first indication of CaSCs in solid tumours 
(Al-Hajj et al., 2003). However, the CaSC concept does not stipulate the cell of origin 
of cancers and it is possible for CaSCs to arise from transformed mature, progenitor or 
normal stem cells. The characterization of breast CaSCs have been assisted by the use 
of putative CaSC markers such as CD24
-
/CD44
+
, aldehdye dehydrogenase 1 
(ALDH1) and CD61
+ 
for different tumour subtypes. Even so, there is currently not a 
consensus for markers that are able to enrich for CaSCs from differing tumour 
subtypes. This may be a result of CaSCs arising from different cells of origin and/or 
their dependence on diverse oncogenic pathways.   
Phenotypically, CaSCs have also been shown to be more resistant to 
chemotherapy (Li et al., 2008) and radiotherapy (Diehn et al., 2009). This has 
important implications with regards to therapeutics because targeting the bulk of the 
tumour will leave residual CaSCs which can remain dormant and lead to relapse of 
disease. In addition, it has been shown that plasticity can exist within a tumour cell 
population where non CaSCs can be induced to acquire CaSC phenotypes (Meyer et 
al., 2009). This is further supported by the fact that EMT can induce the acquisition of 
CaSC phenotypes in cancer cells (Mani et al., 2008, Polyak and Weinberg, 2009). As 
such, the EMT process could also contribute to intratumour heterogeneity. Taken 
together, this would imply that the elimination of CaSCs by itself is not sufficient for 
preventing the recurrence of disease and pathways which enable plasticity in cancer 
cells need to be targeted simultaneously.   
 
1.2.8 Breast cancer epidemiology        
Breast cancer is the main cause of cancer related deaths in women worldwide 
(Murray and Lope, 1997). In general breast cancer incidence is much higher in 
developed countries relative to developing countries. The hormone oestradiol 
accounts for most of the epidemiology of breast cancer (Key et al., 2001). When 
women are within their reproductive age, incidence of breast cancer increases rapidly 
with age and this increase occurs at a slower rate once women reach the average age 
of menopause (about 50 years) (cancer., 1997). Risk factors for breast cancer include 
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the age for menarche, where an early menarche is associated with increased risk of 
breast cancer (Kelsey et al., 1993) Childbearing has a protective effect against breast 
cancer where women who have gone through more full term pregnancies have a lower 
risk relative to nulliparous women (Layde et al., 1989). In addition, the age during 
first full term pregnancy also determines breast cancer risk and this effect is 
independent of the total number of pregnancies. Women with an early age (younger 
than 20 years) of first term pregnancy have been shown to have a lower risk of breast 
cancer relative to women with a first term pregnancy after 35 (Kelsey et al., 1993). 
Apart from that, breastfeeding also has significant protective effects against breast 
cancer (Lipworth et al., 2000). The onset of menopause also affects breast cancer risk, 
with an increased risk observed for later onset (cancer., 1997). 
 Oral contraceptives (cancer., 1996) and hormone replacement therapy for 
menopause (Magnusson et al., 1999) have both been associated with increased risk for 
breast cancer and this illustrates the effects of hormones (oestrogen and progesterone) 
on the epidemiology of breast cancer . Other lifestyle factors which increase the risk 
of breast cancer include high fat diets (Hunter et al., 1996) and consumption of 
alcohol (Smith-Warner et al., 1998), whereas exercise appears to have a protective 
effect (Friedenreich et al., 1998). 
 A large number of environmental and lifestyle risk factors determine the 
incidence of breast cancers. Genetic determinants, particularly high risk mutations 
such as p53, PTEN, BRCA1 and BRCA2 account for only about 5% of breast cancer 
cases (Easton, 1999, Ford et al., 1998, Peto et al., 1999). 
 
1.2.9 Breast cancer incidence and survival rates 
Even though breast cancer predominantly affects women, it is the most 
common form of cancer in the United Kingdom (UK) with about 46,000 people 
diagnosed within 2007 (Northern Ireland Cancer Registry, 2010, Office for National 
Statistics, 2010, Welsh Cancer Intelligence and Surveillance Unit, 2010). On the 
global scale, figures from 2008 indicate that 1.38 million women were diagnosed and 
that accounts for about 11% of all cancer cases (Ferlay et al., 2010). This highlights 
the extent of this disease and stresses the need to understand the risks of developing 
breast cancer and finding ways of managing the disease to improve the lifestyles of 
people affected. Fittingly, much progress has been made and this is reflected by the 
increase in five year relative survival rates of patients in the UK, from 52% in the 
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early 1970s to 82% at present (Rachet et al., 2009). This is also illustrated by the 
decrease in mortality rates where breast cancer is no longer the leading cause of 
cancer related deaths. Even so, the reality is that breast cancer is a heterogeneous 
disease which comprises many subtypes. While prognoses have improved for certain 
subtypes, some remain less adequate. This is mainly due to therapeutic resistance, 
metastasis and tumour relapse. 
 
1.2.10 Heterogeneity of breast cancers and intrinsic subtypes 
The advent of gene expression microarrays has led to the classification of 
breast cancers into intrinsic subtypes based on their molecular profiles. At the outset, 
the classification was based on gene clusters correlating to proliferation, hormone 
receptor signalling, Her2 signalling and a basal cluster which is associated with basal 
epithelial cells of the breast (Perou et al., 2000). As a result, the different gene profiles 
can now be used to segregate breast cancers into six groups designated luminal A, 
luminal B, Her2-enriched, basal-like, normal-like and claudin-low (Carey, 2010). 
Both the luminal subtypes as their names suggest, have expression profiles 
reminiscent of the luminal epithelial cells. In exact, they usually express luminal 
cytokeratins (CKs) 8 and 18, oestrogen receptor (ER), progesterone receptor (PgR) or 
ER associated genes such as GATA3. Both luminal A and luminal B are very 
common subtypes which make up around 40% and 20% of breast cancers 
respectively. These subtypes can be distinguished based on the fact that luminal A 
subtypes have higher expression of ER associated genes but lower expression of 
proliferation and Her2 related genes. 
 The Her2-enriched is one of the hormone receptor negative subtypes and 
comprise about 10% of breast cancers. These have high expression of genes in the 
Her2 cluster which include genes which are in proximity to the Her2 locus in the 
genome. These neighboring genes are expressed in tandem because aberrant 
expression of Her2 in breast cancers is usually a result of gene amplification events 
(Couturier et al., 2008). The tumours are usually high-grade based on histological 
analysis and have relatively poor prognoses. 
 
 In the basal-like group, these tumours do not express ER, PgR or Her2 and are 
closely associated to ‘triple negative’ (ER
-
 PgR
- 
Her2
-
) breast cancers. Although these 
two subsets overlap to a large degree, they are not synonymous. As this subtype is 
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categorized based on expression of basal epithelial genes, the tumours typically 
express CK 5, CK14, CK17, vimentin and epidermal growth factor receptor (EGFR) 
(Lerma et al., 2007a). Moreover, the basal-like tumours also over-express genes of the 
proliferation cluster. Up to 20% of breast cancers are of this subtype and most of them 
show high-grade histologies. Interestingly, BRCA1 germline mutations have been 
identified as risk factors for basal-like breast cancer and give rise to tumours with 
identical features (Turner et al., 2004).  
 One of the other subtypes that were initially characterized was the normal-like 
group but its attributes remain elusive and it could be an artifact of stromal tissue 
contamination. The claudin-low subtype has also emerged after larger scale gene 
expression analyses were carried out. It is another ‘triple negative’ subtype with low 
expression in all gene clusters and especially cell adhesion and interaction genes such 
as claudin and E-cadherin. Until now, not much is known about the clinical aspects of 
the claudin-low subtype but it is associated with metaplastic carcinoma and is 
enriched with tumour initiating phenotypes (Carey, 2010).    
 
1.2.11 Targeted therapeutics in breast cancer 
Targeted therapeutics are drugs which specifically target a signalling pathway 
and due to its specific mode of action, reduce the level of systemic toxicity. This is in 
contrast to conventional chemotherapy which target highly proliferative cells. The 
concept of targeted therapy has been employed in breast cancer since the early 1970s 
with the use of tamoxifen, an antagonist for ER. The rationale behind tamoxifen was 
that a proportion of breast cancers depend on estrogen signaling for growth. By 
interrupting this signalling between ligand and receptor, it is possible to restrict the 
growth of breast cancers. Tamoxifen had a great impact on survival rates of hormone 
dependent breast cancers and was a gold standard of targeted therapies for decades. 
This provided proof of principle and paved the way for the development of targeted 
therapeutics in breast cancer (Jordan, 2007). Following tamoxifen’s success in 
estrogen responsive breast cancers, aromatase inhibitors and improved ER antagonists 
such as fulvestrant have been successful in targeting the estrogen signalling pathway, 
albeit with different mechanisms (Hiscox et al., 2009). Luminal subtypes of breast 
cancer have benefited greatly from these advances but some challenges such as 
endocrine resistance remain, especially in the luminal B subtypes. 
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 Another fundamental breakthrough for target based approaches was 
trastuzumab, a monoclonal antibody (MoAb) which interfered with Her2 receptor 
signalling. Prognoses for the Her2-enriched subtype improved markedly and relapse 
rates for endocrine resistant breast cancers can be decreased significantly when 
trastuzumab is administered with conventional treatment regiments (Normanno et al., 
2009).  
 Unfortunately, effective treatments specifically targeting the basal-like 
subtype are still lacking at present. The fact that basal-like tumours are mostly ‘triple 
negative’ (i.e. lack expression of ER, HER2 and PgR) means that they do not respond 
to endocrine therapy or trastuzumab. One of the prospective targets for this subtype 
was EGFR because its expression correlates with the basal-like intrinsic profile. As 
with trastuzumab, cetuximab is a MoAb designed to abolish EGFR mediated 
signalling. However, only modest results were seen for patients treated with 
cetuximab. This highlights some of the challenges faced by targeted therapies. The 
specific nature of such drugs could be ineffective because of redundant pathways, 
multiple patterns of resistance or the adaptive capacity of tumours. This has not halted 
the search for ‘magic bullets’ for this disease subtype and instead have stimulated the 
need for understanding its mechanisms further. There are many targeted therapies in 
development at present and the poly ADP ribose polymerase (PARP) inhibitors carry 
much promise for treatment of basal-like cancers. PARP inhibitors function by 
impairing the DNA damage repair mechanism, leaving cancer cells more susceptible 
to DNA damaging agents such as cisplatin. The clinical efficacy of this class of drugs 
will be apparent in the near future but until then, the search for potential targets 
continues (Carey, 2010).   
 
1.2.12 Targeting breast cancer stem cells 
As it is becoming more apparent that CaSCs are the cause of therapeutic 
resistance, disease relapse and the seeding of metastases in a range of breast cancer 
subtypes, it is only sensible that CaSCs are accounted for when designing targeted 
therapeutics. However, due to the plasticity that exists in tumours, the bulk of tumour 
cells should also be eliminated to prevent reemergence of CaSCs. Ideally, treatments 
would target CaSCs and bulk tumour cells with minimal adverse effects to patients 
(McDermott and Wicha, 2010).  
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A number of pathways pertinent to normal stem cells have been shown to be 
important in breast CaSCs. These include Hedgehog (Liu et al., 2006), 
PTEN/AKT/WNT signalling axis (Korkaya et al., 2009) and Notch (Harrison et al., 
2010). Inhibition of these particular pathways either decreased mammosphere 
formation and/or tumour initiation, indicating the loss of CaSCs. In addition, a 
number of cytokines such as IL-6 (Sansone et al., 2007) and IL-8 can also regulate 
breast CaSCs. By targeting CXCR1, the cognate receptor for IL-8, CaSCs can be 
sensitized to a bystander killing effect mediated by FAS ligand (Charafe-Jauffret et 
al., 2009). Another pathway that has been increasingly associated with breast CaSCs 
is the NF-κB pathway, where its inactivation led to the decrease of CaSCs in Neu-
driven tumours (Liu et al., 2010). All these pathways represent possible avenues 
where CaSCs can be selectively targeted.   
 
1.2.13 Mouse models of breast cancer 
Mouse models have provided an important understanding into the 
development of breast cancer. Moreover, these models also serve as important pre-
clinical platforms to verify efficacy of potential drugs. In some of the early models, 
mammary lesions were induced by external factors such as the mouse mammary 
tumour virus (MMTV) and chemical carcinogens. Progress in transgenic technology 
then led to the development of a new generation of models where tumour suppressors 
can be knocked out or onocogenes over-expressed. Apart from providing an 
understanding for the role of a gene in breast carcinogenesis or progression, these 
models have also been useful in elucidating molecular pathways. Moreover, the use of 
mammary gland specific promoters such as MMTV-long terminal repeat (MMTV-
LTR), β-lactoglobulin (BLG) and whey acidic protein (WAP) promoters have allowed 
spatial control of transgene expression in the mammary compartment. Even so, there 
are limitations with using constitutively active promoters especially when the 
transgene of interest has unwanted effects throughout development. This problem can 
be resolved with the use of inducible transgenic systems. Added to that, conditional 
expression systems such as the tetracycline-controlled system have also proved useful 
in revealing mechanisms such as oncogene addiction. This is possible with 
conditional systems because expression of a gene can be switched on or off in the 
presence or absence of its inducer (Allred and Medina, 2008). 
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1.2.14 The tetracycline conditional expression system 
The basic components required in conditional inducible systems are an 
inducing agent, a regulatory unit and a responsive element linked to the promoter of a 
gene of interest (Figure 1.7a). The tetracycline-controlled transcriptional regulator is 
one of the most widely used conditional systems. Two variants of the system exist, 
namely, the tTA (tet-off system) and the rtTA (tet-on system). In each system, there 
are two features required. First, either the tTA or rtTA will be driven by a constitutive 
promoter. Second, the gene of interest will be under the control of a tetracycline 
responsive element (TRE) which is made up of promoter sequences from human 
cytomegalovirus promoter IE (Pcmv) and E. coli tet operator (tetO) sequences 
(Gossen and Bujard, 1992).  The tTA unit consists of the tetracycline repressor (tetR) 
fused with the transcription activation domain of virion protein 16 (VP16) of herpes 
simplex virus. When doxycycline (dox), an analogue of tetracycline is present, it 
induces a conformational change in tTA, causing it to dissociate from the TRE. As a 
result, the gene of interest will not be transcribed in the presence of dox, hence the tet-
off system (Figure 1.7b). The rtTA system works in a similar fashion except that the 
rtTA is a mutant derivative of tTA which only binds TRE in the presence of dox. With 
the rtTA, presence of dox will then switch on expression of a gene of interest (Figure 
1.7c).  
The main advantages of the rtTA system are that gene expression can be 
reversibly switched on rapidly in the presence of dox and off by removing dox. In 
contrast to the tTA system, there is less delay and no need to administer dox for long 
periods to keep a gene off, especially while growth and development is taking place. 
However, the setback of the rtTA system is leaky expression due to undesired 
interactions between rtTA and the TRE when dox is not present.  Despite its leaky 
expression, the rtTA system has been used successfully to discern phenotypes as a 
consequence of transgene induction (Ray et al., 1997, Zheng et al., 2000). 
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Figure 1.7 The tetracycline inducible system. (a) Basic components of the 
system; doxycycline as inducing agent, TetR fused with VP16 as the regulatory 
element , tetO and Pcmv as the responsive element. (b) The tTA system: In the 
presence of dox, tTA is unable to bind the TRE element and transgene expression is 
switched off. (c) The rtTA system: Presence of dox allows rtTA to bind to TRE 
element inducing expression of transgene. 
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1.2.15 Transplantation models of breast cancer  
An alternative approach to modelling breast cancer has been the use of cell 
lines for transplantation into the mouse. This could either be syngeneic transplants of 
murine cells into an appropriate host, giving rise to allografts or the transplant of cells 
into immuno-compromised mice, resulting in xenografts. All of these approaches 
have their limitations and advantages. Xenografts could produce tumours which are 
more closely related to breast cancers in human, since human cancer cell lines can be 
transplanted. However, the use of immuno-compromised mice to establish xenografts 
neglects the contribution of certain components of the immune system to tumour 
progression. In general, the use of established cancer cell lines in transplantation 
means that aspects related to tumour initiation are omitted. On the other hand, 
transplantation could be a way of rapidly elucidating questions pertaining to the latter 
steps of breast cancer progression. Hence the selection of a particular model depends 
largely on the questions to be addressed because as of now, none of the available 
models fully encompass all the features of breast cancer (Vargo-Gogola and Rosen, 
2007). 
 
1.3 NF-κB signaling 
1.3.1 NF-κB and IκB superfamily of proteins 
The NF-κB proteins are transcription factors which were initially identified as 
regulators of the immune system. There are five different subunits which can form 
homo- or heterodimers to regulate the expression of genes. Namely, these are RelA 
(p65), RelB, c-rel, p50 and p52 (Figure 1.8a). All of these subunits have a conserved 
Rel homology domain (RHD) which facilitates DNA binding and dimerization. 
However, the Rel proteins differ from p50 and p52 in two ways. Firstly, they contain 
trans-activating domains which are important in initiating transcription. Secondly, p50 
and p52 are translated from precursor proteins p105 and p100 respectively. These 
precursor proteins are inhibitor of NF-κB (IκB) proteins characterized by the presence 
of ankyrin repeats at the C-terminus (Figure1.8b). These motifs are removed upon 
partial proteasomal processing into p50 or p52 respectively. The glycine rich regions 
prevent complete degradation of the precursor protein. Apart from p105 and p100, 
other IκB proteins include IκBα, IκBβ, IκBε and Bcl-3. The IκB proteins function by 
masking the nuclear localization signal (NLS) of NF-κB subunits and thus, 
retaining
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Figure 1.8: NF-κB and IκB super-family of proteins. (a) Illustration of domains 
present in NF-κB sub-units. LZ: leucine zipper domain, RH: Rel homology 
domain, TA: trans-activating domain, GRR: glycine rich region, DD: death 
domain, numbers indicate amino acid positions, grey arrows represent points 
where proteasomal processing terminates. (b) Illustration of domains present in 
IκB family of proteins. Grey boxes represent ankyrin domains, PEST: proline 
glutamate serine threonine, TA: trans-activating domains, numbers indicate amino 
acid positions. Adapted from Perkins 2007.  
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them in the cytoplasm. Bcl-3 is an exception amongst IκB proteins because it is 
nuclear localized and can function as a transcriptional co-activator (Ghosh and 
Hayden, 2008). 
 
1.3.2 Activation of NF-κB pathways 
There are two main NF-κB pathways, namely, the canonical and alternative 
pathways (Figure 1.9). Transcriptional activity induced by canonical NF-κB signalling 
involves RelA-p50 dimers whereas the alternative pathway is dependent on RelB-p52 
dimers. In total, there are more than 150 known extracellular stimuli that can activate 
these pathways leading to diverse outcomes and this epitomizes the role of NF-κB as 
a central mediator.  Inflammatory stimuli such as tumour necrosis factor α (TNF-α), 
lipopolysaccharide (LPS) and interleukin-1 (IL-1) induce the activation of the 
canonical pathway. Stimuli across the respective receptors activate the IκB kinase 
(IκK) complex which consists of IκKα, IκKβ and IκKγ. This stimulates 
phosphorylation of IκBα at two conserved serine residues which leads to its 
proteasomal degradation. Consequently, RelA-p50 dimers can translocate into the 
nucleus and are able to induce transcription.  
Similarly in the alternative pathway, p100 preferentially binds and sequesters 
RelB in the cytoplasm. Proteasomal processing of p100 is triggered by activation of 
CD40, lymphotoxin-β receptor (LTβR), B-cell activating factor of the TNF family 
(BAFF) or receptor activator of NF-κB ligand (RANKL). Transduction of signals 
across these receptors sets off a signalling cascade involving NF-κB inducing kinase 
(NIK) and IκKα dimers, resulting in p100 phosphorylation and processing into p52. 
The loss of ankyrin domains from the C-terminus of p100 then allows translocation of 
RelB-p52 heterodimers into the nucleus  (Baud and Karin, 2009, Perkins, 2007). 
In addition to the various immune regulatory stimuli that activates the 
canonical and alternative NF-kB pathways, signalling via the epidermal growth factor 
receptor (EGFR) family members can also trigger the activation of NF-kB. This mode 
of activation is termed the atypical NF-kB pathway as it can trigger IκBα 
phosphorylation without invoking the usual IκK complexes. Instead, IκBα is 
phosphorylated by casein-kinase-II (CK2) (Sethi et al., 2007). Interestingly, CK2 can 
also induce the expression of IκKε (Eddy et al., 2005), a kinase that is able to promote 
the transactivation potential of p52 through formation of a RelA-p52-IκKε complex 
(Wietek et al., 2006). These studies highlight the complexity of interactions between 
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NF-kB subunits and hence, their involvement in physiology and pathology should not 
be limited to the canonical and alternative pathways.   
 
1.3.3 Gene targets of NF-κB 
NF-κB transcription factors can either induce or repress gene targets by 
binding to specific DNA sequences termed κB sites. In addition to the permutation of 
κB sites, the binding of specific sub-units at these sites are dependent on the 
recruitment of co-activators or co-repressors. It is through the differential recruitment 
of NF-κB subunits by co-regulators that each sub-unit plays a distinct and non 
overlapping role (Hoffmann et al., 2003). Crosstalk between other transcription 
factors such as AP-1 and C/EBPβ provides an additional layer of complexity into NF-
κB signalling. As a consequence, transcriptional output will be context dependent 
(Perkins and Gilmore, 2006).  
In general, gene targets of NF-κB have a role in immune modulation, stress 
response, proliferation, survival and apoptosis. Among these are some genes which 
have a role in cancers such as Cyclin D1, Bcl-xL, Cox2, VEGF C and c-myc. 
Paradoxically, some tumour suppressor genes such as p53 and pro-apoptotic genes 
such as Fas are also regulated by NF-κB. This reiterates the need to regard NF-κB 
signalling based on the context of specific stimuli and cell type (Pahl, 1999, Perkins, 
2007).  
 
1.3.4 Modulation of NF-κB subunit activity  
As described, activation of the main NF-κB pathways converges upon IκK 
complexes where they then induce degradation of IκB proteins to allow translocation 
of NF-κB subunits into the nucleus. Additionally, NF-κB activity is also governed by 
direct post-translational modifications. Such modifications regulate the interaction of 
NF-κB subunits with either co-activators or co-repressors and this allows integration 
of stimuli from other signalling pathways (Perkins and Gilmore, 2006). 
Despite the importance of post-translational modifications on the 
transcriptional output of NF-κB subunits, the true extent of these modifications is 
currently unknown. In the case of Rel A, examples of stimulatory phosphorylations 
which enhance its transcriptional activity include Ser-276 phosphorylation by protein 
kinase A (PKAc), Ser-311 by PKCζ and Ser-468 by glycogen-synthase kinase-3β 
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(Perkins and Gilmore, 2006). Moreover, acetylation of Rel A by p300 and CBP can 
enhance its transactivation potential (Chen and Greene, 2004). On the other hand, Rel 
A can also be subjected to inhibitory phosphorylation at Thr-505 by the checkpoint 
kinase CHK1, which inhibits its trans-activation and increases its association with 
histone deacetylase 1 (HDAC1) (Campbell et al., 2006, Rocha et al., 2005).    
  As for p52, it has been shown that this NF-κB subunit can regulate gene 
targets of the tumour suppressor p53. The co-operative regulation of these genes such 
as p21 and death receptor 5 (DR5) does not rely on the DNA binding properties of 
p52 (Schumm et al., 2006). In such cases, p52 functions by recruiting the co-activator 
p300/CBP or co-repressor HDAC1 to p53 promoter sites. This proves that the range 
of genes that can be regulated by NF-κB subunits is not restricted to those with κB 
sites. Accordingly, phosphorylation of p52 has been shown to be important in 
determining the association of p52 with co-regulators. In a study addressing the 
regulation of the Skp2 gene by p52 and p53, phosphorylation of p52 at Ser-222 by 
GSK-3β was crucial in determining whether transcription takes place. Upon 
phosphorylation of p52 by GSK-3β, p52 homodimer/Bcl-3 trans-activating complexes 
were disrupted and this shifts the balance towards formation of p52/c-rel/HDAC1 
complexes which are transcriptionally repressive. This demonstrates that Ser-222 
phosphorylation of p52 induces the formation of transcriptionally repressive 
complexes under the conditions investigated  (Barre and Perkins, 2010b).  
 
1.3.5 Role of NF-κB in development  
The function of NF-κB subunits during development have largely been 
dissected through genetically engineered knockout mouse models of individual or two 
subunits in combination (Gerondakis et al., 1999). An important anti-apoptotic role 
for NF-κB was identified from RelA 
-/-
 mice, where they die in utero due to extensive 
liver apoptosis (Beg et al., 1995). As for Nfkb1
-/-
 mice which lack both p105 and p50, 
no histo-pathological effects have been reported (Grumont et al., 1998, Sha et al., 
1995, Snapper et al., 1996). On the other hand, Nfkb2
-/-
 mice which lack both p100 
and p52 display defects in splenic micro-architecture and diminished peripheral 
lymph nodes (Caamano et al., 1998, Franzoso et al., 1998). However, when both 
Nfkb1 and Nfkb2 genes were ablated in combination, lymph nodes were absent 
altogether, suggesting overlapping and compensatory roles between p50 and p52 
which were only evident when both genes were depleted (Lo et al., 2006). Even so, 
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respective NF-κB subunits have distinct functions in the development and function of 
immune cell populations, as revealed by knockouts of Relb, c-rel, Nfkb1 and Nfkb2 
(Beinke and Ley, 2004, Gerondakis et al., 1999).   
 
1.3.6 NF-κB signalling during  post-natal mammary gland development 
Expression of RelA and p50 have been shown in mammary epithelia of virgin, 
pregnant and involuting mice (Brantley et al., 2000). The levels of these subunits 
remain low until pregnancy where its activity peaks at D16 of gestation in mice and 
drops to undetectable levels during lactation. A second wave of NF-κB signaling is 
triggered after lactation ceases and peaks by day 3 of involution (Clarkson et al., 
2000a).  
A role for NF-κB during ductal morphogenesis is highlighted by a study where 
mammary epithelial cells (MECs) with the deletion of IκBα show that the lack of this 
repressor leads to increased ductal branching and intraductal hyperplasia (Brantley et 
al., 2001). This illustrates a positive regulatory role for NF-κB towards epithelial 
proliferation and branching at this developmental timepoint. The increase in the levels 
of NF-κB in mammary epithelia are coherent with the rate of lobuloalveolar 
development during pregnancy and again this illustrates a positive regulatory role for 
NF-κB in epithelial proliferation through the regulation of Cyclin D1 (Cao and Karin, 
2003). In fact, knock in mice with a kinase inactive IκKα (IκKα 
AA/AA
) and mice over-
expressing a dominant IκBα super-repressor, both with defective NF-κB activation, 
showed defective lobuloalveolar development and lactational defects (Cao et al., 
2001b). As lactation commences, levels of NF-κB and its activity decreases and this 
can be attributed to the activation of the prolactin receptor-JAK2-Stat5 pathway which 
is important for alveolar differentiation and milk production (Hennighausen and 
Robinson, 2001). Negative crosstalk between the two pathways exists and it is likely 
that NF-κB activity diminishes when Stat5 is functionally induced (Geymayer and 
Doppler, 2000, Luo and Yu-Lee, 2000). During involution, NF-κB plays an important 
role along with Stat3 to regulate the balance of apoptotic and inflammatory stimuli 
(Clarkson et al., 2004, Watson, 2006). The presence of nuclear RelA in a 
subpopulation of non-apoptotic cells during involution supports the notion that NF-κB 
has a role in survival of mammary epithelial cells (Clarkson et al., 2000b).   
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 The dynamic and tightly regulated activity of NF-kB throughout postnatal 
mammary gland development emphasizes its importance in regulating proliferation 
and survival of MECs. 
 
1.3.7 Aberrant NF-κB activity in breast cancer  
The idea that aberrant NF-κB signaling may contribute to the aetiology and 
progression of breast cancers can be derived from observations where elevated levels 
of NF-κB subunits have been observed in breast cancer cell lines as well as primary 
human breast tumours  (Dejardin et al., 1995, Sovak et al., 1997). In another study, 
constitutive levels and DNA binding of p52, Bcl3 and c-rel were much higher in 
human breast tumors relative to adjacent normal tissue (Cogswell et al., 2000). 
However, it is only in ER negative breast cancers that elevated NF-κB activity is 
widespread and this is due to the negative crosstalk that exists between the signaling 
pathways (Nakshatri et al., 1997). While this opposing relationship exists between ER 
and NF-κB signalling, a correlative linkage between EGFR family members and NF-
κB signalling is evident (Biswas and Iglehart, 2006). This is not surprising as the 
EGFR family members can trigger NF-κB activation. In support of this, a study 
looking into 35 human breast cancer cell lines revealed that constitutive NF-κB 
activation was preferentially higher in the basal-like subtype cell lines where EGFR 
over-expression is common (Yamaguchi et al., 2009). Despite all these findings, it is 
not clear whether the activity of distinct NF-κB subunits have a role in defining the 
gene expression profiles of particular subtypes of breast cancer. 
There have been many studies which have demonstrated a role for NF-κB in 
breast carcinogenesis. From mouse models, we know that over-expression of c-rel in 
the mammary gland leads to the development of tumours and similarly for p100/p52, 
hyperplastic glands develop (Connelly et al., 2007, Romieu-Morez et al., 2003). A 
role for the canonical NF-κB pathway in tumourigenesis has been coherently 
demonstrated via over-expression of the IκBα super repressor (SR), where inhibition 
of canonical NF-κB signaling delayed the tumour latency of Neu-oncogene (Liu et al., 
2010, Pratt et al., 2009) and Polyoma middle T oncogene (PyVT) driven tumours 
respectively (Connelly et al., 2010). Moreover, these studies also demonstrated that 
NF-κB activity is important for the expansion of CaSCs (Liu et al., 2010, Pratt et al., 
2009). It is not surprising that NF-κB activity contributes to the maintenance of CaSC 
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populations, since it induces EMT and promotes metastasis in a model of breast 
cancer (Huber et al., 2004b), both of which are traits associated with CaSCs.   
 During pregnancy, the expansion of normal mammary stem cells is dependent 
on the effects of progesterone but these mammary stem cells (MaSCs) lack expression 
of hormone receptors. However, these MaSCs express receptor activator of NF-κB 
(RANK) and it is through paracrine RANK ligand (RANKL) signalling by hormone 
receptor positive cells that mammary stem cells are stimulated to proliferate (Asselin-
Labat et al., 2010). In the context of cancer, over-expression of RANK in MECs have 
been shown to promote progesterone-driven and carcinogen induced mammary 
tumours, and this effect can be mitigated through pharmacological inhibition of 
RANK. This is also true for Neu-oncogene driven tumours where tumourigenesis and 
formation of lung metastases can be decreased through RANK inhibition (Gonzalez-
Suarez et al., 2010). Similarly, ablation of RANK in mammary epithelia resulted in 
delayed onset of tumours induced by synthetic progesterone analogues in combination 
with the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) (Schramek et al., 
2010). The importance of this signalling axis in maintaining the self –renewal 
properties of CaSCs is further supported by kinase dead IκKα 
AA/AA
 knockin mice. In 
these experiments the tumourigenicity of DMBA-induced and Neu-oncogene driven 
tumours were retarded and was associated with a reduction in tumour-initiating 
CaSCs (Cao et al., 2007).  
 The extent of RANKL-RANK-IκKα signalling is not limited to regulating the 
proliferation and tumour-initiating properties of breast cancer cells. This signalling 
axis appears to play a role in breast cancer progression as well, since breast cancer 
cells stimulated with RANKL exhibit increased migration and metastatic abilities 
(Jones et al., 2006). Moreover, the metastatic spread of Neu-driven mammary tumours 
has been shown to be dependent on RANKL production by tumour-infiltrating 
regulatory T cells (Tan et al., 2011). Alternatively, RANK and RANKL expression 
can also be induced by hypoxia through hypoxia inducible factor 1alpha (HIF-1α) 
(Tang et al., 2011). Taken together, these studies demonstrate how the RANKL-
RANK-IκKα can be induced to promote metastases by various components of the 
tumour microenvironment. Overall, the RANKL-RANK-IκKα axis appears to be 
important not only in tumour initiation and maintenance of CaSCs but also in 
promoting metastasis. Although this signalling axis lies upstream of the alternative 
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NF-κB pathway, there has not been direct evidence to show a role for p52 in these 
processes.       
   
1.3.8 The NFKB2 gene and its relevance to breast cancer 
The NFKB2 gene which encodes for p52 and its IκB precursor p100 has also 
been implicated in breast cancer. In mouse models of breast cancer, high levels of p52 
have been found in mammary gland tumours from MMTV-PyVT mice (Connelly et 
al., 2007). Increased RelB-p52 DNA binding was also detected in DMBA induced 
mammary tumours (Demicco et al., 2005).     
In addition, the levels of RelB, which dimerizes with p52 in the alternative 
pathway, have been shown to be higher in ER negative breast cancer cell lines (Wang 
et al., 2007). Notably, RelB knockdown in these cells inhibited their invasive 
phenotype, illustrating an important role for RelB and possibly p52 mediated 
transcription in metastasis.  
As of now, evidence for a role of p52 in tumour initiation and breast cancer 
progression remains inadequate. Although increased p52 levels and DNA binding 
have been observed in some of the studies, the transcriptional activity of p52 would be 
a better gauge of its aberrant role in cancer. This is because p52 dependent 
transcription can be regulated by other means such as the levels of trans-activating 
partners and its preference for forming active or repressive transcriptional complexes  
(Rocha et al., 2003). Furthermore, it has recently been demonstrated that post-
translational modifications such as phosphorylation at serine-222 regulates the type of 
p52 complexes formed (Figure1.10) (Barre and Perkins, 2010b). Such insights 
warrant the need for further investigations to fully understand p52’s role in breast 
cancer and to evaluate its potential as a therapeutic target. 
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1.4 Aims & Objectives 
During mammary gland involution, cell death is an important feature which 
allows its regression to a state that is similar to pre-pregnancy. However, the exact 
mechanisms responsible for cell death and whether caspases have a key role during 
involution is unclear. Hence, the aim of the initial study was:  
 
• To address the effects of caspase inhibition during mammary gland involution.  
 
Whilst it is well accepted that the ability to evade apoptosis is essential for 
tumourigenesis and metastasis, evidence for this has come from genetic studies 
involving regulators of apoptosis rather than the core caspase machinery itself. In 
addition, many of these apoptosis regulators have additional roles apart from 
inhibiting caspase activation. For that reason, experiments in this section were aimed:  
 
• To substantiate the importance of evading apoptosis during breast cancer 
progression. 
 
As described, evading apoptosis is an important feature of cancer cells and 
thus, disrupting a central regulator of apoptosis would be a sensible therapeutic 
strategy. The NF-κB pathway regulates a number of anti-apoptotic genes in mammary 
epithelial cells. Moreover, various genes pertinent to angiogenesis, proliferation and 
metastasis are regulated by NF-κB. It is known that the canonical pathway is 
important for tumourigenesis in ErbB2
+
 breast cancers. In the case of the alternative 
NF-κB pathway, although increased levels of p52 have been observed, a role for p52 
and its potential as a therapeutic target remains to be addressed. Accordingly, through 
genetic manipulations on breast cancer cell lines we aim: 
  
• To determine the effects of silencing Nfkb2 in breast cancer cells. 
• To address the potential of diminishing p52 activity by promoting Ser-222 
phosphorylation in breast cancer cells. 
 
Based on the observed differential effects of silencing Nfkb2 on different cell 
lines, we went on to address whether particular subtypes of breast cancer are more 
Chapter I: An introduction to the mammary gland, breast cancer and NF-κB signaling 
 
 
  SK Yeo                                                                 - 39 -                                               Cardiff University 
dependent on p52 activity.  Consequently in the final part of the study, the objective 
was: 
• To identify possible correlations between p52 levels and breast cancer 
subtypes. 
 
 - 40 - 
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2 Materials and methods 
2.1 Animal experiments 
 Maintenance, breeding and scientific procedures involving animals were 
carried out according to the guidelines set by the U.K. Home Office Regulations 
(Animals [Scientific Procedures] Act 1986). 
 
2.1.1 Animals 
P35 transgenic mice were generated by N. Omidvar in our lab. In these mice, 
the p35 transgene is under the control of a second generation tetracycline-regulatable 
promoter (Agha-Mohammadi et al., 2004). MMTV-rtTA and MMTV-Neu mice have 
been previously described (Guy et al., 1992, Gunther et al., 2002). These mice were 
acquired from Jax Mice and Services (Bar Harbor, Main, US). All mice were in-bred 
onto FvB genetic backgrounds for at least 6 generations to obtain appropriate 
transgenic animals for experiments. 
 Transgenic animals were fed with RM3 (E) expanded diet (Special Diets 
Service, Surrey, UK) and tap water ad libitum. Mice were housed in specific cages 
(maximum of 5/cage) according to designated colonies. Lights were kept constant at a 
12  hour day/night cycle in breeding rooms. By about 4 weeks of age, mice were 
weaned and ear-marked for identification purposes. 
 For transplantation experiments, BalbC and NOD/SCID/BalbC mice of six to 
eight weeks of age were obtained from Charles River Laboratories (Wilmington, US). 
BalbC mice were housed in conventional cages and maintaned in similar conditions as 
transgenic FvB mice. NOD/SCID/BalbC mice were housed in individually vented 
cages (Allentown Inc., New Jersey, US) and were fed with Teklad global 19% protein 
extruded rodent diet (Harlan Laboratories, Indianapolis, US) along with water ad 
libitum. These cages were housed in a room with 12 hour day/night cycles. To ensure 
sterile habitation, chow, water, saw dust and water bottles were autoclaved before use. 
Procedures involving NOD/SCID/BalbC mice were carried out in a sterilized laminar 
flow hood (Allentown Inc., New Jersey, US). 
 
2.1.2 Genotyping 
To identify mice with desired transgenes, mice were genotyped by polymerase 
chain reaction (PCR) at 6-8 weeks of age. For this, DNA was obtained from tail or ear 
biopsies upon weaning at 4 weeks of age. 
Chapter 2: Materials and Methods 
 
 
  SK Yeo                                                                 - 42 -                                               Cardiff University 
2.1.2.1 DNA extraction   
Ear or tail biopsies were collected in 1.5ml micro-centrifuge tubes and stored 
at -20
o
C until ready for extraction. DNA isolation was preceded by lysing tissues in 
500ul of lysis buffer (100mM Tris-HCl; pH8.5 [Sigma], 5mM EDTA [Fisher 
Scientific, Loughborough, UK], 0.2% w/v sodium dodecyl sulphate [SDS; Sigma], 
200mM NaCl [Fisher Scientific, Loughborough,UK]) and 5ul of 20mg/ml proteinase 
K (Roche, Welwyn Garden City, UK) overnight at 55
o
C. Lysed tissues were then 
mixed thoroughly and centrifuged for 10 minutes at a speed of 10,000rpm. The 
supernatant was then extracted and an equal volume (~500ul) of isopropanol (Fisher 
Scientific, Loughborough, UK) was added. The mix was left for 5 minutes to allow 
precipitation of DNA. Then, samples were centrifuged for 5 minutes to obtain a DNA 
pellet. After removal of isopropanol, 70% ethanol was added to the pellet without 
agitation to wash off any residual isopropanol. Consequently, the ethanol was 
discarded and the pellet was left to dry at 55
o
C before reconstitution in 100ul of 
nuclease free water at 55
0
C for an hour. The reconstituted DNA samples were then 
utilized in PCR reactions as depicted in Tables 2.1-2.3. 
 
2.1.2.2 Generic PCR protocol 
DNA oligoneucleotides (Sigma-Genosys, Dorset, UK) for priming PCR 
reactions were designed using primer 3 software (http://frodo.wi.mit.edu/primer3/) or 
obtained from previously published sequences (Table 2.2). The sequences of primers 
used were validated by in silico PCR software to prevent any potential mis-priming 
(http://genome.csdb.cn/cgi-bin/hgPcr). 
In general, PCR reactions were set up with 2ul of extracted DNA or with 
nuclease free water as negative controls. Reactions were carried out in 0.2ml 8-strip 
PCR tubes and 23ul of mastermix was added per reaction. The mastermix contains 
other reaction components as described in Table 2.3. Upon addition of mastermix to 
DNA samples, solutions were mixed by gentle pippetting. Then, reaction samples 
were spun briefly in a Technico Mini Centrifuge (Fisher Scientific, Loughborough, 
UK) before loaded into an iCycler PCR machine (BioRad, Hempstead, UK) according 
to respective cycling conditions (Table 2.1).  
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2.1.2.3 DNA gel electrophoresis 
DNA gels were prepared by dissolving agarose tablets (Bioline, London, UK) 
in Tris-Acetic Acid-EDTA (TAE) buffer (Sigma, Dorset, UK) with addition of 
SafeView nucleic acid stain (NBS Biologicals, Huntingdon, UK) to a final 
concentration of 0.006% (v/v). All PCR products were resolved alongside a DNA 
marker, Easyladder I (Bioline, London, UK), in 3% agarose gels ran in TAE buffer at 
150V for 25 minutes. Separated DNA was then visualized under UV light with the aid 
of a GelDoc imager (BioRad, Hampstead, UK). 
 
 
 
  rtTA p35 N2/NK 
Reaction 
Step 
No. 
Cycles 
Temp Time No. 
Cycles 
Temp Time No. 
Cycles 
Temp Time 
  (°C) (°C) (°C) 
Initial  1 94 2 min 1 94 2 min 1 94 2 min 
Denaturation 
Denature 30 95 30 sec 15 95 30 sec 35 94 30 sec 
Anneal 59 30sec 74* 30 sec 60 30 sec 
Extension 72 40 sec 72 25 sec 72 1 min 
Denature - - - 26 95 30 sec - - - 
Anneal - - 58 30 sec - - 
Extension - - 72 25 sec - - 
Final 
Extension 
1 72 5 min 1 72 4 min 1 72 5 min 
Hold 1 4 ∞ 1 4 ∞ 1 4 ∞ 
*Decrease 2
o
C after every 2 cycles. 
 
Table 2.1: Cycling conditions for PCR reactions. 
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Table 2.2: Sequence of primers used for genotyping. 
 
 
 
Table 2.3: Composition of PCR reactions. 
 
 
 
 
 
Primer 
 
 
Sequence 
 
Product 
Size 
 
MMTV-rtTA   S 
MMTV-rtTA   AS 
 
5’-ATC CGC ACC CTT GAT GAC TCC G -3’ 
5’-GGC TAT CAA CCA ACA CAC TGC CAC -3’ 
 
349bp 
 
P35   S 
P35   AS 
 
5’-GTG TAC GGT GGG AGG CCT AT -3’ 
5’-GAT CGC TGT AAT CGC GTT CT -3’ 
 
320bp 
 
 
MMTV-Neu   S 
MMTV-Neu   AS 
 
5’-TTT CCT GCA GCA GCC TAC GC -3’ 
5’-CGG AAC CCA CAT CAG GCC -3’ 
 
600bp 
 
PCR Reaction Component 
 
rtTA 
 
P35 
 
Neu 
 
Crude DNA  
 
2µl 
 
2µl 
 
2µl 
PCR-grade Water (Sigma) 13.75µl 14µl 15.5µl 
Go Taq PCR Buffer (Promega) 5µl 5µl 5µl 
 Magnesium Chloride (25mM; Promega) 2µl 2µl 2.5µl 
 dNTPs (25mM; dATP, dCTP, dGTP, dTTP; Promega) 1µl 1µl 0.2µl 
Forward Primer (Sigma Genosys, 10µM) 0.5µl 0.25µl 0.1µl 
Reverse Primer (Sigma Genosys, 10µM) 0.5µl 0.25µl 0.1µl 
Go Taq DNA Polymerase (Promega) 0.25µl 0.5µl 0.1µl 
Total Reaction Volume 25µl 25µl 25µl 
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2.1.3 Experimental procedures involving animals 
2.1.3.1 Doxycyline administration 
For involution experiments, induction of p35 transgene in rtTA/p35 animals 
were achieved via doxycycline (Sigma, Dorset, UK) administration in drinking water 
at a concentration of 2mg/ml with 5% sucrose (Sigma, Dorset, UK) in opaque 
drinking bottles for 7 days prior to tissue harvest. Doxycycline was also administered 
at a concentration of 100ug in 100ul of saline, intra-peritoneally as indicated in 
experimental sections. 
 In primary tumour growth and metastasis experiments involving 
rtTA/p35/Neu transgenic mice, doxycycline was administered in drinking water 
(2mg/ml doxycycline; 5% sucrose) when tumours reached 5mm in diameter until 
tumours reached 20mm in diameter. Doxycycline solutions were changed twice a 
week along the course of treatment.  
 
2.1.3.2 Orthotopic cell transplants 
Before transplantation, cells were prepared as single cell suspensions. This 
was done by washing the cells in serum free L-15 media (Invitrogen, Paisley, UK), 
then serum free Joklik’s media before another wash in serum free L-15. Cells were 
then passed through a 40um cell strainer (BD Biosciences, Oxford, UK) and kept on 
ice until ready for transplantation. 
For 4T1 and N202.1A cell transplants, Balb/C and NOD/SCID/Balb/C mice 
respectively which were between 8-12 weeks old were used. Before surgery, the mice 
were anaesthetized using a vaporizer to deliver 5% isoflurane (Abbot, Maidenhead, 
UK) with oxygen at a flow rate of 0.8 l/min and nitrous oxide at a flow rate of 0.4 
l/min in an induction chamber. When the animal was anaesthesized, isofluorane was 
delivered at 2.5% through an anaesthetic mask. Consequently, a small patch of fur 
that is dorsal to the fourth abdominal mammary gland is removed and cleaned with 
surgical scrub. Then, a small superficial incision was made to expose the abdominal 
mammary gland and cells were injected directly into the mammary fat pad with a 
Hamilton or 29G needle syringe (BD Micro-Fine). The lymph nodes in the fourth 
abdominal gland were used to orientate the point of injections, where cells were 
transplanted dorsal to the lymph nodes. Wounds were then sealed with Vetbond 
Tissue Adhesive (3M). Animals were then allowed to recover in a temperature 
regulated chamber at 30
0
C for 15 minutes. 
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2.1.3.3 Tumour monitoring and measurementss 
Endogenous tumours from mice carrying the Neu transgene or mice transplanted 
orthotopically with mammary cancer cells were inspected at least twice weekly for 
tumours via palpation. The growth kinetics of tumours were charted by measuring the 
diameter of tumours using digital calipers (Fisher Scientific, Loughborough, UK). The 
size of tumours were calculated as volume in mm
3
 using the formula; Volume = 
(Length X Width
2
)/2. 
 
2.2 Tissue sampling and processing 
2.2.1 Removal and fixation of tissues 
At appropriate experimental endpoints, animals were culled by cervical 
dislocation and subjected to necropsy. 
 
2.2.1.1 Mammary tissues for involution studies 
Animals used for involution studies underwent forced involution at day 9 of 
lactation and tissues were harvested at either 48 or 72 hours after the removal of pups. 
The number of pups per experimental mouse during lactation was kept around 8-12 
and this was to ensure coherent initiation of involution upon forced weaning. Before 
extraction of mammary tissues, the lymph nodes in the fourth abdominal glands were 
excised and discarded. The left abdominal gland was then removed and fixed in 4% 
formalin for histological analysis. For protein and RNA analysis, the remaining 
abdominal and inguinal glands were snap frozen and stored at -80
o
C.    
 
2.2.1.2 Tissues for tumour studies 
Mice were allocated into either doxycyline positive (dox+) or negative (dox-) 
cohorts when tumours reached 5mm in diameter. Respective cohorts of mice were 
then maintained with or without water containing doxycyline until experimental 
endpoints, where tumours were about 3200mm
3
. Upon necropsy, the left abdominal 
mammary gland, liver, lung and a portion of tumour from experimental mice were 
fixed in 4% formalin for histological analysis. The remainder of tumour and normal 
mammary gland tissues was snap frozen and stored at -80
o
C until required for 
molecular analysis.  
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 Tumour sections from BRCA2
-/- 
p53
-/-
 mice were a kind gift from Trevor Hay 
and Alan Clarke from Cardiff School of Biosciences. These mice have been described 
in (Hay et al., 2009). 
 
2.2.2 Tissue processing and sectioning for histology 
After fixing tissues in 4% formaldehyde for 4-8 hours, tissue processing and 
sectioning was carried out by the Histology Unit in Cardiff School of Biosciences. 
 
2.2.2.1 Dehydration of tissues 
Parafin emdedded sections were prepared by the School of Biosciences 
Histology Unit. With the aid of a Leica TP1050 automatic processor in the Histology 
Unit, tissues were dehydrated in a series of solvents for the designated amounts of 
time; 70% ethanol for 1 hour, 95% ethanol for 1 hour, 100% ethanol for 1.5 hours 
twice, 100% ethanol for 2 hours, xylene for 1 hour twice and paraffin for 2 hours 
twice. Following that, tissues were embedded in paraffin wax for sectioning into 5um 
thick slices with the aid of a Leica RM2135 microtome cutter. Tissue sections were 
then immobilized onto poly-L-lysine (PLL) coated slides (Thermo Fisher, 
Loughborough, UK) and heated at 58
o
C for 24 hours. Slides were then stained with 
H&E or used for immuno-histochemistry (IHC).  
 
2.3 Histological analysis of tissue sections 
2.3.1 Dewaxing and rehydration 
Paraffin was removed and tissues were rehydrated by incubating slides in a 
series of solvents for the designated amounts of time; 100% ethanol for 2 minutes 
twice, 95% ethanol for 2 minutes, 70% ethanol for 2 minutes and a rinse in distilled 
water. 
 
2.3.2 Haematoxylin and eosin (H&E) staining 
Slides were stained with H&E after dewaxing and rehydration. This was 
achieved by staining in Meyer’s  Haemalum (Thermo Fisher, Loughborough, UK) for 
5 minutes, followed by a wash under running tap water for 5 minutes. Consequently, 
slides were counterstained in 1% aqueous Eosin (Thermo Fisher, Loughborough, UK) 
for 5 minutes before being washed with tap water for 15 seconds twice. Finally, slides 
were dehydrated, cleared and mounted as described in section 2.3.3.4. 
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2.3.3 Immuno-histochemistry (IHC) 
In general, immuno-labelling of tissue sections was carried out according to 
the sections below and specific alterations for particular antigens are described in 
Table 2.4.  
 
 
 
 
 
Table 2.4: Details of antibodies and conditions used for immuno-histochemistry. 
 
 
 
 
 
 
 
 
 
 
 
 
Antigen 
1
o
 Antibody 
source 
Catalogue 
number 
1
o
 Antibody 
species  
Antigen 
retrieval 
Dilution 
ratio 
 
Cleaved  
Caspase-3 
 
Cell Signalling 
 
9661 
 
Rabbit 
 
 
Pressure 
cooker 
 
1:200 
Ki-67 
 
Vector Labs VP-K452 Mouse Boling 
water bath 
1:20 
p100/p52 
 
Santa Cruz Sc-7386 Mouse Pressure 
cooker 
1:200 
p63 Abcam Ab59561 Mouse Pressure 
cooker 
1:200 
ErbB2 Cell Signalling 2242 Rabbit Pressure 
cooker 
1:200 
CK-14 Lab Vision LL002 Mouse Pressure 
cooker 
1:1 
Vimentin Santa Cruz Sc-7557 Goat Pressure 
cooker 
1:100 
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2.3.3.1 Antigen retrieval and prevention of endogenous staining 
Epitope presentation and antigen retrieval was carried out either by heat alone 
or in a pressure cooker. In the case of heat mediated antigen retrieval, slides were 
boiled in citrate buffer at working concentration (Thermo Scientific, Loughborough, 
UK) for 20 minutes. The buffer was preheated to 99.9
o
C and placed in a coplin jar 
(Thermo Fisher, Loughborough, UK), which is placed in a waterbath to maintain the 
temperature. 
For antigen retrieval using a pressure cooker, the chamber was filled with 
citrate buffer to a level that will ensure slides were fully immersed. The buffer was 
pre-heated to the point of boiling before slides were inserted into the chamber. Slides 
were then heated under pressure for 8 minutes. Consequently, slides that were treated 
with heat alone or with pressure cooker were left to cool at room temperature for at 
least 30 minutes. After a wash with distilled water for 5 minutes, tissue sections were 
treated with 3% hydrogen peroxide solution (Sigma, Dorset, UK) for 20 minutes. 
Then slides were washed in distilled water for 5 minutes twice followed by a 5 minute 
wash in PBS/T (Phosphate buffered saline plus 0.1% TWEEN-20 [Sigma, Dorset, 
UK]). To reduce non-specific antibody interactions, sections were blocked with a 5% 
serum solution from the host species of the secondary antibody (Dako, Ely, UK) made 
up in PBS/T for 20 minutes at room temperature.   
 
2.3.3.2 Antibody incubation 
Slides were then incubated with respective primary antibodies at working 
concentrations as described in Table 2.5. Antibodies were diluted in 5% BSA made up 
in PBS/T. Incubations were carried out in a humidified chamber at 4
o
C overninght 
before slides were washed three times in PBS/T. Consequently, biotinylated antibody  
(DAKO, Ely, UK) of the appropriate species was added onto slides at a dilution ratio 
of 1:200, made up in 5% BSA with PBS/T. 
 
2.3.3.3 Amplification of signal and visualization of positivity by 3,3’-
diaminobenzidine (DAB) 
In order to amplify the signal for immuno-detection, an avidin-biotin complex 
(ABC) based kit, Vectastain ABC kit (Vector Labs, Peterborough, UK) was used. 
ABC reagent was prepared 30 minutes before usage by adding a drop of reagent A 
followed by a drop of reagent B in 5mls of PBS/T and the mixed reagents were 
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vortexed briefly. Upon completion of incubation with secondary antibody, slides were 
washed thrice for 5 minutes in PBS/T. Then, the ABC mix was applied onto slides 
and incubated at room temperature for 30 minutes. After that, slides were washed 
three times in PBS/T for 5 minutes. Signal visualization was achieved using a DAB+ 
kit (DAKO, Ely, UK), which was prepared by mixing a drop of chromogen with 1ml 
of substrate buffer. The resulting solution was then applied onto slides at room 
temperature for 5-10 minutes. Once, brown staining can be visualized, slides were 
washed for 5 minutes in PBS/T followed by two washes for 5 minutes in distilled 
water.   
 
2.3.3.4 Counter-staining, dehydration, clearing and mounting of slides 
Consequently, slides were counterstained with Meyer’s Haematoxylin 
(Thermo Fisher, Loughborough, UK) for 45 seconds. Slides were then washed in 
running tap water. Dehydration of sections was achieved by immersing slides in a 
series of solvents; 70% ethanol for 30 seconds,  95% ethanol for 30 seconds, 100% 
ethanol for 30 seconds twice, xylene for 2 minutes twice. Finally, slides were 
mounted with DPX solution and appropriate sized cover slips. 
  
2.3.4 Terminal deoxy-nucleotidyl transferase dUTP nick end labeling 
(TUNEL) 
Slides were de-waxed and rehydrated as detailed in section 2.3.1. Then, slides 
were pre-treated with 20ug/ml proteinase K diluted in PBS by direct application onto 
slides for 15 minutes. Slides were then washed twice in distilled water for 2 minutes. 
After that, endogenous peroxidase activity was quenched by incubating slides with 
3% hydrogen peroxide solution (Sigma, Dorset, UK) for 5 minutes at room 
temperature. Post-incubation, slides were washed twice with distilled water for 5 
minutes. 
 TUNEL staining was carried out with the aid of Apoptag Peroxidase in situ 
apoptosis kit (Milipore, Watford, UK). The next step involved incubation of slides 
with 75ul/5cm
2 
equilibration buffer which is provided with the kit for 10 seconds at 
room temperature. Consequently, sections were incubated with 55ul/5cm
2 
working 
strength terminal deoxynucleotidyl transferase (TdT) made up in reaction buffer for 1 
hour at 37
o
C. Upon incubation, slides were then immersed in working strength 
stop/wash buffer, agitated for 15 seconds and incubated for 10 minutes at room 
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temperature. During this time, the required amount of anti-dioxygenin conjugate was 
warmed up to room temperature. Then, slides were washed thrice in PBS for 1 
minute. Following that, 65ul/5cm
2
 of anti-dioxygenin conjugate was applied to slides 
and incubated in a humidified chamber for 30 minutes at room temperature. After 
that, slides were washed four times in PBS for 2 minutes each. Next, slides were 
developed by incubating with 75ul/5cm
2 
of working strength peroxidase substrate for 
3-6 minutes. Color development can be monitored under the microscope to gauge 
incubation times. Slides were then washed thrice for 1 minute in distilled water, 
followed by 5 minute incubation in distilled water at room temperature. Counter-
staining, dehydration and mounting of slides were carried out according to section 
2.3.3.4. 
 
2.3.5 Visualization and quantification of stained sections 
Tissue sections were visualized using an Olympus BX41 Light Microscope 
(Olympus, Essex, UK) and images were captured with a Colorview III camera (5 
megapixel, Soft Imaging Systems) utilizng Analysis Software (Version 3.2, Build 
831, Soft Imaging Systems).   
 
2.3.5.1 Quantification of luminal bodies during mammary gland involution 
For quantification of luminal bodies, three random 10x magnification images 
were taken per mammary gland section and the number of luminal bodies counted. 
The mean between these different fields of view were then used to calculate the 
average number of luminal bodies between cohorts of transgenic animals. Cleaved 
caspase-3 negative luminal bodies were quantified as a percentage of total luminal 
bodies present per field of view. 
 
2.3.5.2 Quantification of cleaved caspase-3 and Ki67 positive cells in tumour samples 
Similarly, quantification of cleaved caspase-3 or Ki-67 positive cells in 
tumours was done by taking three random 10x magnification images per section. The 
mean between these different fields of view were then used to calculate the average 
number of positively stained cells. In the case of lung metastases, the percentage of 
positively stained cells was calculated because metastatic nodules were of varying 
sizes within a field of view. 
2.3.5.3 Scoring and ranking of BRCA2-/- p53-/- (BAP) tumours 
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The degree of staining for p100/p52, ErbB2, p63, CK14 and vimentin for each 
tumour section was calculated based on a score. This score was derived from the 
product of two individual scores measuring percentage cover (P) and intensity (I) of 
staining for respective antigens. Scores for percentage cover were between 0-3, where 
0 indicates no staining, 1 for tumour sections with upto 10% of cells stained, 2 for 
tumour sections with between 10-50% of cells stained and 3 for sections with more 
than 50% of cells stained. Scores for intensity were allocated as follows; 0 for no 
staining, 1 for low degree of staining, 2 for moderate degree of staining and 3 for high 
degree of staining. The product of both scores (IxP) would then give rise to an overall 
score which is between 0-9 for each tumour section. Tumours were then ranked based 
on the score for p100/p52 and the corresponding relationship with other antigens 
determined using Spearman’s ranked correlation statistical test.     
 
2.4 DNA sub-cloning and vectors 
2.4.1 Amplification of DNA constructs and general cloning procedures 
2.4.1.1 Transformation of E. coli with DNA 
In general, competent E. coli cells (C2984; NEB, Herts, UK) were transformed 
with DNA constructs by heat shock protocol. With lentiviral vectors that contain long 
terminal repeat (LTR) sequences, Stbl-3 competent E. coli cells (Invitrogen, Paisley, 
UK) were used to prevent unwanted homologous recombination. Before 
transformation, about 50ng of circular DNA was added to bacterial cells and allowed 
to thaw at 4
o
C for 30 minutes. Then cells were immersed in a water bath set at 42
o
C 
for 45 seconds. Bacterial cells were then returned on ice for 2 minutes. Consequently, 
250ul of SOC media (NEB, Herts, UK) were added to bacterial cells and incubated at 
37
o
C for 1 hour. Then cells were spread and plated out onto ampicilin containing agar 
(Invivogen, San Diego, US) coated plates. Plates were incubated for 12-16 hours at 
37
o
C. Resulting colonies were then picked and grown in 2mls of TB-Amp media 
(Invivogen, San Diego, US) for 8 hours with constant agitation. For maxi-prep 
cultures, 1ml of the resulting culture is removed and incubated with 200mls of TB-
Amp media in a 500ml conical flask at 37
0
C for 12 hours with constant agitation. For 
DNA isolation, cells were then pelleted by centrifugation at 5000rpm for 10 minutes. 
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2.4.1.2 Isolation of DNA from bacterial cells 
DNA was isolated from pelleted bacterial growth cultures using QiaPrep 
MiniPrep Kit, Plasmid Maxi Kit or EndoFree Plasmid Maxi Kit (Qiagen, Sussex, UK) 
depending on the size of cultures and amount of DNA to be extracted. Isolation was 
carried out according to the manufacturer’s instructions. In cases where plasmids were 
to be used for transfections, the EndoFree Plasmid Maxi Kit was used. 
 
2.4.1.3 Restriction digest and ligation reactions 
All restriction enzymes were obtained from Promega (Southampton, UK) or 
NEB (Hertz, UK) and enzymatic reactions were carried out in 50ul reaction volumes 
(Table 2.5). In the case of double digests, the appropriate buffer recommended for 
optimal activity of both enzymes was used. Ligation reactions were carried out in 10ul 
reaction volumes and a vector to insert molar ratio of 1:3 was used. 
 
 
 
Table 2.5: Reaction volumes and components for single or double restriction enzyme 
digests. 
 
2.4.2 Packaged Nfkb2 shRNA lentiviral vectors 
Packaged lentiviral vectors encoding shRNA against Nfkb2 (NM_019408) or 
non-target (NT) (SHC002V) control sequences were obtained from Sigma. The vector 
backbone contains a U6 promoter which drives shRNA expression and human 
phosphor-glycerate kinase (hPGK) eukaryotic promoter which drives expression of a 
puromycin resistance gene. 
 
Restriction enzyme digests 
 
Single digest 
 
Double digest 
 
Plasmid DNA (1ug/ul) 
 
1µl 
 
1µl 
PCR-grade Water (Sigma) 43µl 42µl 
10X restriction enzyme buffer 5µl 5µl 
Enzyme A 1µl 1µl 
Enzyme B - 1µl 
 
Total Reaction Volume 
 
50µl 
 
50µl 
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2.4.3 Sub-cloning of p52 constructs into lentiviral vectors 
Plasmids containing wild-type (WT), S222A, S222D or DNA binding mutant 
(DBM) sequences of p52 within a pCMV-HA backbone  were obtained from 
Professor Neil Perkins (Newcastle University). The respective HA-p52 and mutant 
sequences were excised by XbaI-PstI restriction enzyme (Promega, Southampton, 
UK) digestion, extracted after DNA gel electrophoresis, purified using DNA gel 
purification kit (Qiagen, Sussex, UK) and then ligated with XbaI-PstI digested P305 
lentiviral plasmid. (Dr. Riccardo Brambilla, Cardiff University). After ligation of p52 
inserts into p305 vector with T4 DNA Ligase (NEB), constructs were checked by 
XbaI-PstI or XbaI-EcoRV digestion (Figures 2.1a&b). Respective plasmids were then 
sent to the DNA Sequencing Core, Cardiff University to ensure the p52 constructs had 
the appropriate mutated base sequences (Figure 2.1c). The appropriate p52 sequences 
were located downstream of the hPGK promoter in the p305 vector. Primers used for 
sequencing are detailed in Table 2.6. The lentiviral construct was then kindly 
packaged by Dr. Riccardo Brambilla. The p305 plasmid also contains an IRES-GFP 
sequence 3’ of the p52 insert site. 
 
2.4.4 NF-κB Luciferase reporter plasmid 
NF-κB luciferase assays were carried out using the 3x κB luciferase reporter 
plasmid, which was a kind gift from Professor Ron Hay (University of St. Andrews). 
As controls for transfection efficiency, a pcDNA3.1 plasmid containing the LacZ 
sequence was used and this was obtained from Professor Trevor Dale (Cardiff 
University). Positive and negative controls used in luciferase assays were pGL3basic 
(Promega) and pGL3control (Promega) respectively. 
 
2.5 Maintenance and culture of cells 
2.5.1 Experimental cell lines 
4T1 cells are a highly metastatic murine mammary cancer cell line (Aslakson 
and Miller, 1992) and were obtained from Dr. Robin Anderson (University of 
Melbourne). These cells were derived from a spontaneous tumour in a Balb/C mouse. 
N202.1A cells over-express the ErbB2 oncogene and were derived from a MMTV-
Neu driven tumour from a mouse of FvB background (Nanni et al., 2000). These cells 
were a kind gift from Dr. Pier-Luigi Lollini (Sezione di Cancerologia, Italy). The 
Eph4 cell line is a spontaneously immortalized, non-transformed mammary epithelial  
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Xba I Pst 
 
p305 IRES 
GFP 
 
 
EcoR V 
p52 WT  S222A  S222D   DBM WT  S222A  S222D   DBM 
kb
10 
8 
6 
4 
3 
2 
1.5 
1.0 
Pst I + Xba I EcoR V + Xba I 
p305 (8.5kb) +  
P52 insert (1.3kb)  
Backbone (7.5kb) +  
EcoRV-XbaI insert(2.3kb)  
a 
b 
c 
WT 
S222A 
S222D 
Ser 
Ala 
Asp 
WT 
DBM 
R52A 
R54A 
222    52 54 
Figure 2.1: (a) Illustration of restriction enzyme sites within p305 plasmid. (b) 
DNA gel electrophoresis of p305:HA-p52 constructs digested with XbaI+PstI or 
XbaI +EcoRV respectively. Arrows indicate positive clones where DNA was then 
sent for sequencing. (c) Sequencing results showing p52 constructs with the 
appropriate mutated base sequences. 
Chapter 2: Materials and Methods 
 
 
  SK Yeo                                                                 - 56 -                                               Cardiff University 
 
 
 
 
 
 
 
Table 2.6: List of primers used for sequencing p305:HA-p52 plasmids. 
 
 
 
 
 
 
 
 
 
 
 
 
Primer 
 
 
Sequence 
 
p52.1 Forward 
 
5’- ATG TAC CCA TAC GAT GTG C -3’ 
 
p52.2 Forward 
 
5’- AAG GAC ATG ACT GCC CA -3’ 
 
p52.3 Forward 
 
p52 R1 
 
p52 R2 
 
p305 hPGK F 
 
5’- AGG TTC GGT TCT ATG AGG A -3’ 
 
 
5’- TCT TTG GCC TCT TGC TC -3’ 
 
 
5’- CAC AAT GGA GGA GTT CAA -3’ 
 
 
5’- CGA ATC ACC GAC CTC TC -3’ 
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cell line (Fialka et al., 1996) and was obtained from Dr. Christine Watson (Cambridge 
University). 
 
2.5.2 Maintenance of cell lines 
For the 4T1 cell line, these cells were cultured in RPMI medium (Invitrogen, 
Paisley, UK) with 10% v/v fetal bovine serum (FBS; Sigma, Dorset, UK), 2mM L-
glutamine (Invitrogen, Paisley, UK) and 50units/ml penicillin-streptomycin 
(Invitrogen, Paisley, UK). Eph4 and N202.1A cells were cultured in DMEM medium 
(Invitrogen, Paisley, UK) that is supplemented with 2mM L-glutamine and 50units/ml  
penicillin-streptomycin. FBS was supplemented into Eph4 and N202.1A cell media at 
10% and 15% v/v respectively.  
Cells were maintained in a sterile, humidified 37
o
C incubator and CO2 levels 
were kept at 5%. All cell lines were routinely cultured in T25 tissue culture flasks 
(Nunc, Leics, UK). When cells reached a confluency of 80-90%, they were passaged 
on at a split ratio of 1:6-1:12 every two days or at appropriate times. Cell passaging 
was carried out by completely removing used medium, followed by a rinse with PBS. 
Then, 2mls of 0.05% Trypsin/EDTA (Invitrogen, Paisley, UK) was added per flask 
and left to incubate at 37
o
C for 5-10 minutes. After that, cells were checked under the 
microscope to ensure that all cells have detached, before being diluted with culture 
medium according to appropriate splitting ratios. All cell lines were not split for more 
than 30 recorded passages. 
 
2.5.3 Long term cell storage 
In order to have sufficient aliquots of cell lines that were of low passage 
number, cells were frozen and cryo-stored. For that, a confluent T75 flask (Nunc, 
Leics, UK) of respective cells were detached and resuspended in 10mls of culture 
medium in a 15ml tube. Then, the cells were pelleted by centrifuging at 1100rpm for 5 
minutes. The pellet was then re-suspended in freezing medium (culture medium with 
10% v/v dimethyl sulfoxide [DMSO; Sigma, Dorset, UK]) and aliqouted into 1ml 
cryo-tubes (Nunc, Leics, UK). The tubes were then placed in a container containing 
iso-propanol to facilitate freezing at -80
o
C overnight. After that, cell aliquots were 
transferred into liquid nitrogen storage.  
 When cells were retrieved from cryo-storage, they were quickly defrosted at 
37
o
C in a waterbath, resuspended in 10mls of culture medium in a 15ml tube and 
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pelleted by centrifugation at 1100rpm for 5 minutes. The resulting pellet was then 
resuspended in 7mls of culture medium and cultured in T25 flasks.  
 
2.5.4 Cell counting 
To aid the seeding of cells in assays, cells were counted using a haemo-
cytometer counting chamber (Hawksley, Lancing, UK). For this, cells were detached 
with trypsin/EDTA as described in Section 2.5.2. Trypsinized cells were then pelleted 
by centrifugation at 1100rpm for 5 minutes and resuspended in the appropriate media. 
10ul of cell suspension was loaded into the counting chamber and the number of cells 
in four 1mm
2
 squares was quantified. The four counts were averaged and converted to 
the number of cells per ml of suspension by multiplying with 1x10
4
.   
 
2.5.5 Lentiviral transduction of cell lines 
Prior to transduction with lentivirus, 4T1 and Eph4 cell lines were seeded in 
96-well plates at densities of 10,000 cells per well, whereas N202.1a cells were 
seeded at a density of 12,000 cells per well. One day post-seeding, media was 
removed from wells and replaced with 110µls of respective culture media containing 
hexadimethrine bromide (Sigma, Dorset, UK) at a final concentration of 8ug/ml. 
Plates were gently swirled and 2-15µl of respective lentiviral stock was added per 
well. Cells were incubated at 37
o
C with 5% CO2 for 18-20 hours. After that, the 
medium in wells was replaced with 120µls of fresh culture media. Consequently, cells 
were either harvested for RNA/protein after 24 hours or passaged on to establish 
stably transduced cell lines. 
 
2.5.5.1 Generation of cell lines deficient of Nfkb2 
In order to generate cell lines deficient of Nfkb2 gene products, 4T1 cells were 
transduced with lentivirus encoding shRNA against the Nfkb2 gene (Section 2.4.2). 
4T1 cells were transduced with 5 shRNA sequnces (Table 2.7) targeting the Nfkb2 
gene and cells were then cultured in 4ug/ml puromycin to select for stably transduced 
cells. Cells transduced with lentivirus encoding GFP (Sigma, Dorset, UK) were used 
as controls to show efficiency of transduction and selection at this concentration of 
puromycin (Figure 2.2a). The levels of knockdown achieved by different shRNA 
sequences were compared with cells transduced with non-target (NT) shRNA by qRT-
PCR (Figure 2.2b). 4T1 cells transduced with sh43 and sh44 showed efficient 
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silencing of Nfkb2 and the levels of p100/p52 knockdown in these cells were verified 
by Western blotting (Section 2.6).    
 For N202.1A and Eph4 cell lines, silencing of Nfkb2 was achieved by 
transduction of respective cells with sh44 lentiviral constructs. Selection of stably 
transduced cells was achieved by culturing in 1ug/ml of puromycin for both cell lines. 
 
 
 
 
 
 
Table 2.7: List of shRNA sequences targeting the Nfkb2 gene. 
shRNA 
 
Sequence 
Mouse  
NF-κB2 
Sh43 
Sh44 
Sh45 
Sh46 
Sh47 
 
 
CCGGCCTGTCTAATCGAAATCTTATCTCGAGATAAGATTTCGATTAGACAGGTTTTT 
CCGGGCGAGGCTTCAGATTTCGATACTCGAGTATCGAAATCTGAAGCCTCGCTTTTT   
CCGGCCTGCATGTAACCAAGAAGAACTCGAGTTCTTCTTGGTTACATGCAGGTTTTT 
CCGGCGTCATTTATCACGCTCAGTACTCGAGTACTGAGCGTGATAAATGACGTTTTT 
CCGGCGGACTCCAAACAGTTCACATCTCGAGATGTGAACTGTTTGGAGTCCGTTTTT 
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Phase GFP 
a 
b 
c 
p<0.05 
Non specific band 
 α- 
Figure 2.2: Establishing stable 4T1 cell lines with Nfkb2 knocked down.        
(a) Phase and GFP image of 4T1 cells transduced with GFP expression vectors 
and selected with 4ug/ml puromycin media. (b) QPCR analysis of Nfkb2 
transcript levels normalized against GAPDH expression for 4T1 cells transduced 
with lentiviral vectors. Data is presented as mean of duplicates and error bars 
represent SEM. Significant decreases were observed for p52 43 and p52 44 
(p<0.05, one-tailed  t-test). (c) Western blot showing p100/p52 levels in 4T1 
cells. Alpha-tubulin was probed as loading control. * indicates non specific 
band. 
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2.5.5.2 Generation of cell lines over-expressing p52 
Stable 4T1 cells over-expressing either WT, S222A, S222D or DBM p52 were 
established by transduction with respective lentiviral constructs (Section 2.4.3). Cells 
successfully transduced also expressed green fluorescent protein (GFP) and were 
selected by fluorescence assisted cell sorting (FACS) using a FACS Aria cell sorter 
(BD Biosciences, Oxford, UK). Cell sorting was carried out with assistance from Dr. 
Kirsty Richardson from the Stem Cell Suite and Flow Cytometry Unit, Cardiff 
University.  
 
2.5.6 NF-κB luciferase reporter assays 
2.5.6.1 Transfection of cells with reporter plasmids 
For luciferase assays, cells were seeded into clear bottom black 96-well plates 
(Corning Inc., Lowell, US) in antibiotic free culture media. 4T1 and Eph4 cells were 
seeded at a density of 10,000 cells per well while N202.1A cells were seeded at a 
density of 12,000 cells per well.  
After 24 hours, cells were transfected with 10ng of 3x κB luciferase plasmid 
and 10ng of pcDNA3.1-LacZ plasmid per well. Empty pcDNA3.1 plasmid was also 
included to normalize the total weight of DNA transfected to 100ng. For positive and 
negative controls respectively, 10ng of pGL3control or pGL3basic were transfected in 
place of 3x κB luciferase plasmid. Transfection of cells were carried out using 
Lipofectamine LTX (0.3ul/well) with PLUS reagent (0.1ul/well) (Invitrogen, Paisley, 
UK). The appropriate amounts of plasmids were diluted in Opti-MEM media 
(Invitrogen, Paisley, UK) and PLUS reagent was added to the plasmid mixture. This 
mixture was left at room temperature for 5 minutes. Then, appropriate amounts of 
Lipofectamine LTX reagent was added to the mixture and this was incubated at room 
temperature for 30 minutes. Consequently, the transfection mixture was added 
dropwise into wells and cells were incubated for 48 hours at 37
o
C with 5% CO2. If 
cells showed signs of toxicity, media was refreshed with respective culture media 
after 24 hours. 
 
2.5.6.2 Luciferase reaction assays 
After 48 hours post-transfection with luciferase reporter plasmid, cells were 
lyzed using 50ul/well of Glo-lysis buffer (Promega, Southampton, UK). The cells 
were left on a rocker for 20 minutes. Then, 20ul of lysate from each well is removed 
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and transferred into new clear bottom black wells for measuring LacZ activity 
(transfection efficiency control). Consequently, 30ul/well of Bright-Glo luciferase 
substrate (Promega, Southampton, UK) were added to wells with 30ul of lysate to 
measure luciferase activity. In the case of lacZ activity, 20ul/well of Beta-Glo 
substrate (Promega, Southampton, UK) were added to wells with 20ul of lysate. The 
luminescence produced from either reactions were then read using a Flurostar Optima 
plate reader (BMG Labtech, Bucks, UK). The resulting luciferase activity was then 
calculated as relative light units (R.L.U), where luciferase activity was normalized 
against lacZ activity.   
 
2.5.7 Cell Titer Blue viability assays 
The viability of cells at experimental endpoints for particular assays were 
determined using Cell Titer Blue (Promega, Southampton, UK) reagent. This reagent 
allows the measurement of cellular metabolic activity using resazurin as an indicator 
dye. Viable cells which are metabolically active will have the ability to convert 
resazurin into resofurin, a highly fluorescent derivative. Hence, the viability of cells 
can be determined by measuring fluorescence levels after incubation with the 
substrate. 
Before use, Cell Titer Blue reagent was thawed to room temperature. For 
assays carried out in 96-well plates, 20ul/well of Cell Titer Blue reagent was added 
and incubated at 37
o
C with 5% CO2 for 1 hour. The resulting fluorescence was then 
measured by setting excitation/emission wavelengths to 560/590nm on a Flurostar 
Optima plate reader (BMG Labtech, Bucks, UK).  
 
2.5.8 Trypan blue exclusion cell viability counts 
In order to estimate the number of cells present in a culture, cells were lifted 
from plates by 0.05% trpsin/EDTA incubation at 37
o
C for 5-10 minutes. The cells 
were then resuspended in a known volume of culture media. Trypan blue dye was 
then added to 10ul of cell suspension at a 1:1 ratio and this was loaded onto a 
haemocytometer cell counting chamber. Only viable cells which were not stained blue 
were counted and the number of cells in a ml of suspension can be calculated by the 
average number of cells per square multiplied by 2x10
4
.   
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2.5.8.1 Proliferation assay 
For proliferation assays, 4T1, N202.1A and Eph4 cells were seeded at a 
density of 10,000 cells/well in 6-well plates (Nunc, Leics, UK). For each cell line, 
nine wells were seeded to represent triplicates of three timepoints. After 24 hours, 
cells from triplicate wells for the first time point were trypsinized and individually 
counted as described in Section 2.5.8. The same was done for each cell line at 48 
hours and 72 hours post-seeding. The average cell counts for respective cell lines 
were then plotted on a log scale, normalized against the number of cells present at 24 
hours. 
 
2.5.9 Colony formation assays 
Colony forming assays were carried out by seeding 4T1 (500cells/well), 
N202.1A (1000cells/well) or Eph4 (500cells/well) cells in 6-well plates. Before 
plating, cells were checked under the microscope to ensure that cells have been 
dissociated into single cell suspensions. After incubation at 37
o
C with 5% CO2 for 7 
days, cells were fixed with methanol:acetone (1:1) for a few seconds, air dried and 
rinsed with water. Then cells were stained with Giemsa Stain (1:10 dilution in water, 
Sigma) for 1 minute and wells were then rinsed with water. The number of colonies 
with more than 50 cells was then quantified by inspecting under a microscope.  
 
2.5.10 Boyden chamber (Transwell) migration and invasion assays 
The motility of mammary cancer cell lines was assessed by Boyden chamber 
trans-well migration assays. In this assay, cells were seeded in a chamber with porous 
membrane as solid support (cell culture insert) and this was placed into a well with 
normal culture media. Within this chamber, cells were seeded with limiting serum 
conditions and thus, cells were stimulated by a serum gradient to migrate across the 
membrane through the pores. For invasion assays, the upper side of the membrane in 
the chambers was coated with Matrigel basement membrane matrix. 
 4T1, N202.1A and Eph4 cells were suspended by trypsinization and prepared 
in respective culture media containing 0.1% FBS. 750uls of respective culture media 
with standard amounts of serum (10% for 4T1 and Eph4, 15% for N202.1A) were 
added into each 24-well cell culture insert companion plate (BD Biosciences, Oxford, 
UK). Cell culture inserts for motility or invasion assays respectively were then 
inserted into the wells containing standard culture media with the aid of a tweezer. 
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The inserts used had transparent polyethylene terephthalate (PET) membranes with 
8µm pores (BD Biosciences, Oxford, UK). For invasion assays, BD BIOCoat
TM
 
Growth Factor Reduced Matrigel Invasion chambers (BD Biosciences, Oxford, UK) 
were used. 350ul of respective cell suspensions prepared in 0.1% FBS were then 
added into the chambers in 24-well plates. 4T1, N202.1A and Eph4 cells were seeded 
at a density of 25,000 cells/chamber. Cells were then incubated at 37
o
C with 5% CO2 
for 24 hours.    
 
2.5.10.1 Visualization of migrated cells 
After the incubation period, cells were fixed by replacing the media in the top 
and bottom sections of the chamber with 70% ice cold ethanol and left for at least an 
hour. Upon fixation, inserts were washed by dipping into a beaker with tap water. 
Then, the cells on the upper surface of the insert were removed mechanically using a 
moist cotton bud. This was followed by staining of inserts in Harris’ Haematoxylin 
(Sigma, Dorset, UK) for 1 minute, a wash in tap water to remove excess stain and 
then staining in 0.5% eosin for 1 minute. Stained inserts were then washed in a beaker 
of tap water. 
 Stained membranes were then mounted onto microscope slides (R.A. Lamb, 
Loughborough, UK) with glycerol gelatin (Sigma, Dorset, UK). The glycerol gelatin 
solution was heated in a beaker of boiling water to ensure that it did not solidify. 
Membranes were excised from inserts using a sharp scalpel and transferred onto slides 
with a tweezer. Glycerol gelatin was then added onto the membrane and a coverslip 
was placed over with application of firm pressure. Slides were then air dried before 
counting. 
 
2.5.11 Anoikis and mammosphere formation assays 
2.5.11.1 Anoikis assay 
To assess the surivival of mammary cells under non-adherent conditions, cells 
were plated at a density of 10,000cells/well into 96-well ultra-low attachment plates 
(Corning Inc., Lowell, USA). As a control for the number of cells seeded, the same 
amount of cells was plated into a standard 96-well plate (Nunc, Leics, UK). After 24 
hours, the viability of cells in both plates were determined with the Cell Titer Blue 
assay (Section 2.5.7). The viability of cells under anoikis conditions was then 
determined as a percentage of fluorescence produced by cells in ultra-low attachment 
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plates normalized against fluorescence produced by cells under normal culture 
conditions.  
 
2.5.11.2 Mammosphere assay 
The mammosphere assay is a surrogate cancer stem cell (CaSC) assay which 
selects for CaSCs based on their ability to survive under non-adherent conditions and 
also their ability to self-renew and form spherical colonies. The spheres are enriched 
for stem/early progenitor cells and their self-renewal characteristics allow the 
formation of new colonies after disaggregation and re-seeding in consequent passages. 
In this assay, cells were dissociated into single cell suspensions by mechanical 
agitation and re-suspended in mammosphere culture medium which consists of 
mammary epithelial basal media (MEBM; Lonza, Slough, UK) supplemented with 
B27 (Invitrogen, Paisley, UK), 5mg/ml insulin (Sigma), 20ng/ml Epidermal growth 
factor (EGF; Sigma, Paisley, UK), 1mg/ml hydrocortisone (Sigma) and 0.0008% v/v 
β-mercapthoethanol (Sigma, Paisley, UK). Cells were seeded at a density of 
500cells/well in ultra-low attachment 96-well plates (Corning Inc., Lowell, USA) and 
incubated at 37
o
C with 5% CO2 for 7 days. Then, the number of spheres formed per 
well were quantified and the percentage of mammosphere forming units (MFUs) were 
calculated as the number of spheres formed per cells seeded. The size of spheres 
formed was determined by capturing images of individual spheres through an 
Olympus BX41 Light Microscope (Olympus, Essex, UK) and Colorview III camera 
(Soft Imaging Systems). The diameter of spheres was then measured with ImageJ 
software. 
Spheres could then be passaged on by enzymatic dissociation with 0.05% 
trypsin/EDTA and re-seeded at a similar density under mammosphere culture 
conditions. After a 7 day incubation period at 37
o
C with 5% CO2, the number and size 
of spheres in subsequent passages were determined as in the first passage.  
 
2.5.12 Treatment of cells with NF-κB inhibitor, BAY 11-7082 
Dose response curves for mammary cancer cell lines were determined by 
treating respective cell lines with BAY 11-7082 (Cayman Chemical, San Diego US) 
with concentrations ranging from 0.05µM to 5µM diluted in respective media. BAY 
11-7082 treated mammary cancer cells subjected to motility or mammosphere assays 
were maintained with 1µM BAY 11-7082 throughout the time period of the assay.  
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2.6 Protein analysis by immuno-blotting 
2.6.1 Protein extraction from cells 
For protein extraction, the medium from cells cultured in flasks were removed 
and cells were rinsed twice with ice cold PBS. Then, 5mls of PBS was added into the 
flask and cells were removed by scraping with a cell scraper (Nunc, Leics, UK). The 
solution of cells was then transferred into 15ml tubes and cells were pelleted by 
centrifugation at 1100rpm for 5 minutes. At this point, the cell pellet was either stored 
at -80
o
C or immediately used for extraction. 
 
2.6.1.1 Radio immuno-precipitation assay (RIPA) protein extracts 
RIPA protein extracts were isolated by adding 100-300ul of RIPA buffer 
(150mM sodium chloride [Fisher Scientific, Loughborough, UK], 1% v/v Nonidet-
P40 [Roche],0.1% w/v sodium dodecyl sulphate [SDS, Sigma, Dorset, UK], 0.5% w/v 
sodium deoxycholate [Sigma], 50mM Tris pH8 [Sigma]) with the addition of 
complete mini protease inhibitor tablets (Roche, Welwyn Garden City, UK) and 
phosphatase inhibitors (10mM sodium fluoride [Fluka Biochemika], 1mM sodium 
orthovanadate [Sigma], 10mM sodium pyrophosphate [Sigma]) to cell pellets from 
section 2.6.1. Cell lysing was facilitated by passing the cell pellet with RIPA buffer 
through a 23G needle 10 times, before incubation on ice for 30 minutes. Cell debris 
was then pelleted by centrifuging the lysate at 10,000rpm for 15 minutes at 4
o
C. The 
supernatant was then removed and aliquoted into fresh tubes and snap frozen. Protein 
lysates were stored at -80
o
C until required. 
 
2.6.1.2 High salt nuclear and cytoplasmic protein extraction from cells 
Cytoplasmic and nuclear protein from cells were fractionated from cell pellets 
as prepared in section 2.6.1. 400µl of NEBA+ buffer (filtered NEBA [10mM Hepes 
pH7.9, 10mM potassium chloride, 0.1mM EDTA pH8.0, 0.1mM EGTA pH8], 1mM 
1,4 dithiothreitol [DTT, Fluka Biochemika], 50mM sodium chloride, 1mM sodium 
orthovanadate, 1mM sodium pyrophosphate and one complete mini protease inhibitor 
tablet) was then added and the cell pellet was re-suspended by pipetting. The mixture 
was then placed on ice for 15 minutes. Then, 25 µl of 10% v/v Nonidet-P40 [Roche] 
was added and the mixture was vortexed vigorously for 30 seconds. After that, 
nuclear fractions were separated by centrifuging the mixture at 10,000rpm for 30 
seconds at 4
o
C. The cytoplasmic fraction which is contained within the supernatant is 
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then removed and aliqouted into 500µl tubes. Extraction of nuclear proteins were then 
achieved by adding 100ul of NEBC+ buffer (filtered NEBC [10% v/v glycerol, 20mM 
Hepes pH7.0, 0.4M sodium chloride, 1mM EDTA pH8.0, 1mM EGTA pH8.0], 1mM 
1,4, dithiothreitol, 50mM sodium floride, 1mM sodium orthovanadate, 1mM sodium 
pyrophosphate and one complete mini protease inhibitor tablet), followed by 
vortexing the mixture for 5 seconds. This mixture was then incubated on ice for 30 
minutes. To remove cell debris, the mixture was then centrifuged at 13,000rpm for 5 
minutes at 4
o
C and the supernatant which contains the nuclear fraction is aliquoted 
into 500µl tubes. Nuclear and cytoplasmic cell extracts were stored at -80
o
C until 
ready for use. 
 
2.6.2 Determination of protein concentrations 
The concentrations of protein extracts were then determined with the aid of 
BCA protein assay kit (Pierce, Loughborough, UK) according to manufacturer’s 
instructions. Respective protein samples were diluted 1:5 and 1:10 in RIPA buffer. In 
duplicates, 12.5µl of diluted sample was deposited into a 96-well round bottomed 
plate (Nunc, Leics, UK). The colorimetric assay reagent was prepared by adding BCA 
protein assay reagent A to reagent B at a ratio of 50:1 and 100µls of this mixture was 
added to each protein sample. The samples were then mixed thoroughly and left to 
incubate at 37
o
C for 30 minutes. The resulting colorimetric changes were then 
measured using a nanodrop spectrophotometer (ND-1000; Labtech International) at 
562nm. A standard curve determined from bovine serum albumin of known 
concentrations was used to extrapolate the relative concentrations of protein extracts. 
 
2.6.3 Analysis of proteins by Western blotting 
2.6.3.1 Preparation of protein samples for loading onto gel 
Protein extracts with known protein concentrations were then diluted with 
RIPA buffer to a final volume of 10µl containing between 30-70µg of protein. Then 
2.5µl of 5x Laemmli buffer (0.125M Tris-HCl pH6.8, 4% w/v SDS, 40% v/v glycerol, 
0.1% w/v bromophenol blue [Sigma, Dorset, UK], 6% v/v beta-mercaptoethanol 
[Sigma, Dorset, UK] in distilled water) was added per protein sample. Prior to loading 
onto gels, samples were denatured by heating at 95
0
C for 5 minutes. 
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2.6.3.2 Casting of polyacrylamide gels 
SDS-PAGE gels were set with the aid of Mini-Protean III (Biorad, Hempstead, 
UK) gel casting apparatus. The % of acrylamide used in resolving gels were 
dependent on the sizes of proteins to be probed. The mixture for resolving gels as 
described in Table 2.8 were poured into gel casts and allowed to set for 30 minutes. 
Then, the mixture for stacking gels (4% acrylamide, Table 2.8) was made up and 
poured on top of the resolving gel. Well combs with 10 or 15 wells were then inserted 
immediately into gel cast and the stacking gel was left to set for 30 minutes. 
Subsequently,, combs were removed and wells were rinsed with distilled water. 
 
 
 
 
Table 2.8: Composition of gels for SDS-PAGE. 
 
 
 
 
Reagent 
8% 
Resolving Gel 
10% 
Resolving Gel 
12% 
Resolving Gel 
4% 
Stacking Gel 
 
Molecular weight of 
protein 
 
40-150kDa 
 
25-100kDa 
 
15-75kDa 
 
 
- 
Distilled water 
 
4.7ml 4.1ml 3.4ml 6.1ml 
30% Acrylamide/Bis 
(Sigma) 
 
2.7ml 3.3ml 4.0ml 1.3ml 
1.5M Tris-Hcl, pH8.8 2.5ml 2.5ml 2.5ml - 
0.5M Tris-Hcl, pH6.8 - - - 2.5ml 
10% w/v SDS 100µl 100µl 100µl 100µl 
10% ammonium 
persulphate (Sigma) 
50µl 50µl 50µl 50µl 
TEMED (Sigma) 5µl 5µl 5µl 5µl 
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2.6.3.3 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein separation was carried out in Mini-Protean III (Bio-Rad, Hempstead, 
UK) electrophoresis tanks with 1x Tris-Glycine buffer (Table 2.9). Protein samples 
were loaded into appropriate gels along with protein molecular weight marker 
(PageRuler Plus, Fermentas, Loughborough, UK) and gels were run for 45-60 minutes 
at 150V. 
 
2.6.3.4 Transfer of proteins onto PVDF membranes 
Before transfer, Immobilon-P polyvinylidene difluoride (PVDF, Milipore, 
Watfor, UK) membrane was cut to a size appropriate for gels and activated by soaking 
in methanol (Fisher Scientific, Loughborough, UK) for 10 seconds. The membrane 
was then rinsed with 1x Tris-Glycine transfer buffer (Table 2.9). Gels with separated 
proteins were then removed from glass plates and soaked in Tris-Glycine transfer 
buffer for 10 minutes. After that, the stacking gel was removed whilst the resolving 
gel was placed onto the activated membrane within a wet electroblotting system 
(BioRad, Hempstead, UK). The gel was rolled after each layer was added to ensure no 
air bubbles were present in between the surfaces. Proteins were transferred in 1x Tris-
Glycine buffer (Table 2.9) with an ice block within the transfer apparatus to prevent 
over-heating. The transfer procedure was carried out for 1hour with a constant current 
of 0.4mA.  
 
2.6.3.5 Immuno-probing of proteins on membranes 
 
After proteins were immobilized onto PVDF membrane, it was blocked with 
milk blocking solution with agitation for 1 hour at room temperature. Subsequently, 
membranes were incubated with 5mls of appropriate primary antibody (Table 2.10) 
overnight at 4
0
C on a roller mixer (Stuart, Merton, UK). Post-incubation, membranes 
were washed thrice for 5 minutes in PBS/T before incubation in appropriate 
horseradish-peroxidase (HRP))-conjugated secondary antibody (Tables 2.10) at room 
temperature on a roller mixer for 1 hour. Then, membranes were washed thrice for 5 
minutes in PBS/T before visualization of protein bands.  
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Solution Composition 
10 x Electrophoresis Buffer 30.3g Tris base (Sigma), 144.4g Glycine (Sigma), 
Upto 1L dH20 
1 x Tris-Glycine SDS-PAGE  
Running Buffer (1L) 
890ml dH20, 100ml 10 x Electrophoresis Buffer, 
10ml 10% w/v SDS 
1 xTris-Glycine Transfer Buffer 700ml dH20, 100ml 10 x Electrophoresis Buffer, 
200ml Methanol  
Milk Blocking Solution 5% w/v non-fat milk powder (Marvel) in PBS/T 
Stripping Buffer 62.5mM Tris-HCl (pH6.8), 2% w/v SDS, 100mM 
2-beta-mercaptoethanol  
 
Table 2.9: Buffers and respective compositions used for Western blot analysis. 
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Table 2.10: Details of antibodies used for Western blotting analysis. 
 
 
 
 
 
 
 
Antigen 
1
o
 Antibody 
source 
Catalogue 
number 
1
o
 Antibody 
species  
Dilution 
ratio 
Antigen 
size 
β-actin Abcam Ab8227 Rabbit 1:5000 43kDa 
γ-tubulin Abcam Ab6160 Rat 1:10000 50kDa 
p100/p52 
 
Santa Cruz Sc-7386 Mouse 1:200 100/52 kDa 
ERα Santa Cruz Sc-7207 Rabbit 1:200 68kDa 
ErbB2 Cell Signaling 2242 Rabbit 1:200 185kDa 
p105/p50 Santa Cruz Sc-114 Rabbit 1:200 105/50 kDa 
p65 Abcam Ab7978-1 Rabbit 1:200 65KDa 
RelB Santa Cruz Sc-226 Rabbit 1:200 70kDa 
c-rel Santa Cruz Sc-71 Rabbit 1:200 78kDa 
IκBα 
 
Cell Signaling 9242 Rabbit 1:1000 39kDa 
Lamin A/C Cell Signaling 2032 Rabbit 1:1000 70kDa 
E-cadherin Upstate 07-697 Rabbit 1:500 106kDa 
Vimentin Santa Cruz Sc-7557 Goat 1:100 57kDa 
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2.6.3.6 Visualization of protein bands 
Immuno-labelled proteins were detected by chemiluminescence with 
ECL/ECL+ reagent kit (GE Healthcare, Bucks, UK) according to manufacturer’s 
instructions. ECL solutions were made up and mixed before addition onto membranes 
(1.5mls per membrane). Membranes were incubated with ECL or ECL+ reagent in the 
dark for 1 minute or 5 minutes respectively. Subsequently, excess reagent was 
removed and the membrane was transferred into a light-proof cassette. Light sensitive 
films (Amersham Hyperfilm ECL; GE Healthcare, Bucks, UK) were then exposed to 
the membranes under safelight conditions for appropriate amounts of time to produce 
bands with fitting intensities. Films were developed using a Xograph Compact X4 
automatic X-ray film processor.   
 
2.6.3.7 Stripping and re-probing of membranes 
Before probing of membranes with a subsequent antibody of interest, 
membranes were stripped in stripping buffer (Table 2.9) for 30 minutes at 55
o
C with 
agitation. Then, the membrane was rinsed thrice in distilled water for 5 minutes, 
followed by incubation for 30 minutes in PBS/T at room temperature. Membranes 
were then blocked is milk solution, probed with appropriate antibodies and visualized 
as described in Sections 2.6.3.5 and 2.6.3.6. 
 
2.6.3.8 Quantification of protein bands 
Where appropriate, protein bands were semi-quantified by measuring the 
intensity of bands on images of Western blots with ImageJ. The quantitiy of protein 
was determined by normalizing the intensity of a particular antigen against that of a 
loading control. 
 
2.7 RNA analysis 
2.7.1 RNA isolation 
When working with RNA, all reagents and consumables used were RNAse 
free. Bench surfaces and equipment were also treated with RNAseZAP (Ambion, 
Paisley, UK) to prevent contamination by RNAses during isolation and purification 
processes.  
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2.7.1.1 RNA extraction from tissue samples 
For tissue samples, RNA was extracted using Trizol (Invitrogen, Paisley, UK) 
reagent. Tissues were weighed (50mg) and cut on a petri dish resting on dry ice. 
Tissue slices were then placed into a spinLyse tube containing 1ml of Trizol reagent. 
Homogenization of tissue was achieved with the aid of a Precellys 24 machine, with 
the spinLyse settings set at 6500rpm for 45 seconds twice. Then, samples were 
centrifuged for 10 minutes at 8000x g at 4
o
C. Next, the supernatant was moved into a 
fresh micro centrifuge tube, before addition of 200ul of chloroform. Samples were 
then mixed vigorously for 30 seconds by hand and allowed to rest at room 
temperature for 3 minutes. The solvent fractions were then separated by centrifuging 
at 8000x g at 4
o
C for 15 minutes. Subsequently, the aqueous phase was extracted and 
transferred into a tube containing 400ul of isopropanol. The mixture was then shaken 
gently to precipitate the RNA and was then purified using RNeasy Mini Kit (Qiagen, 
Sussex, UK) according to the manufacturer’s instructions. The quality and 
concentration of resulting isolates were then determined using a NanoDrop 
spectrophotometer (ND-1000, Labtech International).   
 
2.7.1.2 RNA purification from cells 
Isolation of RNA from cells was carried out by lysing cells in RLT buffer 
(RNeasy Mini Kit; Qiagen, Sussex, UK) prior to using the RNeasy Mini Kit (Qiagen, 
Sussex, UK) according to manufacturer’s instructions. Similarly, the quality and 
concentration of isolated RNA was determined using a NanoDrop spectrophotometer. 
 
2.7.2 Reverse transcriptase (RT)  cDNA synthesis 
Complementary DNA (cDNA) was synthesized from RNA samples using 
RevertAID Premium Reverse Transcriptase (Fermentas, Loughborough, UK). RNA 
samples were diluted to concentrations between 500-1000ng with RNAse free water 
upto 12.5µl in volume for cDNA synthesis. Random primers and dNTPs which have 
been prepared as a mastermix (Table2.11) was then added to each sample (2µl) to 
make up a total volume of 14.5µl. Then, samples were mixed gently, briefly 
centrifuged and incubated at 65
O
C for 5 minutes, before being placed on ice. 
Consequently, a mastermix solution containing reverse transcriptase (Table2.11) was 
added (5.5µl) to each sample, making up a final reaction volume of 20µl. The reaction 
mix was then incubated at 25
O
C for 10 minutes, 50
O
C for 30 minutes and 85
O
C for 5 
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minutes before being cooled on ice. Negative controls lacking reverse-transcriptase 
were also prepared in parallel with similar reaction components. The synthesized 
cDNA was then used immediately or stored at -70
O
C for future use. 
 
 
 
 
Table 2.11 : Components of master mix for reverse transcriptase reactions. 
 
 
2.7.3 Quantitative real-time polymerase chain reaction (qRT-PCR) 
2.7.3.1 Primer design 
In order to distinguish PCR products of cDNA templates from that of genomic 
DNA sequences, primers were designed across exon boundaries with the aid of Primer 
3 software available through http://frodo.wi.mit.edu/primer3/. The specificity of 
primers was then verified by in silico PCR software available through 
http://genome.csdb.cn/cgi-bin/hgPcr. Sequences for oligonucleotides used are detailed 
in Table 2.12 and all oligonucleotides were purchased from Sigma-Genosys.  
 
 
 
 
Master Mix 1 components 
 
 
Volume per reaction 
dNTPs (10mM; dATP, dCTP, dGTP, dTTP, Promega) 
Random Primers (500ug/ml, Promega) 
 
1µl 
1µl 
 
 
 
 
Master Mix 2 components Volume per reaction 
5x RT Buffer (Fermentas) 4µl 
RNasin Plus (40u/ul, Promega) 0.5µl 
RevertAID Premium Reverse Transciptase        
(200u/ul, fermentas) 
1µl 
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2.7.3.2 qRT-PCR 
 Thermal cycling for qRT-PCR reactions was carried out with a Step One Plus 
Realtime PCR System (Applied Biosystems) with the aid of StepOne software (v2.1, 
Applied Biosystems). Three technical repeats were carried for each sample and a 
minimum of three biological replicated samples were examined. To control for 
differences in starting material, the amount of transcript was normalized against the 
level of a housekeeping gene (Cyclophilin B or GAPDH). 
Respective control and cDNA samples (2.5µl) were loaded into separate wells 
of a 96-well qPCR plate (MicroAmp Fast Optical 0.1ml; Applied Biosystems, 
California, USA). A mastermix as detailed in Table 2.13 was then prepared and added 
into respective wells with cDNA template. SYBR Green reagent (Invitrogen) was 
used in the mastermix. The reaction mixture was then mixed by gentle pipetting 
before sealing plates with caps (MicroAmp Optical 8-capstrip; Applied Biosystems, 
California, USA). The reaction plate was then loaded into Step One Plus Realtime 
PCR machine. The cycling conditions used for all reactions consisted of; initial 
denaturation for 10 minutes at 95
o
C, followed by 45 cycles of 95
o
C for 15 seconds 
and 60
o
C for 1 minute. At the end of each cycle, readings were measured. Upon 
completion of cycles, the integrity of reaction products were examined by performing 
a melting curve cycle which consisted of; 95
o
C for 15 seconds, 60
o
C for 1 minute 
[with optics off], 60
o
C to 95
o
C at 0.2
o
C increments every 15 seconds [with optics on]. 
Data collection throughout cycling was automated by StepOne software. 
 
2.7.3.3 QRT-PCR data analysis 
CT values obtained from qRT-PCR experiments were calculated using  the 2
-
∆∆Ct
 relative quantification method (Livak and Schmittgen, 2001). Briefly, the levels 
of transcript for a sample were normalized by calculating the difference between the 
CT values of a target gene and that of a housekeeping gene, to give the value ∆CT. A 
relative value of the difference in transcript levels between two samples can then be 
calculated by determining the difference between the ∆CT of both samples, giving rise 
to the ∆∆CT value. Relative fold changes between samples were then calculated as 2
-
∆∆Ct
. 
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Table 2.12: List of primers and respective sequences used for qRT-PCR reactions. 
 
 
Primer 
 
 
Sequence 
 
Product 
Size 
 
Cyclophilin B F 
Cyclophilin B R 
 
5’- CCA TCG TGT CAT CAA GGA CTT CAT  -3’ 
5’- TTG CCA TCC AGC CAG GAG GTC T -3’ 
 
216bp 
GAPDH F 
GAPDH R 
5’- CAC AGT CAA GGC CGA GAA TG  -3’ 
5’-  TCT CGT GTT CAC ACC CAT C -3’ 
242bp 
 
P35   F 
P35   R 
 
5’- TGG ATT CCA CGA TAG CAT CA -3’ 
5’- GAC CAA TTT GGG CAA ACA GT -3’ 
 
149bp 
 
P52 F 
P52 R 
 
5’- GAT CTC CCG AAT GGA CAA GA -3’ 
5’- AAC CGA ACC TCA ATG TCG TC -3’ 
 
99bp 
SNAIL F 5’- TGA GAA GCC ATT CTC CTG CT -3’ 91bp 
SNAIL R 5’- CTT CAC ATC CGA GTG GGT TT -3’  
SLUG F 5’- TCT GCA GAC CCA CTC TGA TG -3’ 101bp 
SLUG R 5’- AGC AGC CAG ACT CCT CAT GT -3’  
Twist1 F 5’- CAG GCC GGA GAC CTA GAT GTC AT -3’ 158bp 
Twist1 R 5’- TGC CCC ACG CCC TGA TTC TTG -3’  
Twist2 F 5’- CTT CTC CGT GTG GCG CAT -3’ 133bp 
Twist2 R 5’- CCG CAT CCA GTT CCG CAT -3’  
ZEB2 F 5’- CCG GGA GCT GTT TCT TCG -3’ 120bp 
ZEB2 R 5’- CGC AGG CTC GAT CTG TGA -3’  
E cadherin F 5’- CAG ATG ATG ATA CCC GGG ACA A -3’ 136bp 
E cadherin R 5’- GGA GCC ACA TCA TTT CGA GTC A -3’  
N cadherin F 5’- AGG ACC CTT TCC TCA AGA GC -3’ 117bp 
N cadherin R 5’- ATA ATG AAG ATG CCC GTT GG -3’  
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Table 2.13: Reagents and components for qRT-PCR reactions. 
 
2.8 Statistical analysis 
2.8.1 Student’s t-test 
In order to determine statistical significance in differences between two data 
sets, two-tailed unpaired student’s t-test was used. Calculations were done with 
Microsoft Excel software and p<0.05 was the threshold for significance. 
 
2.8.2 Spearman’s ranked correlation test 
For comparison in IHC studies, the relationship between the degrees of 
staining for different antigens were determined by ranking tumours according to the 
staining scores (IxP), as described in Section 2.3.5.3. The difference between ranks 
for two antigens (D) was then calculated. In the case where tumours had the same 
ranking positions, they were assigned an averaged rank between tied tumours. The 
Spearman’s rho coefficient can then be calculated based on the formula below 
(D=difference between ranks, N=number of tumour samples): 
 
 
 
PCR Reaction Component 
 
qRT-PCR 
 
cDNA template 
 
2.5µl 
PCR-grade Water (Sigma) 12.65µl 
Go Taq PCR Buffer (Promega) 5µl 
 Magnesium Chloride (25mM; Promega) 2.5µl 
 dNTPs (25mM; dATP, dCTP, dGTP, dTTP; Promega) 0.5µl 
Forward Primer (Sigma Genosys, 10µM) 0.25µl 
Reverse Primer (Sigma Genosys, 10µM) 0.25µl 
Go Taq DNA Polymerase (Promega) 0.1µl 
Sybr Green (Invitrogen) 1.25µl 
Total Reaction Volume 25µl 
Chapter 2: Materials and Methods 
 
 
  SK Yeo                                                                 - 78 -                                               Cardiff University 
Rho values lie between the range of 1>rho>-1, where 1 indicates direct 
correlation, -1 indicates inverse correlation whereas 0 shows no correlation. The 
degree of correlation is portrayed by the rho value and a t value is calculated to 
determine whether a given rho value is statistically different from 0, using a Student’s 
t distribution. Rho values were considered significantly different from 0 when p<0.05 
for t values corresponding to (n-2) degrees of freedom. t values were calculated using 
the formula below: 
 
 
 
 
 
2.8.3 Analysis of variance (ANOVA) test and Tukey’s post-hoc analysis test 
In order to determine whether the means between more than two independent 
groups were significantly different, ANOVA test was performed with the aid of SPSS 
software (Version 16.0, IBM). The means between at least two groups were 
considered significantly different when p values were less than 0.05. In the case where 
p<0.05 for ANOVA tests, Tukey’s post hoc test was then carried out to determine the 
specific groups where statistically significant differences were observed. Again, 
p<0.05 was taken as the threshold for significance and Tukey’s post-hoc test was 
carried out with the aid of SPSS software. 
 
2.8.4 Analysis of co-variance (ANCOVA) test 
ANCOVA test was used to determine whether growth curves for cell 
proliferation or in vivo tumour growth across varying time points were significantly 
different. Calculations were done with the general linear model (GLM) function for 
univariate analysis in SPSS software (Version 16.0, IBM) and p<0.05 was the 
threshold for significance. 
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3 Elucidating the effects of caspase inhibition during 
mammary tumour growth and metastasis 
 
3.1 Introduction 
The ability to resist death stimuli has been recognized as a significant trait of 
cancer cells which can contribute to tumourigenesis (Hanahan and Weinberg, 2000b). 
Metastasis remains a major cause of death in breast cancer patients and there is 
evidence which suggests that the ability to evade apoptosis is important in this 
process. Although the role of apoptotic resistance in breast cancer metastasis has been 
addressed by previous studies (Bufalo et al., 1997, Martin et al., 2004), certain 
limitations exist with the experimental models used. In these studies, mammary 
cancer cells over-expressing anti-apoptotic proteins such as Bcl-2 or Bcl-XL 
respectively were shown to increase the metastatic potential of these cells when 
injected intravenously into immuno-compromised mice. However, a number of the 
initial steps of the metastatic cascade such as invasion and intravasation are omitted, 
along with the lack of immune surveillance due to xeno-transplantation. These issues 
were addressed in a study where mitogen-activated protein kinase kinase (MEK) 
transformed Eph4 cells were transplanted into the mammary glands of syngeneic 
mice. Indeed, increased spontaneous lung metastases were observed in cells that over-
express Bcl-2 relative to parental cells (Pinkas et al., 2004). Nonetheless, anti-
apoptotic proteins such as Bcl-2 have other roles in a cell which are distinct from its 
regulation of apoptosis (Furth et al., 1999) and the effects of these other signalling 
roles on metastases cannot be discounted.  
For that reason, we set out to substantiate the importance of apoptotic 
resistance in primary tumour growth and metastasis of breast cancer using an 
inducible pan-caspase inhibitor (p35) mouse model that forms mammary tumours 
driven by the Neu oncogene. With this model, caspases, the core machinery of the 
apoptotic pathway can be inhibited by ectopic expression of p35 at designated time 
frames in endogenously formed tumours rather than transplanted cell lines.      
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3.2 Characterization of rtTA/p35 transgenic mice 
3.2.1 Induction of p35 transcript levels in rtTA/p35 double transgenic mice is 
dependent on doxycycline administration 
In rtTA/p35 double transgenic mice, expression of the inducible trans-
activator, rtTA, is driven by the MMTV promoter whereas the p35 transgene is under 
the control of a tetracycline responsive element (TRE). Hence, p35 can be induced 
mainly in mammary epithelial cells when doxycyline (dox) is administered. Since the 
rtTA/p35 mouse model is novel, we set out initially to characterize the inducibility of 
p35 expression when these mice are administered with dox.  
The levels of p35 transcript expression were determined by quantitative 
reverse transcriptase polymerase chain reaction (qRT-PCR). Only double transgenic 
mice which had been administered with doxycycline expressed significant levels of 
p35 mRNA relative to mice lacking dox or the p35 transgene  (Figure 3.1). 
Accordingly, there was a dose dependent effect where mice subjected to 5 daily intra-
peritoneal (IP) injections of dox expressed p35 mRNA at about two orders of 
magnitude higher (~18000) relative to mice subjected to only 3 daily IP injections 
(~150). This difference is observed despite the fact that both these groups of mice 
received dox in their drinking water for a week, indicating that induction levels can be 
boosted more effectively when dox is administered via IP injections. On the other 
hand, both double transgenic mice that were not induced with dox and mice with only 
the rtTA transgene but induced with 5 IP injections, only showed background levels 
of p35 transcript. Thus, the expression of p35 in these mice is dependent on the 
administration of dox and due to the fact that there was a dose dependent induction, 
subsequent experiments were carried out with 5 daily IP injections before 
experimental endpoints.  
 
3.2.2 Caspase inhibition during mammary gland involution results in the 
accumulation of atypical luminal bodies 
During mammary gland involution, extensive cell death takes place and 
apoptosis has been implicated in this process (Chapman et al., 2000). In view of that, 
the functional characterization of rtTA/p35 double transgenic mice was carried out at 
this time point, in particular at 48 hours and 72 hours post-weaning. At both these 
time points, in DOX+ cohorts, where p35 induction is expected, the presence of 
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Figure 3.1: Expression of p35 mRNA in rtTA/p35 mice is dependent on 
doxycycline administration. Mice with respective transgenes (rtTA or rtTA/p35) 
were administered with indicated amounts of daily dox IPs prior to harvest. 
Mammary glands were harvested at 2-3 days post involution. Levels of p35 
transcript were determined by qRT-PCR and normalized against cyclophilin B 
Values were plotted as fold change relative to uninduced rtTA/p35 mice. Data 
points represent average of at least n=3 per group and error bars indicate standard 
error of the mean (SEM). *** indicates p<0.001, where statistical significance 
relative to uninduced rtTA/p35 mice was determined by two-tailed t-test. 
 
Chapter3: Elucidating the effects of caspase inhibition during mammary tumour growth and metastasis 
 
 
 
  SK Yeo                                                                 - 83 -                                              Cardiff University 
atypical luminal bodies can be observed (Figure 3.2a). In normal DOX- glands, 
almost all the luminal bodies observed have hypercondensed nuclei and compact 
cytosol compartments, whereas a proportion of luminal bodies in the DOX+  glands 
lacked nuclear condensation and had large vacuolar structures (Figure 3.2b). 
Furthermore, in DOX+ glands, a larger percentage of cleaved-caspase-3 (CC3) 
negative luminal bodies were present at 48 hours post weaning (Figures 3.3 a&b), as 
determined by immuno-histochemistry (12.4% in DOX +, 3.3% in DOX-). By 72 
hours, there was no longer a difference in percentages of CC3 negative luminal bodies 
(Figure 3.3c), although there was a higher absolute number of these bodies in the 
DOX+ cohort. A majority of these CC3 negative bodies also exhibited atypical 
morphology suggesting that the morphological phenotypes observed were due to 
caspase inhibition. The fact that mammary epithelial cells (MECs) can detach and 
slough into the lumen without activation of the effector caspase-3 would also suggest 
that extensive caspase activation or apoptosis are not required for this process. It is 
also worth noting that none of the MECs within the alveolar structures stained 
positively for CC3 in either cohorts. This means that caspases are only activated upon 
detachment and cell sloughing at 48 and 72 hour involution time points. 
 In support of this, when these mammary glands were stained by terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), positively stained 
cells were observed in MECs within the alveolar structures of both cohorts (Figure 
3.4). Since TUNEL staining is an indicator of programmed cell death, the presence of 
TUNEL positive cells but not CC3 positive cells within the alveolar structures would 
imply that a caspase-independent death program precedes caspase activation during 
involution.    
 
3.2.3 Inhibition of caspases by p35 does not delay the first phase of 
mammary gland involution 
To further assess whether caspases play an important role in the early stages of 
involution, we then appraised the gross morphology of mammary glands at 48 and 72 
hours involution time points. In accordance with our previous observations that 
caspase-3 activation is not required for initiation of cell death and sloughing into the 
lumen, qualitative assessment of gross mammary gland architecture in both DOX+ 
and DOX- showed no differences (Figure 3.5). At 48 hours post weaning, there was  
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Dox + Dox - 
48 
hours 
72 
hours 
Dox + Dox - 
Figure 3.2: Caspase inhibition during mammary gland involution leads to the 
formation of atypical luminal bodies. (a) High power images of haematoxylin 
and eosin stained mammary gland sections from rtTA/p35 mice with or without 
dox at 48 hours and 72 hours involution time points. (b) Representative images of 
luminal bodies present in dox + and – cohorts. Scale bars represent 20um. 
a 
b 
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Figure 3.3: Cleaved-caspase-3 staining of involuting mammary glands from 
rtTA/p35 mice. (a) High power images of cleaved-caspase-3 stained mammary 
gland sections from rtTA/p35 mice with or without dox at 48 hours and 72 hours 
involution time points. Arrows indicate cleaved-caspase-3 negative atypical 
luminal bodies. Scale bars represent 20um.  (b) Bar charts showing percentage of 
cleaved-caspase-3 negative luminal bodies present in dox + and – cohorts at 48 
hours involution timepoint. (c) Bar charts showing percentage of cleaved-caspase-
3 negative luminal bodies present in dox + and – cohorts at 72 hours involution 
timepoint. Data points represent means of at least n=3, error bars are standard 
errors of the mean. * indicates p<0.05, n.s. indicates no statistical significance, 
where statistical significance was determined by two-tailed t-test. 
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Figure 3.4: TUNEL staining of involuting mammary glands from rtTA/p35 
mice. (a) High power images of TUNEL stained mammary gland sections from 
rtTA/p35 mice with or without dox at 48 hours and 72 hours involution time 
points. Arrows indicate representative examples of TUNEL + nuclei of cells 
within acinar structures. Scale bars represent 20um.   
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Figure 3.5: Gross morphology of involuting mammary glands from rtTA/p35 
mice. (a) Low power images of haematoxylin and eosin stained mammary gland 
sections from rtTA/p35 mice with or without dox at 48 hours and 72 hours 
involution time points. Scale bars represent 200um. 
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still extensive coverage of alveolar structures in both cohorts. Similarly at 72 hours, 
no qualitative difference between the two cohorts was observed, as the rates at which 
adipocytes repopulated the gland were similar. This is in contrast to phenotypes of 
Stat3 knockout mice during involution, where evident delays in adipocyte 
repopulation can be observed (Chapman et al., 2000)]. 
 When the number of luminal bodies per field of view for each cohort was 
quantified, no difference was observed at 48 hour time points (Figure 3.6a &b). This 
is in line with the gross morphology of glands from DOX+ and DOX– cohorts where 
no delay in involution was observed. However, at 72 hours, more luminal bodies were 
present in the DOX+ when compared to DOX– mammary glands. Although caspase 
inhibition does not affect the sloughing of cells into the lumen, this increase could be 
attributed to the delay in clearance of atypical luminal bodies when caspases are 
inactivated. Since luminal bodies are cleared through phagocytosis by professional 
and non-proffesional macrophages during involution, it is possible that caspase 
inhibition may prevent the exposure of ‘eat me’ signals such as phosphatidyl-serine, 
leading to the accumulation of luminal bodies by 72 hours.  
 Despite the lack of marked phenotypic changes during involution when 
caspases are inactivated, the presence of atypical luminal bodies which stain negative 
for CC3 provides evidence for the functionality of p35 induction in rtTA/p35 mice. 
Nonetheless, in DOX+ mice, the proportion of MECs which attain sufficient levels of 
p35 to be able to inhibit caspase activation remains to be addressed. Thus, it cannot be 
excluded that the lack of penetrance of p35 expression may be the reason for the 
indifferences pertaining to global mammary gland architecture.   
 
3.3 Effects of caspase inhibition during primary tumour growth and 
breast cancer progression 
 
3.3.1 Inhibition of caspases by p35 does not affect the growth rate of MMTV-
Neu driven tumours 
By crossing rtTA/p35 double transgenic mice with MMTV-Neu mice, the 
effects of caspase inhibition in Neu oncogene driven tumours can be assessed in triple 
transgenic rtTA/p35/Neu progeny. In order to evaluate the effects of caspase 
inhibition on primary tumour growth and spontaneous metastasis formation, mice 
were segregated into DOX+ and DOX– cohorts when tumours grew to a size of 5mm  
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Figure 3.6:Caspase inhibition during early phase mammary gland involution 
does not affect the number of luminal bodies. (a) Representative images of 
haematoxylin and eosin stained mammary gland sections from rtTA/p35 mice 
with or without dox at 48 hours and 72 hours involution time points. Arrows 
indicate representative examples of luminal bodies. Scale bars represent 100um. 
(b) Bar charts showing number of luminal bodies present in dox + and – cohorts 
at 48 hours involution time point. (c) Bar charts showing number of luminal 
bodies present in dox + and – cohorts at 72 hours involution time point. Data 
points represent means of at least n=3, error bars are standard errors of the mean. 
* indicates p<0.05, n.s. indicates no statistical significance, where statistical 
significance was determined by two-tailed t-test. 
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in diameter. This experimental design allows the effects of caspase inhibition on 
tumour initiation to be omitted (Figure 3.7a). In the period where tumours were 
between 5mm to 20mm in diameter, administration of dox did not affect primary 
tumour growth rate (Figure 3.7b). This correlates with the proportion of CC3 positive 
cells within tumours from both cohorts, as no difference was observed, showing that 
apoptotic rates within tumours were unchanged (Figures 3.8a & b). 
 
3.3.2 Inhibition of caspases in MMTV-Neu tumours increases their metastatic 
potential 
When rtTA/p35/Neu mice from DOX+ and DOX– cohorts reached the 
experimental endpoint (i.e. 20mm in diameter), they were sacrificed and their lungs 
and livers examined for metastases formation. Interestingly, all the mice administered 
with dox had lung metastases and one of the DOX+ mouse also had liver metastases. 
On the other hand, none of the DOX– mice had any liver or lung metastases (Table 
3.1 & Figure 3.9). This illustrates that p35 expression which confers apoptotic 
resistance can enhance the metastatic potential of Neu oncogene driven tumours. To 
ascertain this observation, the number of animals per cohort will need to be increased. 
The proportion of CC3 positive cells in lung metastatic nodules from the DOX+ 
cohort were also compared to that of wild-type Neu lung metastases to assess whether 
caspase inhibition contributes to secondary tumour growth. However, no difference in 
the percentage of CC3 positive cells was observed (Figure 3.10), suggesting that once 
a metastatic colony is established at a secondary site, apoptotic resistance is less 
essential. Taken together with the data pertaining to primary tumour growth, our data 
would suggest the possibility that resistance to apoptosis is less crucial for sustaining 
primary tumour growth but is a key contributing factor to the formation of metastases. 
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Figure 3.7: Inhibition of caspases does not affect the growth rate of MMTV-
Neu driven primary tumours. (a) Schematic showing the experimental design 
for rtTA/p35/Neu mice. In the dox + cohort, p35 was induced when tumours were 
between 5-20mm in diameter. (b) Line graph showing the average growth rate of 
tumours from dox + and dox – cohorts of rtTA/p35/neu mice. Arrow indicates 
timepoint when dox was administered for the Dox+ cohort. Data points represent 
means of at least n=3 mice, error bars are standard errors of the mean. N.s. 
indicates not statistically significant, where statistical analysis was performed 
using ANCOVA test.    
b 
     n.s. 
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Figure 3.8: Inhibition of caspases does not alter the proportion of 
cleaved-caspase-3 positive cells in MMTV-Neu driven primary tumours.  
(a) Low power images of cleaved-caspase-3 stained tumours from 
rtTA/p35/Neu mice with or without dox. Arrows indicate representative 
examples of cleaved-caspase-3 positive cells. Scale bars represent 200um.  
(b) Bar charts showing number of cleaved-caspase-3 positive cells from dox 
+ and dox – cohorts of rtTA/p35/Neu mice. Data points represent means of 
at least n=3, error bars are standard errors of the mean. n.s. indicates no 
statistical significance, where statistical significance was determined by 
two-tailed t-test. 
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Figure 3.9:  Caspase inhibition increases the metastatic potential of MMTV-Neu 
driven tumours. Representative images of haematoxylin and eosin stained lung 
and liver sections from rtTA/p35/Neu mice with or without dox. Arrows 
indicate metastatic nodules. Scale bars represent 200um. 
Table 3.1: Caspase inhibition increases the metastatic potential of MMTV-Neu 
driven tumours.  Table showing number of mice from rtTA/p35/Neu cohorts with 
or without dox and the respective number of mice with liver or lung metastases   
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Figure 3.10:  Inhibition of caspases does not alter the proportion of 
cleaved-caspase-3 positive cells in lung metastases from MMTV-Neu 
driven primary tumours.  (a) Low power images of cleaved-caspase-3 
stained lung metastases from rtTA/p35/Neu mice with dox or wild type 
Neu mice. Scale bars represent 100um.  (b) Bar charts showing number of 
cleaved-caspase-3 positive cells from dox + rtTA/p35/Neu mice or wild-
type Neu dox - mice. Data points represent means of at least n=3, error 
bars are standard errors of the mean. n.s. indicates no statistical 
significance, where statistical significance was determined by two-tailed t-
test. 
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3.4 Discussion 
From the characterization of rtTA/p35 double transgenic mice, we have shown 
that expression of p35 transcript is dependent on administration of doxycycline. 
Functionally, p35 induction in the mammary glands of these mice during involution 
resulted in the formation of atypical luminal bodies which stain negative for cleaved-
caspase-3 (Figures 3.2 & 3.3). However, we only observed a marginal increase in the 
proportion of cleaved-caspase-3 negative luminal bodies at 48 hours post weaning 
when p35 is induced. This may be due to p35 expression levels that are not sufficient 
to inhibit caspase activation in a majority of the cells. It would be useful to show the 
extent and levels of p35 expression in histological sections of the involuting glands to 
address this. There is also the possibility that caspase inhibition by p35 is only 
transiently effective, where caspases will eventually be activated in the cleaved-
caspase-3 negative luminal bodies due to overriding stimuli. The transient nature of 
this population could explain the small proportion of cleaved-caspase-3 negative 
luminal bodies observed.  
Nonetheless, from the small population of cleaved-caspase-3 negative luminal 
bodies, it appears that MEC sloughing into the lumen does not require caspase 
activation (Figure 3.3). Also, the presence of atypical luminal bodies when caspases 
are inhibited show that caspase activity after cell sloughing is important for the 
formation of luminal bodies with hyper-condensed nuclei and compact cytosol 
(Figure 3.2). As we observed an accumulation of luminal bodies at 72 hours post 
weaning in p35 expressing glands (Figure 3.6c), it would be interesting to investigate 
whether this would be exaggerated at later time points of involution or whether 
compensatory mechanisms will take place to remove the excess luminal bodies. This 
increase in luminal bodies when caspases are inhibited is not surprising because 
phosphatidyl-serine exposure is dependent on caspase activity (Martin et al., 1996). 
Consequently, caspase inhibition will prevent the exposure of such ‘eat me’ signals 
which are important for clearance by macrophages. It would be worthy to address 
whether this delay in clearance of luminal bodies can phenocopy MerTK or MFG-E8 
knockout mice, where the absence of these receptors that recognize phosphatidyl-
serine resulted in secondary necrosis, inflammation, fibrosis and defective 
development of mammary glands in subsequent pregnancies (Atabai et al., 2005, 
Hanayama and Nagata, 2005, Sandah et al., 2010). 
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From observations that DNA fragmentation (TUNEL +) is already prominent 
in MECs within the alveolar structures, and therefore precedes caspase activation in 
luminal bodies (Figures 3.3 & 3.4), it appears that caspase-independent cell death 
programs are initiated during involution prior to cell sloughing in the lumen. This 
would correlate with the absence of any delay in mammary gland remodeling when 
caspases are inhibited (Figure 3.5). However, we cannot exclude the possibility that 
p35 may be expressed at levels which are insufficient to inhibit apoptosis in a 
proportion of cells and thus, the overall involution of p35 expressing glands appears 
unaffected. Although a previous study of Stat3 knockout mice implicated a role for 
apoptosis during involution (Chapman et al., 2000), our data supports a more recent 
study where knockout of effector caspases in the mammary gland does not delay 
involution (Kreuzaler et al., 2011). This supports our observations that caspase 
activation is dispensable for the death of MECs during involution. Instead, it was 
shown in the study that a lysosomal mediated cell death program which is initiated by 
Stat3 through the regulation of cathepsins, drives the involution process. As lysosomal 
death pathways can crosstalk to apoptotic pathways (Stoka et al., 2001), it is not 
surprising that cleaved caspase-3 positive luminal bodies can be observed in 
involuting mammary glands (Figure 3.3). Taken together, this shows that the default 
physiological death pathway for MECs during involution is caspase-independent and 
not apoptosis as previously thought. In the context of diseases such as cancer, it is 
possible that aberrant cells may acquire the ability to circumvent this lysosomal 
mediated cell death pathway which is normally important for the homeostasis of the 
mammary gland through pregnancy cycles. Thus, the resistance of cancer cells to 
alternative forms of cell death should also be considered when designing therapeutics.  
 When p35 was expressed in established Neu-driven tumours, we found from a 
preliminary cohort of animals (n=3 for each arm) that caspase inhibition did not affect 
primary tumour growth but enhanced the formation of metastases (Figures 3.7-3.10). 
As p35 is induced only after tumours have reached a size of 5mm in diameter, the 
specific effects of caspase inhibition on tumour growth can be dissected from its co-
operative effects with the Neu-oncogene on tumour initiation. Although, we did not 
address the effects of p35 expression on Neu-driven tumourigenesis, the model used 
can be easily employed for this purpose by changing the dox treatment regime. It is 
worth noting that our observations on the differential effects of p35 expression during 
primary tumour growth and metastasis formation mimics studies of those where Bcl-2 
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family members were over-expressed in breast cancer cells (Martin et al., 2004, 
Pinkas et al., 2004). This would imply that apoptotic stimuli at the primary site of 
these tumours are not sufficiently high enough such that caspase inhibition would 
confer a growth advantage. It could be possible that the homeostatic mechanisms 
limiting mammary tumour growth are non-caspase dependent, as with normal MECs 
during mammary gland involution (Figures 3.3& 3.4) (Kreuzaler et al., 2011).  
 Contrastingly, the formation of metastases can be enhanced by inhibition of 
apoptosis (Figure 3.4). This is not surprising as the metastatic cascade consists of 
many steps where apoptosis would be induced. Hence, with this model, we have 
managed to obtain preliminary evidence supporting the importance of apoptosis 
resistance in the formation of metastasis from endogenous mammary tumours. It 
remains an interesting prospect to identify the particular steps within the metastatic 
cascade where p35 confers a survival advantage. In order to address that, primary 
tumour cells could be harvested from rtTA/p35/Neu mice and subjected to in vitro 
assays which assess survival under anoikis conditions, motility and also tail vein 
transplantation assays. The expression of p35 can be regulated similarly in vitro 
through doxycycline treatment. Tail vein transplantation experiments would give 
insights into the effects of p35 expression during the latter stages of the metastatic 
cascade such as survival during circulation and at secondary sites. Intravital imaging 
techniques would need to be employed if the initial steps of invasion and intravasation 
were to be assessed in vivo. Another interesting aspect of the rtTA/p35/Neu mouse 
model is that p35 expression can be switched off upon removal of dox and this would 
be an important feature to address whether sustained apoptotic resistance is required 
for maintenance of metastatic nodules from endogenous tumours.  
From these observations, it is plausible that therapeutics which reduce the 
apoptotic threshold in cancer cells might not affect primary tumour growth but still 
prove useful in preventing the formation of metastases. As mentioned, the resistance 
of breast cancer cells to alternative cell death mechanisms should also be considered 
as they may be important in promoting tumour growth. 
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3.5 Summary 
Through the characterization of rtTA/p35 mice, our data suggests that 
apoptosis is not essential for MEC death and cell sloughing during involution but 
caspase activation may be important for proper clearance of luminal bodies. In the 
context of mammary cancers, we have managed to provide preliminary evidence to 
reiterate the fact that caspase inhibition does not affect primary tumour growth but is a 
key factor in promoting the formation of metastases. The results substantiate the 
rationale for preventing the formation of breast cancer metastases by targeting 
pathways to re-sensitize breast cancer cells to apoptosis. 
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4 Elucidating the effects of silencing Nfkb2 in mammary 
cancer cell lines 
4.1 Introduction 
From the previous chapter (Section 3.3), our preliminary data supports the 
importance of apoptotic resistance in promoting breast cancer metastasis. Since 
metastasis is a major cause of cancer related deaths, it is important to develop 
therapeutics to prevent the spread of cancer cells to secondary sites. Consequently, a 
promising therapeutic strategy would involve targeting pathways that confer apoptotic 
resistance in breast cancer cells such that they would be re-sensitized to the milieu of 
death stimuli along the metastatic cascade. 
For that reason, the NF-κB pathway is a prospective target as it regulates a 
range of anti-apoptotic genes (Clarkson and Watson, 1999) and have also been shown 
to negatively regulate lysosomal mediated cell death (Liu et al., 2003). Hence, it 
appears to be an important survival factor for MECs under physiological conditions 
and could represent a possible route by which aberrant cells are conferred with a 
survival advantage. In addition, a range of genes which have been implicated in 
promoting metastasis are also regulated by NF-κB (Pahl, 1999). The involvement of 
NF-κB signalling in maintaining CaSC properties (Cao et al., 2007) strengthens the 
rationale further as CaSCs are believed to be responsible for seeding new tumours. 
The canonical NF-κB pathway has been shown to be important for 
tumorigenesis and CaSC properties especially in Neu/ErbB2 driven tumours (Liu et 
al., 2010, Pratt et al., 2009). The majority of studies focus on the canonical pathway in 
cancer, yet the alternative pathway is also known to play a key role in driving 
oncogenic pathways, [e.g. cyclin D1 (Rocha et al., 2003, Viatour et al., 2003)]. Less is 
known of the role of the alternative pathway in breast cancer tumourgenesis, yet 
aberrant levels of p52 pathway components have been described (Cogswell et al., 
2000, Dejardin et al., 1995). A similarly important role for the RANKL-RANK-IκKα 
signalling axis has also been established (Cao et al., 2007, Gonzalez-Suarez et al., 
2010, Schramek et al., 2010). Although this signalling axis can potentially drive the 
activation of the alternative pathway, there are many other functions ascribed to IκKα. 
Hence, it remains to be addressed whether the NF-κB subunit p52 has a role in one or 
more breast cancer subtypes, downstream of specific oncogenic pathways. Thus, we 
set out to define the involvement of p52 in regulating the properties of breast cancer 
cells through silencing of the Nfkb2 gene and at the same time, assess the therapeutic 
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potential of such an intervention. Mouse mammary cancer cell lines were used in this 
study to allow the use of syngeneic transplantation mouse models. This circumvents 
the omission of certain components of the hosts’ immune system which may have a 
role in promoting the tumourigenic properties of cancer cells studied. 
 
4.2 Effects of silencing Nfkb2 in mammary cancer cell lines 
 
4.2.1 Silencing of Nfkb2 leads to elevated basal NF-κB activity in ErbB2-ve 
4T1 and EPH4 cell lines but decreases the basal NF- κB activity of 
ErbB2+ve N202.1a cells 
In order to assess the effects of Nfkb2 silencing, three mammary cell lines 
were transduced with lentivirus encoding shRNA against Nfkb2. The 4T1 cell line is 
highly metastatic with ER
+
 ErbB2
- 
receptor status, the N202.1A cell line is derived 
from a MMTV-Neu driven tumour and has ER
+ 
ErbB2
+
 receptor status whereas the 
Eph4 cell line is an immortalized non-tumourigenic cell line with ER
+
 ErbB2
-
 
receptor status (Figure 4.1a). The levels of p100 protein were reduced to undetectable 
levels when shRNA against Nfkb2 was expressed in all three cell lines, indicating 
effective silencing of the gene.  
 Initially, the effects of silencing Nfkb2 on basal NF-κB transcriptional activity 
were assessed by luciferase reporter assays (Figure 4.1b). Interestingly, NF-κB 
activity was increased when p100/p52 is depleted in 4T1 and Eph4 cells, compared to 
respective cells that have been transduced with non-target (NT) shRNA. Conversely, 
the N202.1A cell line exhibited a decrease in basal NF-κB activity relative to NT 
control. It is also worth noting that the basal NF-κB activity for 4T1 NT and Eph4 NT 
cell lines were lower relative to N202.1A NT cells. This observation is in accordance 
with the fact that EGFR family members can drive the activation of NF-κB (Biswas 
and Iglehart, 2006), hence the higher NF-κB activity in N202.1A cells which are 
ErbB2
+
. 
 One explanation for the varying outcomes on NF-κB activity in different cell 
lines when Nfkb2 is silenced could be the relative contribution of p100 and p52 to NF-
κB signalling in different signalling backgrounds. Thus, it is possible that in 4T1 and 
Eph4 cells where the basal NF-κB activity is lower, loss of the inhibitory IκB protein, 
p100, is dominant over that of p52. This would eventually lead to an increase in NF-
κB activity when p100/p52 is silenced. On the other hand, it is possible that p52 
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Figure 4.1: Silencing of Nfkb2 alters the basal NF-κB activity of mammary 
cell lines.  (a) Protein lysates from 4T1, N202.1A and EPH4 cell lines transduced 
with non target (NT) and shRNA against Nfkb2 were harvested and separated by 
SDS-PAGE. Western blot shows levels of p100, ErbB2 and ER with β-actin as 
loading control in these cell lines. (b) 4T1, N202.1A and EPH4 cell lines 
transduced with non target (NT) and shRNA against Nfkb2 were transfected with 
NF-kB luciferase reporter and pcDNA3.1:lacZ as transfection control. 48 hours 
after transfection, cell lysates were harvested and the ratio of luciferase to lacZ 
activity measured. Bar charts show basal NF-kB activity plotted as relative light 
units (RLU) in the respective cell lines. Data points represent average of at least 
n=6 and error bars indicate standard error of the mean (SEM). ** indicates 
p<0.01, * indicates p<0.05, where statistical significance relative to non target 
controls were determined by two-tailed t-test. 
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contributes to the higher basal NF-κB activity in N202.1A cells and thus, the effects 
of losing p52 overweigh that of losing p100, leading to an overall decrease in NF-κB 
activity upon  Nfkb2 silencing. Alternatively, the differential responses may be the 
result of more specific differences in the relative availability of canonical NF-kB  
components (eg. p50), heterodimer partners (eg. RelB) or co-factors (eg. p53, Bcl-3, 
HDAC1). Irrespective of the underlying mechanism for this difference however, it 
would be  interesting to evaluate whether the changes in NF-κB activity correlate with 
respective cancer associated phenotypes. 
 
4.2.2 Loss of Nfkb2 in 4T1 cells is associated with an increase in nuclear and 
cytoplasmic p50 levels 
Consequently, we also investigated the levels of NF-κB subunits and their 
nuclear localization in 4T1 cells. This was to determine whether the increase in basal 
NF-κB activity after Nfkb2 silencing is associated with changes in the levels or 
localization of other NF-κB subunits. The first two rows (Figure 4.2) show complete 
depletion of p100/p52 protein in 4T1 cells when two different shRNAs (p52 shRNA 
43&44) against Nfkb2 were used. Interestingly, when p100/p52 is depleted, the levels 
of nuclear and cytoplasmic p105 were decreased. This was accompanied by increases 
in nuclear and cytoplasmic p50 in cells that express shRNA against Nfkb2. From these 
observations, it appears that more p105 is processed into p50, in order to compensate 
for the loss of p100/p52. Hence, it is possible that the increase in nuclear p50 levels is 
responsible for the increase in basal NF-κB activity of 4T1 cells when Nfkb2 is 
silenced (Figure 4.1), since the levels of RelA, RelB and c-rel in the nucleus appear 
unperturbed. Although an increase in cytoplasmic c-rel is evident, it is unlikely that 
this would affect NF-κB transcription. 
 
4.2.3 Loss of Nfkb2 sensitizes N202.1a cells to anoikis under non-adherent 
culture conditions in vitro 
We then went on to look at the survival of mammary cell lines under anoikis 
conditions upon Nfkb2  knockdown because it represents the initial challenges faced 
by cancer cells in the metastatic cascade. In the 4T1 and EPH4 cell lines, no 
significant differences in the viability of these cells under anoikis conditions were 
observed when Nfkb2 was silenced (Figure 4.3), despite increases in basal NF-κB  
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Figure 4.2: Silencing of Nfkb2 in 4T1 cells is associated with an increase in 
nuclear and cytoplasmic p50 levels. Nuclear and cytoplasmic extracts from 4T1 
cells transduced with non target (NT) and shRNA against Nfkb2 (p52 shRNA 
43&44) were harvested and separated by SDS-PAGE. Western blot shows levels 
of p100, p52, p105, p50, RelA, RelB and c-rel. Lamin A/C and γ-tubulin were 
used as loading controls for nuclear and cytoplasmic extracts respectively in 
these cell lines. * indicates non specific band. Arrow indicates p52 band. 
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Figure 4.3: Silencing of Nfkb2 sensitizes N202.1A cells to anoikis in vitro.  
4T1, N202.1A and EPH4 cell lines transduced with non target (NT) and shRNA 
against Nfkb2 were plated under non-adherent culture conditions and the viability 
of these cells were measured after 24 hours. Bar charts show viability of cells 
determined by Cell Titer Blue assay, plotted as relative fluorescence in the 
respective cell lines. Data points represent average of at least n=6 and error bars 
indicate standard error of the mean (SEM). * indicates p<0.05, where statistical 
significance relative to non target controls were determined by two-tailed t-test. 
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activity in both 4T1 Nfkb2 kd and EPH4 Nfkb2 kd cell lines (Figure 4.1). On the 
other hand, N202.1A cells displayed a marginal decrease (~10%) in cell viability 
upon depletion of p100/p52. This suggests that p100/p52 does contribute to the 
survival of N202.1A cells under non-adherent culture conditions.    
 
4.2.4 Silencing of Nfkb2 does not affect the proliferation of mouse mammary 
cancer cell lines 
As p52 has been shown to be able to regulate the expression of Cyclin D1 and 
proliferation (Cao et al., 2001a, Rocha et al., 2003), we then examined the effects of 
Nfkb2 knockdown on the proliferative potential of mammary cell lines. Despite the 
association between p52 and proliferation in previous studies, we did not observe any 
effects on the growth rate of cells (Figure 4.4). In the case of the tumourigenic cell 
lines, 4T1 and N202.1A, the fact that no change in proliferation was observed would 
suggest that p100/p52 is not the main driving stimulus which promotes cell division in 
these cells. This is not surprising as many other oncogenes such as c-Myc could 
induce cell cycle progression. Similarly with EPH4 cells, the results would indicate 
that p100/p52 is not crucial in regulating the rate of cell division in these non-
tumourigenic cells.    
 
4.2.5 Silencing of Nfkb2 does not affect the colony forming potential of 
mouse mammary cancer cell lines 
In order to assess whether the loss of p100/ p52 has any effects on the 
proportion of cells capable of extensive replication, we performed a colony forming 
assay on NT and Nfkb2 kd cells of 4T1, N202.1A and EPH4 lineage respectively. No 
significant differences in the colony forming efficiency were observed between NT 
controls and Nfkb2 kd cells for all three cell lines (figure 4.5). Hence, p100/p52 
depletion does not affect the replicative potential of tumourigenic and non-
tumourigenic mammary cell lines. 
 
4.2.6 Silencing of Nfkb2 increases the motility of 4T1 cells 
Another important feature for cancer cells to metastasize is the ability to be 
motile and invade into surrounding tissues. We addressed the role of p100/p52 in the 
regulation of these phenotypes in vitro through transwell migration assays. The loss of 
p100/p52 increased the motility of 4T1 cells but had no effect on N202.1A and EPH4  
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Figure 4.4: Silencing of Nfkb2 does not affect proliferation of 4T1, N202.1A 
and EPH4 cells.  4T1, N202.1A and EPH4 cell lines transduced with non target 
(NT) and shRNA against Nfkb2 were plated in 6-well plates. At respective 
timepoints, the number of cells in each well was counted with the aid of a 
haemo-cytometer. Line graphs showing cell counts relative to day 1 plotted on a 
log scale against time in days. Data points represent average of at least n=6 and 
error bars indicate standard error of the mean (SEM).  
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Figure 4.5: Silencing of Nfkb2 does not affect the colony forming potential of 
mammary cell lines.  4T1, N202.1A and EPH4 cell lines transduced with non 
target (NT) and shRNA against Nfkb2 were plated in 6-well plates at a density of 
1000 cells per well. The number of colonies formed after 7 days were counted.  
Bar charts show the % colony forming efficiency, which is a percentage of the 
number of colonies formed per cells seeded. Data points represent average of at 
least n=6 and error bars indicate standard error of the mean (SEM). N.S. 
indicates a non significant difference, where statistical significance relative to 
non target controls were determined by two-tailed t-test. 
0
5
10
15
20
25
4T1 N202.1A Eph4
%
 C
o
lo
n
y
 F
o
rm
in
g
 E
ff
ic
ie
n
c
y Non Target
Nfkb2 kd
n.s. 
Chapter 4: Elucidating the effects of silencing Nfkb2 in mammary cancer cell lines 
 
 
  SK Yeo                                                                 - 109 -                                              Cardiff University 
 cells (Figure 4.6a). As the increase in motility in 4T1 cells correlates with an increase 
in basal NF-κB activity when Nfkb2 is silenced (Figure 4.1), there is a possibility that 
NF-κB activity regulates the motility of these cells. Although an increase in basal-NF-
κB activity was also observed in EPH4 cells, our results do not show a change in the 
motility of these cells upon Nfkb2 knockdown. This would suggest that elevated NF-
κB activity in a tumourigenic setting can promote motility, possibly in cooperation 
with other oncogenic stimulus but not in non-tumourigenic cells.  
In addition, we also investigated the invasive ability of 4T1 and N202.1A cell 
lines through trans-well invasion assays. However, no significant differences were 
observed when Nfkb2 was silenced in both cell lines (Figure 4.6b). Thus, perturbation 
of p100/p52 levels does not affect the invasive ability of 4T1 and N202.1A cells. 
 
4.2.7 Loss of Nfkb2 leads to EMT in 4T1 cells 
We went on to elucidate the possible mechanisms responsible for the increased 
motility in 4T1 cells (Figure 4.5a) upon Nfkb2 silencing. Since we observed an 
increase in basal NF-κB activity in 4T1 Nfkb2 kd cells (Figure 4.1) and NF-κB is 
known to be able to induce epithelial to mesenchymal transition (EMT) (Huber et al., 
2004b), we wanted to determine whether EMT was induced in 4T1 Nfkb2 kd cells. 
The levels of EMT-inducing transcription factors between 4T1 NT and 4T1 Nfkb2 kd 
cells were compared by quantitative RT-PCR (Figure 4.7a) and we found a 1.6 fold 
increase in Zeb2. Accordingly, we observed a decrease in levels of E-cadherin and an 
increase in levels of N-cadherin relative to NT controls, which is characteristic of the 
EMT process. When we probed the levels of E-cadherin and vimentin proteins (Figure 
4.7b), we observed diminished levels of E-cadherin which supports the quantitative 
RT-PCR data but no changes in the levels of vimentin was observed. It is possible that 
not all mesenchymal markers show increased expression upon EMT, since only N-
cadherin expression was increased upon Nfkb2 silencing. 
 
4.2.8 The motility of 4T1 cells is dependent on NF-kB activity 
As we have now established an association between increased NF- κB activity, 
induction of EMT and increased motility in 4T1 cells when the Nfkb2 gene is 
silenced, we then addressed whether the motile phenotypes observed were dependent 
on canonical NF-κB signalling. For that, we inhibited IκBα phosphorylation and its  
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Figure 4.6: Silencing of Nfkb2 increases the motility of 4T1 cells.  (a) Boyden 
motility assays. 4T1, N202.1A and EPH4 cell lines transduced with non target 
(NT) and shRNA against Nfkb2 were plated in Boyden trans-well migration 
chambers and migration was induced via a serum gradient. The cells that have 
migrated to the underside of the membrane were then stained and counted. Bar 
charts show the relative number of cells migrated (normalized to 4T1 NT). Data 
points represent average of at least n=6 and error bars indicate standard error of 
the mean (SEM). (b) Boyden invasion assays. 4T1 and N202.1A cell lines 
transduced with non target (NT) and shRNA against Nfkb2 were plated in 
Boyden trans-well migration chambers coated with a layer of Matrigel and 
invasion was induced via a serum gradient. Bar charts show the percentage of 
cells invaded normalized against the number of cells migrated without Matrigel. 
* indicates p<0.05, n.s. indicates not significant, where statistical significance 
relative to non target controls were determined by two-tailed t-test. 
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Figure 4.7: Silencing of Nfkb2 induces EMT in 4T1 cells.  (a) mRNA from 
4T1 NT and 4T1 Nfkb2 kd cells were harvested and purified. cDNA was 
synthesized from respective cell lines and the levels of EMT inducing 
transcription factors; Snail, Slug, Twist1, Twist2, Zeb2 and markers for EMT; E-
cadherin and N-cadherin were quantified by qRT-PCR. Bar charts show the 
relative levels of transcripts normalized against NT controls using the ∆∆CT 
method. Data points represent average of at least n=6 and error bars indicate 
standard error of the mean (SEM). * indicates p<0.05, where statistical 
significance relative to non target controls were determined by two-tailed t-test. 
 (b) Protein lysates from 4T1 NT and 4T1 cells transduced with shRNA against 
Nfkb2 (p52 sh43& p52 sh44)  were harvested and separated by SDS-PAGE. The 
levels of E-cadherin and vimentin in these cell lines were then quantified by 
immune-blotting. 
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degradation using a phramacological inhibitor BAY 11-7082. In order to ensure that   
the viability of cells was not a contributing factor in subsequent assays, we assessed 
the effects of BAY 11-7082 at varying concentrations on the survival of 4T1 and 
N202.1A cells. We found that concentrations of up to 1µM did not affect the 
viabilities of both 4T1 and N202.1A cell lines that were transduced with NT or 
shRNA against Nfkb2 (Figure 4.8a). At 5µM, although N202.1A cells were not 
severely affected, 4T1 cells were displaying decreased viabilities. Hence, the BAY 
11-7082 inhibitor was utilized at 1µM for subsequent experiments. The efficacy of the 
inhibitor at this concentration range was also verified by monitoring levels of IκBα in 
4T1 cells. When 4T1 cells were treated with TNF-α, the levels of IκBα was 
significantly reduced and in the presence of 0.1µM BAY 11-7082, this reduction can 
be decreased (Figure 4.8b).  
 In the case of 4T1 cells, transwell migration assays with the presence of BAY 
11-7082 revealed that the inherent motility of 4T1 NT cells was largely dependent on 
NF-κB activity, where a 5-fold decrease in number of cells migrated was observed for 
BAY 11-7082 treated cells (Figure 4.8c). For 4T1 Nfkb2 kd cells, the increased 
motility relative to NT controls was also dependent on NF-κB activity as the motility 
of these cells was diminished by BAY 11-7082, to a level that was similar to 4T1 NT 
cells in the presence of BAY 11-7082. This demonstrates that the increase in motility 
observed in 4T1 cells when Nfkb2 is silenced is dependent on the increase in basal 
NF-κB activity in these cells and most likely occurs through the induction of EMT. 
Although we observed a similar trend for N202.1A cells, these changes were not 
significant (Figure 4.8d). This is likely due to the fact that the differences observed 
were within the magnitude of the error and could be addressed by optimization of 
experimental parameters. 
 
4.2.9 The mammosphere forming potential of mammary cancer cell lines 
correlates with the changes in NF-kB activity after Nfkb2 silencing  
According to the cancer stem cell hypothesis, only a sub-population of CaSCs 
have the ability to seed new tumours and form metastases. In order to determine 
whether p100/p52 has a role in governing the properties of CaSCs, we assessed the 
tumour initiating properties of mammary cancer cell lines by mammosphere assays. 
This in vitro surrogate assay allows the self-renewal potential of cancer cells to be  
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Figure 4.8: The increase in motility in 4T1 cells upon Nfkb2 silencing is 
dependent on NF-κB activity. (a) 4T1 and N202.1A cells transduced with NT 
and shRNA against Nfkb2 were treated with varying concentrations of BAY 11-
7082 for 24 hours and the viability of these cells were then determined by Cell 
Titer Blue assay. Line graphs show dose response curves of 4T1 and N202.1A 
cell lines after BAY 11-7082 treatment. Data points represent average of at least 
n=6 and error bars indicate standard error of the mean (SEM). (b) Protein 
lyasates from 4T1 cells, 4T1 cells treated with 10ng/ml of TNF-α and 4T1 cells 
treated with 10ng//ml TNF-α + 0.1µM BAY 11-7082 were harvested and 
separated by SDS-PAGE. The levels of IκBα in these cell lines were then probed 
by immune-blotting. 
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Figure 4.8: (Continued) The increase in motility in 4T1 cells upon Nfkb2 
silencing is dependent on NF-κB activity. (c) 4T1 NT and 4T1 Nfkb2 kd cells 
were plated in Boyden trans-well migration chambers in the presence or absence 
of 1uM BAY 11-7082 and migration was induced via a serum gradient. The cells 
that have migrated to the underside of the membrane were then stained and 
counted. Bar charts show the number of cells migrated. Data points represent 
average of at least n=6 and error bars indicate standard error of the mean (SEM). 
(b) N202.1A NT and N202.1A Nfkb2 kd cells were plated in Boyden trans-well 
migration chambers in the presence or absence of 1uM BAY 11-7082 and 
migration was induced via a serum gradient. The number of cells that have 
migrated to the underside of the membrane was then stained and counted. Bar 
charts show the number of cells migrated. Data points represent average of at 
least n=6 and error bars indicate standard error of the mean (SEM). * indicates 
p<0.05, n.s. indicates not significant, where statistical significance relative to non 
target controls were determined by two-tailed t-test. 
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evaluated. In the first passage (P1), we did not observe any significant differences in 
the percentage of mammosphere forming units (MFUs) between NT and Nfkb2 kd 
cell lines of 4T1, N202.1A and EPH4 lineage respectively (Figure 4.9a). However, in 
the second passage (P2), there was a two fold increase in % MFUs when Nfkb2 was  
silenced in 4T1 cells (Figure 4.9b). Contrastingly for N202.1A cells, a significant 
decrease in % MFUs was observed when Nfkb2 was silenced. Importantly, these 
changes in mammosphere forming ability of both 4T1 and N202.1A cells respectively 
when Nfkb2 is silenced, implicates for the first time the involvement of p100/p52 in 
regulation of CaSC properties. The lack of correlation between P1 and P2 can be 
explained by the fact that in P1, the assay predominantly selects for cells which have 
the ability to survive anoikis without a strong selection pressure for self-renewing 
ability. When the spheres were dissociated and re-plated in P2, the self-renewal 
potential of CaSCs become more evident as cells without extensive replicative 
potential will no longer be able to form mammospheres. As for the normal EPH4 cell 
line, these cells have a low mammosphere forming efficiency and no difference was 
observed when p100/p52 is lost. Yet again, this would suggest that interfering with 
NF-κB activity through silencing of Nfkb2 only affects tumourigenic cell lines. This 
could be due to a need for NF-κB co-operating in the context of other oncogenic 
signalling pathways.  
The average sizes of spheres formed in these cell lines upon Nfkb2 silencing 
exhibit a similar trend as that of their mammosphere forming potential (Figures 4.9 
c&d). Since we do not observe a change in the rate of proliferation of all three cell 
lines when p100/p52 is depleted (Section 4.2.4), this would suggest that the 
differences in size of mammospheres can be attributed to the self-renewal ability of 
CaSCs. In other words, cells which can go through more cell divisions without 
entering senescence will form larger spheres. Taken together, the mammosphere 
forming efficiency and average sizes of spheres formed in 4T1 and N202.1A cells 
upon Nfkb2 silencing correspond to the changes in basal NF-κB activity of the 
respective cell lines (Figure 4.1b), suggesting a dependence of these phenotypes on 
NF-κB activity.                                                                                                                                                             
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Figure 4.9: Effects of silencing Nfkb2 on mammosphere forming potential of 
mammary cell lines. (a) 4T1, N202.1A and EPH4 cell lines transduced with non 
target (NT) and shRNA against Nfkb2 were plated in non-adherent culture plates 
with mammosphere media and the number of spheres formed after 7 days were 
counted. Bar charts show % mammosphere forming units (MFUs) calculated as 
the number of spheres per cells seeded. (b) The spheres formed by respective cell 
lines in the first passage (P1) were dissociated and re-seeded at an equal density 
(P2) under non-adherent culture conditions in mammosphere media. Bar charts 
show % MFUs. Data points represent average of at least n=6 and error bars 
indicate standard error of the mean (SEM). ** indicates p<0.01, n.s. indicates not 
significant, where statistical significance relative to non target controls were 
determined by two-tailed t-test. 
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Figure 4.9: (continued) Effects of silencing Nfkb2 on mammosphere forming 
potential of mammary cell lines. (c) 4T1, N202.1A and EPH4 cell lines 
transduced with non target (NT) and shRNA against Nfkb2 were plated in non-
adherent culture plates with mammosphere media and the sizes of spheres 
formed after 7 days were measured using ImageJ. Bar charts show diameter of 
mammospheres in um. Data points represent average of at least n=10 and error 
bars indicate standard error of the mean (SEM). ** indicates p<0.01, where 
statistical significance relative to non target controls were determined by two-
tailed t-test. (d) Representative images of the size of spheres formed by 4T1, 
N202.1A and EPH4 mammospheres transduced with NT and shRNA against 
Nfkb2 kd. Scale bar represents 100um.  
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4.2.10 The mammosphere forming potential of mammary cancer cell lines are 
dependent on NF-kB activity 
Accordingly, we then went on to determine whether NF-κB activity is a 
requirement for maintaining self-renewal properties in mammary cancer cells. In P1 
experiments, inhibition of NF-κB by BAY 11-7082 resulted in significant decreases in 
mammosphere forming potentials for 4T1 NT and Nfkb2 kd cells (Figure 4.10a). In 
P2, the mammosphere forming potential of 4T1 cells were completely abolished in the 
presence of BAY 11-7082 (Figure 4.10b). Similarly for N202.1A cells, the numbers 
of MFUs were decreased in P1 (Figure 4.10c) and almost completely depleted in P2 in 
the presence of BAY 11-7082 (Figure 4.10d). These experiments show that the 
mammosphere forming potential of tumorigenic 4T1 and N202.1A cells were 
dependent on NF-κB activity. 
 
4.2.11 Over-expression of p52 rescues the decrease in mammosphere 
forming potential of N202.1a cells but not the increase in motility and 
mammosphere forming potential of 4T1 cells after Nfkb2 silencing 
Although silencing the Nfkb2 gene in mammary cancer cell lines have shown 
some interesting changes with regards to the motility (Section 4.2.6) and 
mammosphere forming potential (Section 4.2.9) of 4T1 and N202.1A cells, we were 
not able to distinguish the specific effects of losing p100 or p52 respectively. This 
distinction is important as both these gene products of Nfkb2 play opposing roles in 
the NF-κB pathway. For that reason, we went on to elucidate whether over-expression 
of the p52 subunit can rescue the phenotypes observed. In 4T1 cells, the increased 
motility upon Nfkb2 knockdown was not changed despite p52 being re-expressed in 
the Nfkb2 kd cell line (figure 4.11a). This would indicate that the increase in motility 
is due to the loss of p100 and not p52. However, over-expression of p52 in the Nfkb2 
kd cell line did not increase the motility of these cells further. This could be due to the 
cells reaching an upper limit of their migration capacity. In the case of the 
mammosphere forming potential of 4T1 cells, the increase in MFUs which results 
from Nfkb2 knockdown is not rescued when p52 is over-expressed (Figure 4.11b), 
implicating the loss of p100 as a possible cointributing factor in this observation. This 
would agree with the increased basal NF-κB activity observed in 4T1 Nfkb2 kd cells 
relative to NT controls (Section 4.2.1), since p100 is an IκBα protein with negative 
regulatory functions in this pathway. 
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Figure 4.10: The mammosphere forming potential of 4T1 and N202.1A cells 
are dependent on NF-κB activity. (a) 4T1 cell lines transduced with non target 
(NT) and shRNA against Nfkb2 were plated in non-adherent culture plates with 
mammosphere media and the number of spheres formed in the presence or 
absence of BAY 11-7082 after 7 days were counted. (b) The spheres formed by 
respective 4T1 cell lines in the first passage (P1) were dissociated and re-seeded 
at an equal density (P2) under non-adherent culture conditions in mammosphere 
media. (c) N202.1A cell lines transduced with non target (NT) and shRNA 
against Nfkb2 were plated in non-adherent culture plates with mammosphere 
media and the number of spheres formed in the presence or absence of BAY 11-
7082 after 7 days were counted. (d) The spheres formed by respective N202.1A 
cell lines in the first passage (P1) were dissociated and re-seeded at an equal 
density (P2) under non-adherent culture conditions in mammosphere media. 
Bar charts show % MFUs. Data points represent average of at least n=6 and error 
bars indicate standard error of the mean (SEM). *** indicates p<0.001, ** 
indicates p<0.01, where statistical significance relative to non target controls 
were determined by two-tailed t-test. 
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Figure 4.11: Rescue experiments by over-expression of p52. (a) 4T1 cells 
transduced with non target (NT) shRNA, shRNA against Nfkb2 and shRNA against 
Nfkb2 with p52 over-expression were plated in Boyden trans-well migration chambers 
and migration was induced by a serum gradient. The number of cells which have 
migrated to the underside of the membrane were then stained and counted. Bar charts 
show number of cells migrated normalized against NT control. (b) 4T1 cells 
transduced with non target (NT) shRNA, shRNA against Nfkb2 and shRNA against 
Nfkb2 with p52 over-expression were plated in non-adherent culture plates with 
mammosphere media and the number of spheres formed after 7 days in passage 2 was 
counted. Bar charts show the number of spheres formed. (c) N202.1A cells 
transduced with non target (NT) shRNA, shRNA against Nfkb2 and shRNA against 
Nfkb2 with p52 over-expression were plated in non-adherent culture plates with 
mammosphere media and the number of spheres formed after 7 days in passage 2 
were counted. Bar charts show the number of spheres formed. Data points represent 
average of at least n=6 and error bars indicate standard error of the mean (SEM). * 
indicates p<0.05, where statistical significance relative to non target controls were 
determined by two-tailed t-test.  
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 For N202.1A cells, silencing of Nfkb2 resulted in decreased basal NF-κB 
activity (Section 4.2.1) which is accompanied by decreased survival under anoikis 
conditions (Section 4.2.3) and mammosphere  forming potential (Section 4.2.9). To 
address whether the decrease in MFUs upon silencing of Nfkb2 was mediated by p52, 
over-expression of p52 in N202.1A cells depleted of p100/p52 rescued the decrease in 
mammosphere forming potential to a level that is comparable with NT controls 
(Figure 4.11c). Hence, this demonstrates for the first time in mammary cancer cells, a 
role for the p52 subunit in regulation of CaSC properties. These experiments could be 
complemented by non-processable p100 over-expression (Maruyama et al., 2010) to 
elucidate the specific phenotypes which are dependent on the IκBα protein. From the 
current results, it appears that the differential effects observed between 4T1 and 
N202.1A cell lines could be due to the p100 and p52 subunits having more dominant 
effects respectively in each of the cell lines.   
 
4.2.12 Loss of Nfkb2 enhances 4T1 tumour growth in vivo 
From previous in vitro experiments, 4T1 cells exhibited more aggressive 
phenotypes when p100/p52 was depleted. Thus, we wanted to address whether these 
features would be recapitulated in vivo. When 4T1 NT and Nfkb2 kd cells were 
transplanted orthotopically into syngeneic hosts, we found that 4T1 Nfkb2 kd cells 
had enhanced growth kinetics (Figure 4.12a). Significant differences in the size of 
tumours between NT and Nfkb2 kd cohorts were evident by day-13 post-transplant 
and this difference was further amplified by day-27 post-transplant. When the 
histology of respective tumours were examined, no difference in the morphology of 
cells between the different cohorts can be observed (Figure 4.12b). Nonetheless, 
immuno-staining for p100/p52 illustrated that these proteins were not detectable in 
Nfkb2 kd tumours, proving that Nfkb2 silencing is maintained within these cells for 
weeks in vivo. 
Although 4T1 Nfkb2 kd tumours were growing relatively faster than 4T1 NT 
tumours, we did not observe any differences in neither the proliferation nor the 
number of apoptotic cells between the two cohorts, as shown by Ki67 and cleaved 
caspase-3 immuno-staining respectively (Figures 4.13 a-c). Analysis of the gradients 
of respsective graphs also suggests no difference in the rate of change in size at 
selected time intervals (Figure 4.12a). Similarly in vitro, we did not observe a 
difference in proliferation rates of 4T1 cells when Nfkb2 is knocked down (Section  
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Figure 4.12: Loss of Nfkb2 enhances 4T1 tumour growth in vivo. (a) 10,000  
4T1 Non Target or Nfkb2 kd cells were transplanted into the right mammary fat 
pads of Balb/C mice respectively. The resulting tumours were measured and the 
growth kinetics plotted as line graphs. Data points represent averages from n=5 
animals per cohort and error bars represent standard error of the mean. * 
indicates p<0.05, where statistical significance between growth curves was 
determined by ANCOVA test; F=8.370, p=0.018.(b)  Representative images 
from 4T1 NT and Nfkb2 kd tumours stained with haematoxylin and eosin or 
immuno-labelled with antibody against p100/p52. Scale bar represents 100um.  
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Figure 4.13: The increased 4T1 tumour growth in vivo is not associated with 
a change in the proliferation to apoptosis ratio. (a) Representative images 
from 4T1 NT and Nfkb2 kd tumours immuno-labelled with antibodies against 
Ki67 and cleaved caspase-3 respectively. Scale bar represents 100um. (b) Bar 
charts showing number of Ki67 positive nuclei per 10x field of view. (c) Bar 
charts showing number of cleaved caspase-3 positive cells per 10x field of view. 
Data represent averages from n=5 per cohort and error bars indicate standard 
error of the mean. n.s. indicates not significant where statistical significance was 
determined by a two-tailed t-test.   
n.s. 
 n.s. 
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4.2.4) but an increase in mammosphere forming ability is evident (Section 4.2.9). 
Thus, it is possible that the difference in tumour size between NT and Nfkb2 kd 
cohorts was due to increased numbers of tumour initiating cells within the 4T1 Nfkb2 
kd population. This would allow the Nfkb2 kd tumours to expand from a larger 
population of replication competent cells, providing a head start in terms of growth 
kinetics, albeit maintaining a similar proliferation rate as 4T1 NT cells. It would be 
interesting to address whether this is the case by limiting dilution experiments. 
Upon necropsy at designated experimental endpoints, we also had a look at the 
lungs of mice transplanted with 4T1 NT or Nfkb2 kd cells for metastases formation. 
Quantification of the area with lung metastases between the two cohorts did not reveal 
any significant differences (Figures 4.14 a&b). The fact that experimental endpoints 
were based on size of tumours (i.e. ~700mm
3
) would mean that there is less time for 
metastases formation in animals transplanted with 4T1 Nfkb2 kd cells because these 
tumours exhibit faster growth kinetics. Hence, we were not able to directly conclude 
whether silencing of Nfkb2 had any effects on metastatic formation. 
 
4.2.13 Loss of Nfkb2 diminishes N202.1A  tumour growth in vivo 
As we observed decereased surivival under anoikis conditions and 
mammosphere forming potential for N202.1A cells after Nfkb2 silencing, we then 
wanted to address whether p100/p52 depletion in these cell lines would retard tumour 
growth in vivo. For that, we transplanted these cells orthotopically into immuno-
commpromized NOD/SCID mice. Interestingly, the tumour size of tumours from 
N202.1A cells lacking Nfkb2 were diminished (Figure 4.15) and this is in contrast to 
the effects of silencing Nfkb2 in 4T1 cells (Section 4.2.12). Again, analysis of the 
gradients of respsective graphs also suggests no difference in the rate of change in 
size at selected time intervals (Figure 4.15). Although the contrasting effects due to 
Nfkb2 silencing on tumour growth correlates with the contrasting effects seen for both 
these cell lines in in vitro experiments, we cannot rule out the possibility that the 
immune-components of transplanted mice were responsible for the differences seen. 
That is, 4T1 cells were transplanted into syngeneic hosts whereas N202.1A cells were 
transplanted into NOD/SCID mice which are deficient in natural killer cells and lack 
both B and T cells. This could be addressed with syngeneic transplants of N202.1A 
cells. Nonetheless, the retardation of N202.1A tumour growth in vivo demonstrates 
the potential of targeting p52 in breast cancer cells.  
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Figure 4.14: Metastatic burden of mice transplanted with 4T1 NT and 
Nfkb2 kd cells. (a) Representative images from lungs of mice transplanted 
orthotopically with 4T1 NT and Nfkb2 kd cells. M indicates metastatic nodules. 
Scale bar represents 200um. (b) Bar charts showing average area of lung 
metastases from mice transplanted orthotopically with 4T1 NT and 4T1 Nfkb2 
kd cells. Data represent averages from n=5 per cohort and error bars indicate 
standard error of the mean. n.s. indicates not significant where statistical 
significance was determined by a two-tailed t-test.   
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Figure 4.15: Loss of Nfkb2 diminishes N202.1A tumour growth in vivo. (a) 
50,000  N202.1A Non Target or Nfkb2 kd cells were transplanted into the right 
mammary fat pads of NOD/SCID mice respectively. The resulting tumours were 
measured and the growth kinetics plotted as line graphs. Data points represent 
averages from n=5 animals per cohort and error bars represent standard error of 
the mean. * indicates p<0.05, where statistical significance between growth 
curves was determined by ANCOVA test; F=7.754, p=0.021.  
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4.3 Discussion 
From our experiments on 4T1, N202.1A and EPH4 cell lines, it appears that 
the effects of silencing Nfkb2 are context dependent. In the non-tumourigenic EPH4 
cell line, despite elevations in basal NF-κB activity after Nfkb2 knockdown, there 
were no changes in the ability to survive under anoikis conditions, proliferation, 
colony forming potential, motility or mammosphere forming potential. These 
observations would suggest that in normal mammary epithelial cells, negative 
regulatory mechanisms exist to counter-act the increase in basal NF-κB activity. In 
fact, it has been shown in breast cancer cell lines that oncogenic stimulus such as Src 
can induce epigenetic changes which results in maintenance of a positive feedback 
loop involving NF-κB and inflammatory pathways (Illiopoulus et al., 2009). Thus, it 
is likely that in non-transformed Eph4 cells, such epigenetic changes have not been 
established and this prevents the acquisition of malignant traits in these cells. 
 On the other hand, in 4T1 cells, the increase in basal NF-κB activity after 
Nfkb2 knockdown resulted in more aggressive cancer phenotypes. This increase in 
basal NF-κB activity correlated with increased nuclear and cytoplasmic p50 levels. It 
is also possible that the loss of p100 contributes to elevations in NF-κB activity in this 
cell line because it can sequester other NF-κB subunits such as p50 in the cytoplasm. 
To address this, a non-processable mutant form of p100 (Maruyama et al., 2010) can 
be over-expressed in 4T1 cells and the corresponding NF-κB activity measured. Due 
to its non-processable nature, any contribution from p52 can be eliminated. In 
addition over-expression of wild-type (WT) p100 would demonstrate whether both 
p100 and p52 are required to rescue the increase in NF-κB activity, since p100 can be 
processed into p52. Additional knockdown of p50 in cells lacking Nfkb2 could also 
indicate whether compensatory activity by p50 is responsible for the increased 
malignancy in 4T1 cells lacking Nfkb2. 
As a result of increased NF-κB activity in 4T1 cells after p100/p52 depletion, 
we observed changes in markers which were indicative of EMT. Consequently, this 
correlates with increased motility and mammosphere forming potential, both 
attributes associated with the EMT process. We showed that both these changes were 
dependent on NF-κB activity (Section 4.2.8&4.2.10) and cannot be rescued by over-
expression of p52, again suggesting that the phenotypes observed could be due to loss 
of p100. We cannot rule out the possibility that increased compensatory activity by 
other NF-κB subunits such as p50 were responsible for the phenotypes observed. 
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However, it would be interesting to indentify and distinguish whether knockdown of 
p50 or overexpression of p100 can rescue the phenotypes observed. Tumour growth in 
vivo was also accelerated upon Nfkb2 silencing and this increase is likely due to the 
increase in tumour initiating cells, since no difference in proliferation and apoptosis 
were observed in these tumours. Although we did not detect any difference in 
metastatic burden between mice with transplanted tumours from 4T1 NT and Nfkb2 
kd cells, this could be due to unequal lengths of time for metastatic formation. Tail 
vein transplant experiments can be carried out to eliminate the differences in tumour 
growth kinetics between the two cell lines. Nonetheless, the enhanced motility in 4T1 
Nfkb2 kd cells that was observed in vitro might become less apparent in such an assay 
because the initial steps of metastasis are omitted. Even so, it will be interesting to 
investigate whether the increased tumour initiating potential in 4T1 Nfkb2 kd cells 
will lead to increased metastatic burden upon tail vein transplantation. Overall, our 
data demonstrates that Nfkb2 silencing leads to acquisition of more aggressive 
phenotypes in 4T1 cells and suggests that p100 may have important suppressive roles 
with regards to disease progression. Accordingly, activation of the alternative NF-κB 
pathway may affect breast cancer progression not only by increased p52 mediated 
transcription but also by inducing the loss of p100. Hence, targeting p52 at the gene 
level will not be an appropriate therapeutic strategy because the loss of p100 could 
lead to detrimental effects in certain breast cancer subtypes.     
 Contrastingly, targeting Nfkb2 by gene silencing resulted in some 
therapeutically beneficial effects in N202.1A cells. These cells exhibited decreased 
NF-κB activity which then resulted in diminished anoikis resistance, mammosphere 
forming potential and tumour growth in vivo. The decreased mammosphere forming 
ability upon Nfkb2 silencing could be rescued by over-expression of p52 and through 
these experiments, we have demonstrated for the first time a role for p52 in regulating 
self-renewal properties of CaSCs. This is in line with findings that the RANKL-
RANK-IκKα signalling axis is important for maintenance of stem cell functions in 
normal mammary stem cells, mammary cancers and metastasis (Asselin-Labat et al., 
2010, Gonzalez-Suarez et al., 2010, Liu et al., 2010, Tan et al., 2011). Thus, it is 
likely that RANKL signalling promotes CaSC properties at least in part through 
activation of the alternative NF-κB pathway. To further address the importance of 
alternative NF-κB pathway activation downstream of RANKL signalling in regulating 
CaSC properties, the differential effects on breast cancer cell lines expressing WT or 
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the unprocessable mutant form of p100 respectively upon RANKL stimulation can be 
assessed. It is also important to histologically characterize the N202.1A transplanted 
tumours in order to understand the mechanisms behind diminished tumour growth 
upon Nfkb2 silencing in these cells. The metastatic burden especially in the lungs of 
these mice will also need to be quantified to reveal whether Nfkb2 knockdown reduces 
N202.1a metastasis formation.        
 Despite the clear differential effects of Nfkb2 silencing between various cell 
lines studied, the mechanisms responsible for these context dependent effects are not 
clear. It is plausible that N202.1A cells which over-express the EGFR family member, 
ErbB2, have increased activation of NF-κB and this makes them more dependent on 
NF-κB activity for their tumourigenic properties. As for 4T1 cells, lower basal NF-κB 
activity could mean less p100 processing into p52 and consequently, the loss of p100 
will be more pronounced than that of p52 when Nfkb2 is silenced. To address whether 
the differential effects are dependent on ErbB2 mediated signalling, Nfkb2 can be 
silenced in N202.1E cells, a sub-line related to N202.1A cells  which has reverted to 
low levels of ErbB2 expression. Perhaps in a cell lineage similar to that of N202.1A 
but with lower NF-κB activity, Nfkb2 silencing may lead to more malignant 
phenotypes. An unbiased analysis involving global gene expression analysis might 
also reveal the various co-operating pathways required to bring about the differential 
effects due to Nfkb2 silencing in the cell lines studied. 
 Compensatory mechanisms between NF-κB subunits have been detailed in 
various studies involving knockout mice (Moellering et al., 2009). From our 
observations, this also occurred in 4T1 cells, where increased p50 was observed after 
Nfkb2 silencing. It would be worth determining whether such compensation has taken 
place in N202.1A cells as well. This highlights some of the potential problems when 
targeting the NF-κB pathway through manipulation of subunit levels. From 
experiments involving pharmacological inhibition of the canonical NF-κB pathway 
(Sections 4.2.8 & 4.2.10), we showed that inhibition of canonical NF-κB signalling 
alone in both 4T1 and N202.1A cell lines could effectively diminish motility and 
mammosphere forming potential. This would indicate that targeting the canonical NF-
κB pathway independently might suffice to achieve a therapeutic outcome in these 
cell lines. However, it remains to be addressed whether certain subtypes of breast 
cancers are more dependent on the canonical or the alternative NF-κB pathways. This 
is possible as NF-κB subunits have certain non-overlapping functions and they can 
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regulate subsets of unique genes respectively. Hence, targeting p52 mediated 
transcription may be more relevant to particular subtypes of breast cancer than others.  
 Even so, in N202.1A cells, we have demonstrated decreased tumour initiating 
potential and growth in vivo after Nfkb2 silencing and this illustrates the prospects of 
targeting p52 mediated transcription in breast cancers. Importantly, the effects of p52 
depletion are context dependent, as demonstrated by the outcomes in 4T1 and 
N202.1A cell lines. Hence, it will be crucial to identify the subtype of breast cancers 
which are dependent on p52 and most likely to benefit from its targeting.  
 
4.4 Summary 
In this chapter, we have shown that the effects of silencing Nfkb2 in mammary 
cancer cells are context dependent (Figure 4.16). Although the exact mechanisms 
behind the differential effects have not been elucidated, it is likely due to p100 or p52 
having more dominant roles respectively in varying cell lines. We have also 
demonstrated a role for p52 in maintenance of CaSC properties and this strengthens 
its prospects as a therapeutic target. However, targeting p52 at the gene level could be 
detrimental as the loss of p100 or compensatory mechanisms by other NF-κB subunits 
may exacerbate the malignant phenotypes of breast cancer cells. Hence, other 
therapeutic strategies for targeting p52 will need to be addressed and particular 
subtypes of breast cancer which depend on p52 mediated activity identified. 
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Figure 4.16: Summary of changes due to silencing of Nfkb2 in Eph4, 4T1 
and N202.1A cells. Red arrows show an increase after silencing relative to non-
target controls, green arrows show a decrease after silencing and blue arrows 
indicate no significant changes after silencing. N/a indicates not addressed.  
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5 Elucidating the effects of Ser-222 phosphorylation of p52 
on the phenotypes of mammary cancer cells 
 
5.1 Introduction 
The findings from Chapter 4 showed that depletion of p100/p52 can be 
therapeutically beneficial in N202.1A cells but such an intervention resulted in 
increased malignancy in 4T1 cells. As the increased malignancy in 4T1 cells was 
likely due to the loss of the inhibitory functions of p100 and/or compensatory activity 
by p50, prospective strategies for diminishing p52 activity, downstream of p100/p52 
processing, ought to circumvent the loss of p100 and not depend on altering the levels 
of p52 in a cell. This would prevent exacerbation of disease progression in cases 
where misdiagnosis may occur, or where tumour phenotype may change during 
treatment.  
For these reasons, our next approach was to address whether altering the trans-
activating ability of p52 by manipulating its post-translational modifications could 
result in therapeutically beneficial outcomes. As it has been shown that 
phosphorylation of p52 at serine-222 (S222) can regulate the preference for p52 to 
form transcriptionally active or repressive complexes (Barre and Perkins, 2010a), we 
wanted to address whether such changes could alter the oncogenic phenotypes of 
mammary cancer cells. In the study by Barre and Perkins, S222 phosphorylation 
promoted p52 complex formation with histone deacetylase 1 (HDAC1) and such 
complexes repressed transcription. Conversely, the lack of S222 phosphorylation 
promoted p52 homodimers and complex formation with B-cell lymphoma 3 (Bcl-3) 
which can drive transcription. Thus, we wanted to investigate whether promoting Ser-
222 phosphorylation of p52 would diminish NF-κB activity and consequently the 
malignant phenotypes of mammary cancer cells. Another plausible outcome for this 
targeting strategy is that both classical and alternative NF-κB gene targets with κB 
promoter sites that are recognizable by p52 can be repressed. This would abrogate the 
concerns pertaining to compensatory activity and at the same time, broaden the 
effective scope of such a therapeutic to breast cancers that depend on NF-κB activity 
in general, rather than just the alternative pathway itself. If therapeutic outcomes were 
observed through such manipulations, the results from the following experiments 
would substantiate targeting of upstream regulators of Ser222 phosphorylation of p52.  
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5.2  Over-expression of phospho-mimetic p52 mutant in 4T1 cells 
 
5.2.1 Effects of over-expressing phospho-mimetic p52 mutant on basal NF-
κB activity  
4T1 cells that were transduced with non-target (NT) or shRNA against Nfkb2 
were subsequently infected with lentivirus encoding either wild-type (WT), S222A, 
S222D or DNA binding mutant (DBM) versions of p52 respectively. The S222A and 
S222D mutations in p52 represented phospho-deficient and phospho-mimetic states of 
serine-222 of p52 respectively. The expression levels of respective p52 constructs in 
4T1 cells were demonstrated by Western blotting (Figure 5.1a). All sub-lines 
expressed haemagglutinin (HA) tagged p52 to a significant degree. It is also worth 
noting that over-expression of WT, S222A and S222D p52 in 4T1 Nfkb2 kd cells 
resulted in re-expression of p100 at minute levels. This is not surprising as p52 can 
drive the transcription of the Nfkb2 gene as a negative feedback mechanism. Both NT 
and Nfkb2 kd cells were evaluated because NT cells which express p100 may mask 
the effects of p52 over-expression through its IκBα functions.  
When the basal NF-κB activities of 4T1 cells over-expressing respective p52 
were examined by luciferase reporter assays, no significant differences were observed 
between 4T1 NT sub-groups. In the case of 4T1 Nfkb2 kd cells, the changes in basal 
NF-κB when various p52 were over-expressed were also not significantly different 
(Figure 5.1b). As these results represent p52 transcriptional activity from a promoter 
with three consensus κB sequences, it is possible that p52 dependent transcription in 
these cells may require other enhancer elements or presence of cooperative binding 
partners which are not permissive with the use of these luciferase reporter constructs. 
Thus, we were not able to ascertain whether over-expression of varying p52 
constructs had any effect on the levels of its gene targets in these 4T1 sub-lines.     
 
5.2.2  Effects of over-expressing phospho-mimetic p52 mutants on the 
sensitivity of 4T1 cells to anoikis 
Despite the lack of change in basal NF-κB activity as determined by luciferase 
assays (Figure 5.1b), we went on to phenotypically assess the effects of over-
expressing various p52 constructs in 4T1 cells. In 4T1 NT cells, over-expression of 
WT p52 increased the survival of these cells relative to parental or cells over- 
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Figure 5.1: Effects of over-expressing p52 and corresponding mutants on the 
basal NF-κB activity of 4T1 cells. (a) 4T1 NT or Nfkb2 kd cells respectively 
were transduced with lentivirus encoding WT, S222A, S222D or DBM versions 
of p52. Selection of p52 over-expressing cells were carried out by FACS sorting 
of green fluorescent protein (GFP) positive cells, since transduced cells co-
expressed GFP. The levels of p100 and HA-p52 were then evaluated through 
Western blotting of respective cell lysates. (b) 4T1 NT or Nfkb2 kd cells over-
expressing either WT, S222A, S222D or DBM p52 were transfected with NF-kB 
luciferase reporter and pcDNA3.1:lacZ as transfection control. 48 hours after 
transfection, cell lysates were harvested and the ratio of luciferase to lacZ activity 
measured. Bar charts show basal NF-kB activity plotted as relative light units 
(RLU) in the respective cell lines. Data points represent average of at least n=3 
and error bars indicate standard error of the mean (SEM). One-way ANOVA test 
was used to determine statistical significance; Non-target cells, F(4,7)=0.861, 
p=0.531; Nfkb2 kd cells, F(4,7)=3.398, p=0.076. N.s. indicates not statistically 
significant. 
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expressing S222A, S222D or DBM p52 (Figure 5.2). The lack of change when S222A 
or S222D p52 was over-expressed would suggest that both p52/c-rel/HDAC1 hetero- 
and p52/p52/Bcl3 homo-dimers are required to increase the survival of 4T1 NT cells 
under anoikis conditions. Similarly for 4T1 Nfkb2 kd cells, over-expression of WT 
p52 led to increased survival under anoikis conditions relative to parental or cells 
over-expressing DBM p52. Although loss of p52 did not result in decreased survival 
(NT parental against Nfkb2 kd parental), over-expression of WT p52 could enhance 
the ability of 4T1 cells to survive under non-adherent conditions. This would imply 
that the inherent ability of 4T1 cells to resist anoikis is not dependent on p52 but this 
ability can be enhanced by p52 over-expression. As no change was observed in 
luciferase reporter assays when WT p52 was over-expressed (Section 5.2.1), we 
cannot rule out the fact that this increase in anoikis resistance is independent of the 
transcriptional activity of p52. However, it is possible that the luciferase reporter 
assay reflects transcription from the canonical NF-κB pathway with preference over 
that of transcription that is mediated by p52. Hence, the changes observed in this 
assay were a result of specific p52 transcriptional activity that is not conveyed by the 
luciferase reporter assays. 
 
5.2.3 Effects of over-expressing phospho-mimetic p52 mutant on the 
proliferative, colony forming potential and mammosphere forming 
potential of 4T1 cells 
In order to further assess whether promoting S222 phosphorylation has any 
therapeutic effects on 4T1 cells, respective cell lines over-expressing either WT, 
S222A, S222D or DBM p52 were investigated in proliferation (Figure 5.3a), colony 
forming (Figure 5.3b) and mammosphere assays (Figure 5.4a&b). However no 
significant differences were observed between 4T1 NT cells over-expressing 
respective p52 variants or 4T1 kd cells over-expressing the different forms of p52 in 
all these assays. These results corroborate the lack of changes observed for basal NF-
κB activity (Figure 5.1b) and indicate that the regulation of these phenotypes in 4T1 
cells cannot be perturbed by p52 over-expression, irrespective of S222 
phosphorylation status. 
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Figure 5.2: Effects of over-expressing p52 and corresponding mutants on the 
ability of 4T1 cells to survive under anoikis conditions. 4T1 NT or Nfkb2 kd 
cells over-expressing WT, S222A, S222D or DBM p52 respectively were plated 
under non-adherent culture conditions and the viability of these cells were 
measured after 24 hours. Bar charts show viability of cells determined by Cell 
Titer Blue assay, plotted as relative fluorescence in the respective cell lines. Data 
points represent average of at least n=6 and error bars indicate standard error of 
the mean (SEM). Statistical significance was determined by one-way ANOVA 
test and in cases where significance were observed, a post-hoc Tukey’s test was 
carried out between individual groups. For 4T1 NT cells; one-way ANOVA 
F(4,10)=4.22, p=0.03; for Nfkb2 kd cells, one-way ANOVA F(4,10)=10.509, 
p=0.001. For post-hoc Tukey’s test, * indicates p<0.05, ** indicates p<0.01. 
    **       ** 
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Figure 5.3: Effects of over-expressing p52 and corresponding mutants on the 
proliferative and colony forming potential of 4T1 cells.  (a) 4T1 NT and Nfkb2 
kd cells over-expressing WT, S222A, S222D or DBM p52 were plated in 6-well 
plates. At respective timepoints, the number of cells in each well was counted 
with the aid of a haemo-cytometer. Line graphs show cell counts relative to day 1 
plotted on a log scale against time in days. Data points represent average of at 
least n=6 and error bars indicate standard error of the mean (SEM). Statistical 
significance was determine by ANCOVA test; for Non-target cells, F(4,8)=0.861, 
p=0.526; for Nfkb2 kd cells, F(4,8)=2.658, p=0.112. (b) 4T1 NT and Nfkb2 kd 
cells over-expressing WT, S222A, S222D or DBM p52 were plated in 6-well 
plates at a density of 1000 cells per well. The number of colonies formed after 7 
days were counted.  Bar charts show the % colony forming efficiency, which is a 
percentage of the number of colonies formed per cells seeded. Data points 
represent average of at least n=6 and error bars indicate standard error of the mean 
(SEM). Statistical significance was determined by one-way ANOVA test; for 
Non-target cells, F(4,37)=1.479, p=0.228; for Nfkb2 kd cells, F(4,34)=1.392, 
p=0.257. N.s. indicates not statistically significant. 
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Figure 5.4: Effects of over-expressing p52 and corresponding mutants on the 
mammosphere forming potential of 4T1 cells.  (a) 4T1 NT and Nfkb2 kd cells 
over-expressing WT, S222A, S222D or DBM p52 were plated in non-adherent 
culture plates with mammosphere media and the number of spheres formed after 7 
days were counted. Bar charts show the number of spheres formed per well. 
Statistical significance was determined by one-way ANOVA test; for 4T1 NT 
cells, F(4,85)=0.228, p=0.922; for Nfkb2 kd cells, F(4,85)=0.841, p=0.503. (b) The 
spheres formed by respective cell lines in the first passage (P1) were dissociated 
and re-seeded at an equal density (P2) under non-adherent culture conditions in 
mammosphere media. Bar charts show number of spheres formed per well. Data 
points represent average of at least n=6 and error bars indicate standard error of the 
mean (SEM). Statistical significance was determined by one-way ANOVA test; 
for 4T1 NT cells, F(4,84)=1.74, p=0.149; for Nfkb2 kd cells, F(4,85)=2.312, 
p=0.064. N.s. indicates not statistically significant. 
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5.2.4 Effects of over-expressing phospho-mimetic p52 mutant on the motility 
of 4T1 cells 
We also investigated the motility of 4T1 NT and Nfkb2 Kd cells upon over-
expression of respective p52 variants. In both cell lines, we found increases of about 
3-fold in motility, relative to respective parental cell lines when the S222A form of 
p52 was over-expressed (Figure 5.5). This is in contrast to the S222D mutant where 
over-expression of this form of p52 did not affect motility. This suggests that the 
activity of p52 homodimer complexes, possibly in cooperation with Bcl-3 was 
responsible for increasing motility in 4T1 cells. Although WT p52 did not result in 
similar increases as the S222A mutant, this can be explained by the fact that negative 
regulatory mechanisms may exist in 4T1 cells which promote the phosphorylation of 
WT p52, resulting in a similar outcome as over-expressing the phosho-mimetic 
S222D mutant. The use of phospho-specific antibodies to determine whether 
increased levels of Ser-222 phosphorylated p52 are detected upon over-expression of 
WT p52 would be needed to verify this. Thus, it appears that the inherent motility of 
4T1 cells cannot be diminished by promoting repressive p52 heterodimers but can be 
further exacerbated by promoting p52 homodimers.   
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Figure 5.5: Effects of over-expressing p52 and corresponding mutants on the 
motility of 4T1 cells. 4T1 NT and Nfkb2 kd cells over-expressing WT, S222A, 
S222D or DBM p52 were plated in Boyden trans-well migration chambers and 
migration was induced via a serum gradient. The cells that have migrated to the 
underside of the membrane were then stained and counted. Bar charts show the 
relative number of cells migrated (normalized to 4T1 NT -). Data points 
represent average of at least n=6 and error bars indicate standard error of the 
mean (SEM). Statistical significance was determined by one-way ANOVA test; 
for 4T1 NT cells, F(4,25)=6.777, p=0.001; for Nfkb2 kd cells, F(4,24)=12.444, 
p<0.001. Post-hoc Tukey’s test was then performed to determine the level of 
significance between individual groups. For post-hoc Tukey’s test, ** indicates 
p<0.01, *** indicates p<0.001. 
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5.3 Discussion 
 In this chapter, we were evaluating the potential therapeutic outcomes of 
promoting p52 repressive complexes in 4T1 cells through over-expression of the 
phospho-mimetic S222D mutant. 4T1 cells were chosen as the experimental model 
because in the previous chapter (Sections 4.2.8 & 4.2.10), the motility and 
mammosphere forming potential of these cells were significantly diminished when 
BAY 11-7082 was administered. This indicates that the motility and mammosphere 
forming potential of these cells were dependent on canonical NF-κB signalling. As we 
were interested to know whether promoting p52 repressive complexes would also 
reduce transcription from the canonical pathway due to repression of κB promoter 
sites in general, the 4T1 cell line seemed appropriate for this purpose.  
 However, we found that over-expression of WT, S222A or S22D forms of p52 
did not affect basal NF-κB activity in 4T1 NT or Nfkb2 kd cells, as determined by 
luciferase assays (Section 5.2.1). Since the κB sequences on the reporter plasmid can 
also be recognized by other NF-κB subunits (e.g. RelA-p50), it is likely that 
competition may exist between the different populations of subunits. In fact, 
preferential recruitment of particular NF-κB dimers to these promoter sites cannot be 
discounted because some dimers may exert dominant binding over others. The 
differential preference for binding of NF-κB subunits can be achieved through 
interactions with binding partners (Basak et al., 2008), recruited through enhancer 
sequences which were not present in the reporter plasmid used. In addition, distinct 
NF-κB dimers bind different κB sequences with varying preference, and thus the use 
of a set of consensus κB sequences in the reporter plasmid may lead to biased 
recruitment of NF-κB dimers. Accordingly, p52 homo- or heterodimers may still 
affect the regulation of certain gene targets despite the lack of change seen in 
luciferase assays.     
No significant changes were observed in proliferation, colony forming and 
mammosphere forming assays when respective p52 variants were over-expressed in 
4T1 NT or Nfkb2 kd cells (Section 5.2.3) and this correlates with the lack of 
difference in basal NF-κB activities (Section 5.2.1). Our results would imply that the 
genes responsible for maintaining these phenotypes in 4T1s cannot be perturbed by 
over-expression of p52, let alone promoting formation of repressive p52 complexes. 
This could be due to the genes not being targets regulated by p52. 
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 In the case of anoikis and motility assays however, changes in levels of p52 
did affect these particular phenotypes in 4T1 cells. Over-expression of WT p52 
increased anoikis resistance in 4T1 NT and Nfkb2 kd cells relative to respective 
parental cell lines (Section 5.2.2). However, there was no significant effect of over-
expressing S222A or S222D mutants on anoikis resistance, suggesting that both 
phosphorylated and non-phosphorylated forms of p52 were required to increase 
anoikis resistance. Whilst this shows the potential involvement of p52 mediated 
transcription in increasing survival of 4T1 cells under anoikis conditions, over-
expression of S222D p52 did not result in a therapeutically beneficial effect.  
Similarly in motility assays, only over-expression of the S222A form of p52 
increased motility of 4T1 NT and Nfkb2 kd cells relative to respective parental cell 
lines (Section 5.2.4). This indicates the involvement of p52 homodimer complexes in 
promoting the motility of these cells. It is possible that these increases in motility 
involve and are possibly dependent on p52 homodimer complexes with Bcl-3. This 
would correlate with data where Bcl-3 was shown to be important for promoting 
metastasis in MMTV-Neu driven tumours and important for motility of EGFR+ or 
ErbB2+ breast cancer cell lines (Wakefield & Clarkson, unpublished data). In order to 
verify this, it would be interesting to investigate whether silencing of Bcl-3 may 
rescue the increases due to p52 S222A over-expression in 4T1 cells. It would also be 
interesting to investigate whether the cell lines which depend on Bcl-3 for their 
metastatic phenotypes can be affected by over-expression of S222D p52. From over-
expression of respective p52 mutants thus far, we have illustrated changes in 
phenotypes of mammary cancer cells which are governed by different 
phosphorylation states of p52. These experiments also show that p52 may exacerbate 
disease progression but only when present in aberrant levels with/without certain post-
translational modifications. Hence, the levels of serine-222 phosphorylated and 
unphosphorylated p52 in breast cancers rather than just absolute levels of p52 may 
need to be accounted for if its transcriptional activity is to be gauged. 
 In all of the assays examined, we did not observe any therapeutically 
beneficial effects when the S222D form of p52 is over-expressed in 4T1 cells. This 
may be due to the fact that the repressive complexes do not exert a dominant negative 
effect, allowing recruitment of other NF-κB subunits at promoter sites to occur 
unperturbed. Another possible explanation for the lack of change in phenotype is the 
requirement for additional proteins or modifications to form repressive complexes. 
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Although S222 phosphorylation promotes p52 heterodimers, it is possible that the 
recruitment of additional proteins such as HDAC1 is dependent on additional 
requirements. Thus, further understanding of the regulatory mechanisms governing 
the formation of such repressive complexes may be needed to achieve the proposed 
therapeutic outcomes in mammary cancer cells. A plausible starting point may be to 
identify the genes repressed by Ser222 phosphorylated p52 by high-throuhput 
chromatin immuno-precipitation (ChIP on chip). By doing so, the DNA regions 
repressed by p52 in a particular context will be known and with that DNA sequence, 
reverse ChIP can be performed to identify the proteins involved in the complex. 
Consequently, it may also be possible to identify the post-translational modifications 
present on the proteins involved in the complex by mass spectrometry. Such 
knowledge may aid the feasibility of our proposed strategy to promote repressive 
complexes in breast cancer cells. Since silencing of Nfkb2 had significant effects on 
the mammosphere forming potential (Section 4.2.9) and tumour growth (Section 
4.2.13) of N202.1A cells, it would be interesting to address the effects of over-
expressing the respective p52 isoforms in these cells.    
Another limitation associated with over-expressing varying p52 constructs is 
that the levels of expression may not recapitulate the normal levels found in the cells 
examined. This may skew the formation of complexes formed especially if p52 exists 
in abundance within the nucleus. Alternatively, the phospho-mimetic and phospho-
deficient p52 mutations can be incorporated into genomic copies of the Nfkb2 gene, 
through utilization of genome editing tools such as zinc finger nucleases. This will 
allow the expression of particular mutants at levels closer to normal in the cells 
investigated. 
 
5.4 Summary 
We set out to induce formation of repressive p52 complexes through over-
expression of the S222D mutant form of p52 in 4T1 cells but did not observe any 
therapeutic effects in the assays examined. However, we did find that over-expression 
of WT p52 increased the survival of 4T1 cells under anoikis conditions whereas over-
expresssion of the S222A form of p52 increased motility in 4T1 cells. These results 
demonstrate that specific functions of p52 are regulated by Ser-222 phosphorylation. 
Further understanding of the mechanisms regulating the formation of p52 repressive 
complexes may be required to achieve therapeutic outcomes in breast cancer cells.    
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6 Identifying a correlation between levels of nuclear p52 
and subtypes of breast cancer 
 
6.1 Introduction 
As we have shown through silencing of the Nfkb2 gene (Chapter 4), only a 
subset of breast cancers may respond positively to therapeutic interventions which 
disrupt p52 mediated transcription. Hence, it would be crucial to identify cases in 
which such therapies may benefit the most. 
For that reason, we set out to examine a small cohort of tumours generated 
from BRCA2
-/-
 p53
-/-
 mice (Hay et al., 2009) and determine whether any correlations 
exist between levels of nuclear p52 and markers relevant to breast cancer subtypes or 
disease progression. Tumours from BRCA2
-/-
 p53
-/-
 mice were used in this study 
because these tumours lacked DNA damage repair mechanisms and represent models 
of genomic instability. Accordingly, the resulting tumours may be driven by different 
oncogenic pathways and this could provide a wide range of tumour subtypes to be 
examined. 
Since elevations in NF-κB activity in general have been associated with ErbB2 
over-expressing (Biswas and Iglehart, 2006) and basal-like subtypes of breast cancer 
(Yamaguchi et al., 2009), the ErbB2 and p63 antigens were selected as markers for 
the respective subtypes to be examined. The basal phenotype in breast cancers have 
been shown to be associated with p63 (Ribeiro-Silva et al., 2005) and thus it was used 
as a putative marker for basal-like breast cancers. In addition, vimentin, a 
mesenchymal marker was also included in the panel of antigens to be examined 
because the NF-κB pathway is a known regulator of the EMT process (Huber et al., 
2004a).    
 In brief, the aim of the experiments in this chapter was to identify via immuno-
histochemistry, the possible correlations between levels of nuclear p52 and ErbB2, 
p63 or vimentin across a panel of BRCA2
-/-
 p53
-/-
 tumours. This could provide some 
insights into the subtypes of breast cancer which are dependent on p52 mediated 
activity.   
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6.2 Identifying possible correlations between the levels of nuclear p52 
and ErbB2, vimentin or p63 in BRCA2-/- p53-/- tumours by 
immuuno-histochemistry 
 
6.2.1 Nuclear p52 levels correlate with p63 expression in a cohort of   
BRCA2 -/- p53-/- tumours 
A total of 20 BRCA2
-/-
 p53
-/- 
tumours were examined in this study and we 
started off by scoring the levels of nuclear p52 in these tumours. The scores for 
staining of a particular antigen (IxP scores) were derived from the intensities of 
staining (I) and the percentage cover of staining across a tumour section (P), as 
described in Section 2.3.5.3 in Chapter 2. Consequently, the respective tumours were 
ranked from highest to lowest IxP scores for nuclear p52 (Figure 6.1a). The degree of 
staining for p63 (Figure 6.1b), ErbB2 (Figure 6.1c) and vimentin (Figure 6.1d) for 
each of the ranked tumours were also determined by IxP scores.  
The relationship between levels of nuclear p52 and respective antigens (Table 
6.1) were then determined by Spearman’s ranked correlation test. Interestingly, 
nuclear p52 levels correlated with p63 staining (Spearman’s R=0.5203, p<0.05) and 
this suggests that increased p52 activity may be associated with basal like breast 
cancers. However, there was no correlation between the levels of nuclear p52 with 
ErbB2 or vimentin. 
 
6.3 Discussion 
From the immuno-histological analysis of nuclear p52 levels in a panel of 
twenty BRCA2
-/-
 p53
-/-
 tumours, we found a positive correlation between nuclear p52 
levels and p63. Although this suggests a possible correlation between increased 
nuclear p52 and basal-like breast cancers, not all basal-like breast cancers express p63 
(Livasy et al., 2006). Thus, this positive correlation may only hold true in a subset of 
basal-like breast cancers which express p63. This may explain the discrepancy 
between our findings and data from a previous study where only 9 out of 64 triple 
negative (ER
-
, ErbB2
-
, PR
-
) human breast tumours expressed nuclear p52 (Lerma et 
al., 2007b). 
 Further analysis will be required to identify the varying forms of p63 (i.e. 
TAp63 and ∆Np63) which are present in the tumours examined because the antibody  
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Tumour ID 
Ranking 
by p52 
staining 
p52 
 
(IxP) 
p63 ErbB2 Vimentin 
(IxP) (IxP) (IxP) 
 
BAP 2231 R3 
 
1 
 
9 
 
9 
 
0 
 
2 
VEG 347 L3 2 9 2 1 6 
BAP 2213 R4 3 6 6 2 0 
VEG 272 R3 4 6 6 1 9 
VEG 347 R4 5 6 9 6 2 
VEG 312 R5 6 6 0 0 2 
VEG 411 L5 7 6 0 1 9 
BAP 2231 L3 8 4 6 0 0 
VEG 532 R3  9 4 3 4 2 
VEG 272 L4 10 4 2 0 1 
VEG 475 L2 11 4 1 0 6 
BAP 2212 R2 12 3 3 0 6 
BAP 2148 R3 13 3 2 3 4 
VEG 417 R3 14 3 2 0 1 
BAP 2268 R4 15 3 1 3 2 
VEG 550 L1  16 2 2 0 2 
VEG 532 L1 17 2 1 0 1 
BAP 2231 L5 18 2 0 3 9 
BAP 2164 R3 19 2 0 1 9 
BAP 2198 R2 20 2 0 2 0 
 
 
 
 
 
 
 
 
 
 
Table 6.1: Table of scores for respective antigens in BRCA2
-/-
 p53
-/-
 tumours. 
Tumours were stained immuno-histochemically and the intensity X percentage 
cover (IxP) scores were determined for respective antigens. Tumours were then 
ranked by the degree of nuclear p52 staining. Statistical significance for the 
relationship between nuclear p52 staining and p63, ErbB2 or vimentin was then 
determined by Spearman’s ranked correlation test. For p63, R=0.5203, p<0.05; for 
ErbB2, R=0.0688, n.s.; for vimentin, R=0.1078, n.s. N.s indicates not statistically 
significant.    
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used does not discriminate between its different splice variants. This is important as 
the varying forms of p63 have different transcriptional activities (Trink et al., 2007). 
Crosstalk between p63 and NF-κB pathways exists, where both transcription factors 
can directly affect the expression levels of the other (Sen et al., 2011) and form 
complexes to cooperatively regulate the expression of genes (Yang et al., 2011). This 
would suggest that the correlation observed in our studies (Table 6.1) may be due to 
mechanistic interactions between p52 and p63. However, the involvement of specific 
p63 subunits and phosphorylation status of p52 would need to be identified to achieve 
a better understanding of the relationship between the two transcription factors.   
The BRCA2
-/-
 p53
-/- 
tumours that were investigated in this study consisted of 
tumours with a large degree of inter-tumour heterogeneity. This is illustrated by the 
histologies of respective tumours (Figure 6.1) where staining patterns for p63, ErbB2 
and vimentin varied extensively between tumours. This inter-tumour heterogeneity 
was ideal as it allowed comparisons between different tumour subtypes to be made. 
However, the cohort used in this study is relatively small and it would be necessary to 
extend our findings in a larger set of samples. The fact that all these tumours were 
deficient in BRCA2 and p53 may also lead to a bias in the subtypes of tumours 
formed. Hence, it would be ideal if the aims of this chapter can be addressed in a 
larger set of human breast cancer tissue samples. Moreover, the availability of gene-
expression profiling data from certain breast cancer tissue banks would enable the 
differences in p52 levels to be mapped directly to the subtypes of breast cancer based 
on their gene expression profiles (Perou et al., 2000, Sorlie et al., 2001). This is much 
more advantageous than using a restricted number of markers if correlations between 
specific tumour subtypes were to be addressed. 
Based on the findings in Chapter 5 and that of Barre & Perkins (Barre and 
Perkins, 2010a), phosphorylation of p52 at Ser-222 governs the type of complexes 
formed by p52, which in turn regulates whether p52 is transcriptionally active or 
repressive. Hence, it would be more appropriate if the phosphorylation status of p52 is 
accounted for when determining any correlations with breast cancer subtypes. This 
could be achieved with phospho-specific antibodies for p52, where the ratio of 
phosphorylated p52 to that of total p52 can be matched to a particular breast cancer 
subtype. For that reason, although our results indicate a correlation between nuclear 
p52 levels and p63 (Table 6.1), it does not necessarily represent increased p52 activity 
in these tumours.       
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6.4 Summary 
In this chapter, we have managed to identify a positive correlation between 
levels of nuclear p52 and p63 in a cohort of BRCA2
-/-
 p53
-/-
 tumours. This suggests 
that p52 could play a role in basal-like breast cancers but this needs to be addressed in 
a larger cohort of samples which are better characterized in terms of tumour subtypes. 
The identification of p52 activity in respective tumours with phospho-specific 
antibodies would also be essential if more specific correlations were to be made.   
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7 General Discussion 
 
7.1 Apoptosis and mammary gland involution 
The notion that apoptosis is crucial in driving the involution process of the 
mammary gland had been long withstanding (Chapman et al., 2000). However, it has 
been demonstrated that cell death is initiated via a lysosomal-mediated pathway 
during the early phase of involution (Kreuzaler et al., 2011) and can proceed without 
the activation of caspases. This is supported by studies from rtTA/p35 mice during 
early involution (Sections 3.2.2 and 3.2.3). We observed sloughing of MECs into the 
lumen of alveoli without activation of caspase-3 when p35 is induced (Figure 3.3) and 
the numbers of luminal bodies in mammary glands of mice with or without p35 
expression were indifferent (Figure 3.5). However, we were not able to address 
whether caspase inhibition had any effects on mammary gland architecture as a whole 
because we were not able to determine the distribution and levels of p35 protein 
expression in these glands. By knowing the extent of p35 expression in the general 
population of MECs, the effects of caspase inhibition on the second phase of 
involution and also clearance of luminal bodies by phagocytes could be addressed.      
 
7.2 Regulators of apoptosis as therapeutic targets in the prevention 
of breast cancer metastasis 
Resistance to apoptosis is an important feature for cancer cells to disseminate 
to secondary sites (Mehlen and Puisieux, 2006). This association has been 
demonstrated with the use of transplantation models of breast cancer (Bufalo et al., 
1997, Martin et al., 2004, Pinkas et al., 2004) but there is still a lack of adequate 
models which fully recapitulate the entire metastatic process, as reviewed by Mehlen 
and Puisieux. With the use of the rtTA/p35/Neu mouse model, inducible expression of 
the pan-caspase inhibitor, p35, has allowed us to demonstrate the importance of 
apoptotic resistance in promoting the formation of metastases from an endogenous 
tumour (Section 3.3.2). Thus, the requirement for apoptotic resistance throughout the 
entire metastatic cascade in whole was addressed. Although this would strongly 
advocate the targeting of apoptosis regulators to curb metastasis, there was no effect 
of inhibiting caspases on primary tumour growth (Section 3.3.1) and this correlates 
with previous findings (Martin et al., 2004, Pinkas et al., 2004). As such, it is possible 
that resistance to alternative forms of cell death may be more important in promoting 
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the growth of mammary tumours examined. This would be in line with the sensitivity 
of normal MECs to lysosomal mediated cell death during the first phase of involution 
(Kreuzaler et al., 2011). In order to address this, the activation of cathepsins (initiators 
of lysosomal mediated cell death) in mammary tumours can be investigated and the 
effects of cathepsin inhibitors on primary tumour growth examined.   
Importantly, the rtTA/p35/Neu mouse model could also be used to address the 
importance of apoptosis resistance once a tumour has been established at a secondary 
site. Removal of doxycycline would halt transgene expression and metastases can be 
monitored longitudinally by in vivo imaging techniques such as magnetic resonance 
imaging. This would provide clinically important insights as to whether a decrease in 
apoptotic resistance can result in the regression of metastases or just serve as a 
strategy for adjuvant therapies to prevent relapse of disease.  
One of the main inefficiencies of the metastatic process is due to the induction 
of anoikis upon loss of cell contact with the extracellular matrix (ECM) (Simpson et 
al., 2008). Cells which manage to overcome anoikis usually exhibit an increased 
apoptotic threshold via up-regulation of anti-apoptotic factors such as c-FLIP or by 
sustaining the activation of ECM dependent surivival pathways mediated by integrins 
(Sakamoto and Kyprianou, 2010). Accordingly, targeting of anti-apoptotic factors to 
reduce the apoptotic threshold could potentially induce cell death in detached cells 
and prevent the dissemination of cancer cells to secondary sites. The limitation of 
transplantation and xenograft models has not allowed this to be experimented in vivo. 
In order to specifically address the importance of anoikis resistance during the initial 
stages of metastasis with the rtTA/p35/Neu mouse model, intra-vital imaging 
techniques (Kedrin et al., 2008) would need to be employed. By monitoring the 
changes in proportion of cells which survive cell detachment and intravasation upon 
caspase inhibition, the importance of anoikis resistance can be fundamentally 
addressed. Such knowledge could guide and provide a rationale for developing 
therapeutics which impede this initial stage of metastasis.  
 
7.3 The NF-κB p52 subunit and its potential as a therapeutic target in 
breast cancer metastasis 
With the aim of sensitizing breast cancer cells to apoptotic stimuli, the NF-κB 
pathway which regulates the transcription of not only a range of anti-apoptotic genes 
(Clarkson and Watson, 1999), but also genes which can promote metastatic traits such 
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as motility and EMT (Huber et al., 2004a) lies at a crucial nodal point for therapeutic 
intervention. Moreover, the induction of EMT itself has been shown to increase the 
anoikis resistance of breast cancer cells (Kumar et al., 2011).          
 Hence, emphasis was placed on addressing whether the NF-κB p52 subunit 
contributed to the malignancy of breast cancer cells and if suppressing its 
transcriptional activity would result in therapeutically beneficial outcomes. 
Interestingly, silencing of the Nfkb2 gene which encodes both p100 and p52 lead to 
opposing outcomes in 4T1 and N202.1A mammary cancer cell lines. In 4T1 cells, loss 
of Nfkb2 lead to increased basal NF-κB activity (Section 4.2.1), induction of EMT 
(Section 4.2.7), increased motility (Section 4.2.6), mammosphere forming ability 
(Section 4.2.9) and accelerated tumour growth in vivo (Section 4.2.12). As over-
expression of p52 in 4T1 Nfkb2 kd cells did not rescue the motility and mammosphere 
forming phenotypes of these cells (Section 4.2.11), it is likely that loss of p100 or 
compensatory p50 activity is responsible for the increased malignancy upon loss of 
Nfkb2. This can be demonstrated by rescue experiments involving over-expression of 
p100 (unprocessable and WT forms) and knockdown of p50 respectively in 4T1 
Nfkb2 kd cells. On the other hand, in N202.1A cells, knockdown of Nfkb2 resulted in 
decreases in basal NF-κB activity (Section 4.2.1) and correspondingly, decreased 
surivival under anoikis conditions (Section 4.2.3), mammosphere forming potential 
(Section 4.2.11) and tumour growth rate in vivo was observed (Section 4.2.13). The 
decreased mammosphere forming ability in N202.1A cells could be rescued by over-
expression of p52 (Section 4.2.11), indicating that it is the loss of p52 and not p100 
that is responsible for the decreased tumour initiating potential in vitro and  in vivo. It 
would also be crucial to examine whether the phenotypes due to Nfkb2 silencing in 
these two cell lines are corroborated by tail vein and serial dilution transplantation 
experiments. This would provide a better indication of the metastatic and tumour 
initiating potentials of the respective cell lines in vivo. 
 The notable contrast when Nfkb2 is silenced in 4T1 and N202.1A cells calls 
for further investigation into the mechanisms governing the differences observed. 
Since receptor status (i.e. ErbB2, ER, PR) is a conventional method of sub-typing 
breast tumours and the 4T1 and N202.1A cell lines differ in ErbB2 expression status, 
it is worth exploring the contribution of ErbB2 signalling on the effects of Nfkb2 
silencing. This is mainly because signalling via EGFR family receptors can activate 
the NF-κB pathway (Biswas and Iglehart, 2006) and this would determine the basal 
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NF-κB activity in these cells. The effects of silencing the Nfkb2 gene in other 
ErbB2/EGFR
+
 and ErbB2/EGFR
-
 cell lines would indicate if active signalling by 
ErbB2/EGFR dictates the outcomes observed. Alternatively, the gene expression 
profiles of the range of breast cancer cell lines studied could be explored to determine 
if certain gene clusters regulate the differential outcomes of Nfkb2 knockdown. This 
will be of great importance in the identification of breast cancer subtypes which are 
most likely to benefit from therapies against p52. In parallel, the positive correlation 
between p52 and p63 (Section 6.2.1) needs to be explored, preferably in clinical 
samples with gene expression profile data. This will determine whether p52 activity is 
elevated in basal-like breast cancers or perhaps a unique sub-group of breast cancers 
which express p63.  
 In the process of evaluating the therapeutic potential of p52, we have 
implicated its importance in the regulation of phenotypes pertinent to metastasis 
formation such as anoikis resistance (Sections 4.2.3 & 5.2.2) and tumour initiating 
potential (Section 4.2.9). In addition, the motility of cancer cells can also be increased 
when S222A p52 is over-expressed (Section 5.2.4). Altogether, these findings indicate 
that aberrant p52 activity can contribute to the metastatic traits of particular cancer 
cells and thus, diminishing its activity may stand as an effective strategy to curb 
disease progression contextually. Activation of the RANKL-RANK-IκKα signalling 
axis which lies upstream of p52 has also been shown to confer breast cancer cells with 
such metastatic traits (Jones et al. 2006; Cao et al. 2007; Gonzalez-Suarez et al. 2010; 
Schramek et al. 2010) and this would suggest that p52 contributes, at least in part to 
the malignancy associated with RANKL-RANK-IκKα signalling. It would be 
interesting to address the effects of RANKL stimulation on breast cancer cells after 
genetically manipulating the p100 and p52 subunits respectively (e.g. via silencing of 
Nfkb2, over-expression of unprocessable p100), to directly demonstrate the 
importance of p52 downstream of RANKL signalling.    
Although the canonical NF-κB pathway has been shown to be important for 
the tumourigenicity of ErbB2 positive breast cancers in particular (Liu et al., 2010, 
Pratt et al., 2009), simultaneous targeting of p52 should be considered in these 
tumours. This is mainly because compensatory activity by the alternative pathway 
may lead to therapeutic resistance, especially since our results demonstrated a role for 
p52 in malignancy.     
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7.4 Strategies for targeting p52  
In this thesis, we have addressed two possible strategies to diminish the 
transcriptional activity of p52. We evaluated the effects of silencing the Nfkb2 gene in 
Chapter 4 and over-expressing S222D p52 in Chapter 5. Although Nfkb2 knockdown 
had therapeutically beneficial effects in N202.1A cells, it exacerbated the malignancy 
of 4T1 cells. As such, there would be risks associated with targeting p52 via shRNA 
in the clinic, making it an inappropriate strategy. In the case of over-expressing the 
S222D form of p52, this did not result in any therapeutic effects. This may be due to 
the lack of other requirements for the formation of transcriptionally repressive p52 
complexes. Further investigations into whether p52 repressive complexes are formed 
and recruited to appropriate promoter sites in cells over-expressing S222D p52 would 
be required to fully understand the reasons for the lack of change. In addition, a better 
understanding of other factors which facilitate the formation of p52 repressive 
complexes may be required.  
The therapeutic strategies evaluated in our studies were based on genetic 
interventions relevant to p52. The specific nature of such interventions was crucial as 
we were also interested in identifying a role for p52 in breast cancer cells. However, 
pharmacological targeting of p52 need not be restricted to gene-based therapies and 
other possible strategies for diminishing p52 activity should be considered. At the 
present time, there are no commercially available drugs which target p52, but based 
on our findings of the role of p52 in the malignancy of certain breast cancer subtypes, 
the development of such agents is warranted. One of the possible strategies would be 
to directly inhibit the DNA binding activity of p52 via specifically interacting 
peptides and such approaches have been proven to be effective in the inhibition of 
other transcription factors such as Notch (Moellering et al., 2009). Alternatively, 
targeting of modifying enzymes of p52 remains a prospective possibility to inhibit its 
transcriptional activity. Although targeting p52 may not result in ‘magic bullet’ type 
therapies, the addition of such a therapeutic agent to the arsenal of drugs that are 
available for breast cancer patients represents a step closer towards personalized 
medicine.  It is possible that in the future, the subtypes of breast cancer will be 
scrutinized further; resulting in more distinct subgroups and the availability of more 
distinct drugs may be required.            
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